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SCOPE OF THIS THESIS 
The lysosome represents a well characterized, membrane-contained 
intracellular digestive system. Iu this important organelle a battery of lysosomal 
hydro lases and accessory proteins work in concert on the step-wise conversion of 
macromolecular substrates into small biological building blocks, which are either 
reutHized by the cell 01' discarded. A failure of any of these enzymes to properly 
exert their hydrolytic activity results in the progressive accumulation of partially 
degraded· metabolltes that are retained ('stored') in the lysosome. The genetic 
disorders caused by a malfunction of the lysosomal system are collectively known 
as lysosomal storage disorders, aud are normally associated with a single enzyme 
deficiency. One known exception is the disease galactosialldosis which is due to 
partial or complete loss of activity of two glycosidases, acid p-D-galactosidase and 
N-acetyl-a-neuraminidase, because of a primary defect in the carboxypeptidase 
protective protein/cathepsin A (PPCA). The latter enzyme associates with both 
glycosidases soon after syntbesis, and is essential for their proper intracellular 
routing, lysosomal stability and activity. Aside from the protective function, PPCA 
has cathepsin Aldeamidase activity on a selected number ofneuropeptides. 
The aim of the experimental work presented in tbis thesis was to gain 
insigbts into the transcription regulation of the PPCA gene and the expression of 
PPCA mRNA and protein In mouse tissues. These studies have coutributed to the 
understanding of the phenotypic abnormalities in the murine model of 
galactosialldosis, which reflected to a large extent the distribution pattern of the 
protein in normal tissues. Given the fact that the observed pathology in 
galactosialldosis is iu part caused by tbe secondary neuraminidase deficiency, the 
isolation and characterization of the murine neuraminidase was instrumental to 
better understand in whicb way tbe two enzymes depend on each otber and 
cooperate ill vivo. 
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Chapter 1 
General introduction 
I 
I 
1.1 ElIkaryotic trallscriptioll alld Its regulntioll 
One of the requirements of the cell to function properly, is the tight control over 
the switching on, or off, of genes involved in various cellular activities. A diversity of 
internal and/or external signals results in an interplay between activating and repressing 
signals, which ultimately detennines the transcriptional activity ofa gene (42,109,123). 
Transcription is the complex enzymatic process of activating a gene and subsequently 
generating an identical RNA copy from the template DNA. These series of events is 
executed by a plethora of proteins and is SUbjected to tight regulation (132). 
In eukaryotes, transcription is mediated by one of the three DNA-dependent 
RNA polymerases, ultimately resulting in the generation of small rRNAs (Pol. I), amino 
acid carrying tRNAs (Pol. III) or protein encoding mRNAs (Pol. II). The transcriptional 
process can be divided into several closely linked and often overlapping steps (see 167). 
I) Recmitment entails the binding of promoter sequences by activators andlor 
repressors, leading to the rearrangement or disruption of the chromatin structure. This in 
tum will allow the preinitiation complex (PIC) to bind to the sequence specific site in 
the promoter of the gene. 2) PIC activation includes the melting, or unwinding, of the 
two DNA strands to make the promoter accessible for the transcriptional machinery. At 
least two groups of proteins are involved in this process: DNA helicases and single-
stranded DNA binding proteins. 3) Initiation involves the production of the first 
phosphodiester bond in the nascent RNA molecule. 4) Promoter clearance defines the 
transition in the transcriptional process from the initiation to the elongation phase. This 
step probably involves the release of the transcriptional machinery from the general 
initiation factors present on the promoter. 5) Elongation is the continuous addition of 
ribonucleotides to the growing RNA molecule, which is in a stable temary complex with 
the DNA and the RNA polymerase (review see 223). 6) Finally, termination is the 
process whereby the RNA polymerase reaches the tennination specific regions at the 3' 
end of the gene, leading to the release of the nascent RNA molecule. Since the topic of 
this thesis is restricted to protein encoding genes, I will focuss on transcription mediated 
by RNA pol II, and refer to literature for RNA pols I and III dependent transcription 
processes (45, 53). 
RNA polymerase II transcribed genes usually consist of a core DNA domain, to 
which the general transcriptional initiation factors bind, and other upstream or 
downstream gene specific DNA elements that are important for the correct regulation of 
the gene. The expression of the gene is regulated and controlled by specific interactions 
between complexes hound to the core promoter and the gene-specific factors bound to 
the regulatory elements. The promoter of a gene is required for the basal level of 
transcription and contains the site where the RNA polymerase holoenzyme, including its 
accessory factors, interacts with the DNA (definition: see 45, 132). The classical 
eukaryotic corc promoter consists of a TAT A-box located 25-30 nucleotides upstream of 
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the transcriptional start site. This box will tether the TATA-Binding Protein (TBP) and 
its interacting TBP-Associating Factors (TAFlIs , 209, 236), resulting in a complex, 
TF"D, mandatory for the precise positioning of the DNA-dependent RNA polymerase 
II, and at least five accessory proteins TFn A, B, E, F and H, the General Transcription 
Factors (GTFs), to the DNA (l67). III vitro experiments have shown a sequential order 
for the general transcription factors and the pol II to associate with the TFIID-DNA 
complex. However, recent data challenge the multistep recmitment of factors to the 
core promoter and suggest that the RNA polymerase II holoenzyme, or part of it, exists 
as a complex before its association with TF"D-DNA complex (87, ISS, 245). Aside 
from the TATA-box, another important DNA core element has been described that may 
initiate transcription either alone or in combination with the TATA-box (17, 194). This 
element, called the initiator (Inr), overlaps with the transcriptional start site and is 
sufficient to correctly position the transcriptional machinery in the absence of the 
TATA-box (81, 194). Various Inr elements have been identified and several factors, 
including TFu-I, USF, YYl and HIPl, have been shown to biud to 1m elements with 
different sequences resulting in the induction of the transcriptional initiation process 
(81). In addition, another conserved motif has been described which is involved in the 
transcription of TATA-less promoters and explains the multiple start sites of many of 
these types of promoters. This motif is downstream of the transcriptional start site and 
is referrcd to as MED-l for Multiple start site Element Downstream (76). Although the 
exact mechanism of the initial binding and activation through the Inr has not yet been 
elucidated, both the TATA-box directed and the 1m regulated expression use the same 
factors and mechanisms to complete the transcriptional process. 
The binding of the RNA polymerase holoenzyme to the core promoter and its 
activity are influenced by the properties of sequence specific activators. These types of 
molecules bind to a specific DNA seqnence and subsequently recruit other factors 
and/or the RNA polymerase holoenzyme, positioning the originating complex on the 
DNA in the vicinity of the transcriptional start site (reviewed in ISS). The specificity of 
a transcriptional activator is solely detennined by its DNA binding domain, whereas its 
activating domain provides an interacting surface for other proteins to access the 
promoter, suggesting a general role for their recmitment abilities (154). Multiple 
activators act in a cooperative manner, leading to synergism between the actions of 
separate molecules. Aside from the recmitment of additional factors needed for 
stabilization and positioning of the basic transcriptional machinery to the promoter of a 
gene, activators also attract proteins that dismpt the nucleosome stmctures to free the 
DNA from its physical limitations (for review see lOll. Eukaryotic DNA is condensed 
through its complex fonnation with histones and packaged into nucleosomes, which are 
stmctures that limit the availability of DNA for interacting proteins (88). Acetylation of 
the core histones by coactivators that possess histone acetyl transferase activity reduces 
the compressed state of the DNA and makes it accessibile for other transcriptional 
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factors. In addition to the acetylase activity of coactivators, the holoenzyme probably 
competes with histones for access to the DNA (89,101,143,155,197,221,240,248). 
There is a close connection between the physical stmcture of the DNA and the 
transcriptional machinery, since chromatin remodelling complexes facilitate the binding 
of sequence-specific transcription factors to the appropriate promoter and the DNA-
bound transcription factors possess the ability to recmit the chromatin remodelling 
complexes (83, 198). Apart from the DNA sequence elements that are located relatively 
close to the transcriptional start site, there are more distant regions that playa role in the 
activation and level of transcripiton, like enhancers, locus control regions and silencers 
(60, 84, 207). 
1.2 Transcriptiollal regulatioll of lysosomal genes 
After the early identification of promoter regions containing the canonical TATA 
- and CAAT boxes, an increasing number of genes have been characterized lacking 
these two domains in their transcriptional initiating site (194). Among these is a family 
of genes that encode proteins with essential metabolic functions and a wide tissue 
distribution, the housekeeping genes (41). The first two well characterized 
housekeeping genes were the murine hypoxanthine phosphoribosyl transferase (HPRT) 
and dihydrofolate reductase (DHFR) genes, soon followed by others, like adenosine 
deaminase (ADA), phosphoglycerate kinase (PGK) and adenine phosphoribosyl 
transferase (APRT, Refs. in 41). Members of this family are characterized by multiple 
transcriptional start sites and a high G/e content in the promoter region. Since the 
majority of the lysosomal enzymes have an essential function in the homeostasis of 
cells, it is not surprising that many of the isolated and characterized lysosomal genes 
have some features in common with housekeeping genes in their promoter (chapter 3 of 
this thesis, 54, 58, 70, 90, 91, 106, 107, 112, 120, 127, 130, 149, 150, 157, 160, 166, 
173,188,200,219,241,255). However, a number of hum all and mouse genes encoding 
lysosomal enzymes bear characteristics in their promoters, which suggest additional 
modes of regulation in comparison to housekeeping genes (chapter 3 of this thesis, 9, 28, 
38, 68, 71, 75, 118, 136, 142, 158, 161, 162, 184, 215, 224, 244). 
The identification of cis-acting elements in promoter regions is merely an 
indication that putative binding sites for specific transcription factors are present, but 
their functionality has to be shown ill vivo. Some of the lysosomal genes have been 
characterized in more detail, and I will discuss just a few examples. For the human 
aspartylglucosaminidase promoter, for instance, footpnnting analysis and electophoretic 
mobility shift assays showed that two SPt binding sites in the core promoter region are 
protected from DNAse I digestion. Whether or not the TATA-Iike sequence, present in 
this promoter, is functional remains to be seen, since it was not protected in the assay 
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(224). Analysis of the human glucocerebrosidase gene revealed that the ubiquitous 
expression levels of the gene depend on the availability of transcription factors, like AP-
I, PEA3 and a CAAT binding protein (118). Cathepsin B is presumably regulated by 
more than one promoter, which are responsible for a non-constitutive expression in spite 
of the presence of a housekeeping-like promoter (156, 157, 176): Expression of the 
gene encoding the human aspartyl proteinase cathepsin D is regulated by a composite 
promoter, leading to an estrogen-inducible, TATA-box dependent transcript and a 
constitutively expressed transcript (2, 21, 114, 116). The human p-glucuronidase gene 
appeared also to have two separate promoters that drive its expression, but this could 
only be demonstrated in transformed cells (188). In chapter 3 of this thesis I will discuss 
our findings on the expression of the murine PPCA gene that is regulated by the activity 
of two functional promoters. 
1.3 Additiollal fill/etiolls of lysosomal prate/lis 
Detailed analyses of the promoter regions of several lysosomal genes have 
suggested that they may be subjected to a level of regulation much tighter than 
anticipated by their overal degradative function. In addition to the effect of estrogen on 
the transcription of the human cathepsin D promoter, other lysosomal enzymes are 
influenced by honnones. For example, p-hexosaminidase, p-glucuronidase and p-
galactosidase are stimulated by testosterone, which leads to an elevated secretion in the 
mouse kidney (204). However, it was never demonstrated that the hormone directly 
induces the secretion, which could represent the secondary effect of an upstream, 
testosterone-dependent process. Nevertheless, it remains suggestive that the promoter of 
the p-hexosaminidase A gene contains two putative honnone binding sites, which could 
be responsible for the effect observed in the kidney (130). Similarily, we found that the 
murine PPCA gene carries a honnone responsive element, a ORE site, in the distal 
promoter, although it remains to be tested whether this element is functional and relates 
to the catalytic activity of PPCA to inactivate specific hormones (chapter 3 of this 
thesis). Other cathepsins, like cathepsins Band D, have also been implicated in the 
processing, secretion, activation and catabolism of hormones and other proteolytic 
enzymes (4, 46, 47, 129, 139, 157, 187, 199). The inducibility of a number of lysosomal 
genes may reflect the need for the encoded protein to be active under certain 
physiological conditions in order for a cell to cope with a defined substrate load. 
Several lysosomal enzymes, including members of the cathepsin family of 
proteases, acid phosphatase, a-mannosidase, arylsulfatase, p-galactosidase, p-
glucuronidase and p-N-acetylglucosaminidase have been implicated in cell proliferation 
and tumor growth (see table I in 15). The increase in specific activity of these lysosomal 
proteins in tumor tissues apparently correlates with the metastatic and invasive potential 
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(40, 57, 98, 108, 168, 191, 193, 251, 256). However, it is not proven yet that the 
observed increase in enzyme activity is the actual cause for the growth or malignancy of 
the tumor. Glucocerebrosidase, for instance, was shown to be upregulated in 
transformed cells, but these cells divide more frequently, are metabolically more active 
and hence may require higher levels of degradative enzymes. Therefore, the induced 
expression of lysosomal enzymes could be merely a consequence of the transfomlation, 
rather than the cause (118). Nevertheless, a change in subcellular localization, from 
lysosome to plasma membrane, of cathepsins B, D and L, as well as /l-N-
acetylglucosaminidase was observed in tumors with high metastatic potential (168, 193, 
256). Furthermore, it was shown that a number of lysosomal enzymes, including PPCA, 
cathepsins Band D, have an intrinsic catalytic activity at neutral pH, supporting the idea 
for a functional role of these enzymes outside the acidic enviromuent of the lysosomes 
(18,79,93,256). Together, these observations support the idea that lysosomal enzymes 
facilitate the invasiveness of tumors by degrading the extracellular matrix (6, 102, 146, 
168, 192, 220, 256). Two of the major constituents of the extracellular matrix are 
laminin and collagen type IV, both of which can be degraded by cathepsin B ill vitro 
(16,93). Degradation of these two stmctural proteins has been related to tumor invasion 
and metastasis as well as a poor clinical prognosis (65, 97). These processes are thought 
to be controlled by multiple proteases (256). In this pathway, cathepsin D can activate 
procathepsin B, elastase, cathepsin G and urokinase-type - and tissue-type plasminogen 
activator. Cathepsin B, in tum, may directly or indirectly act on other proteases and 
subsequently activates pro-urokinase-type plasminogen activator, which then catalyzes 
the conversion of plasminogen into plasmin. Plasmin can degrade components of the 
tumor stroma and may activate gelatinases and various matrix metalloproteinases (see 
also 251). Active proteolytic enzymes in the extracellular space may cause severe 
damage to tissues and lead to serious pathologic conditions by irreversibly hampering 
the nonnal physiological functions. 
Different hypotheses have been postulated to explain the apparent correlation 
between tumorigenic potential and a higher lysosomal enzyme activity (15), which 
include: 1) Proliferating - and dividing cells generally have a higher rate of metabolism. 
2) Certain types of tumors have been shown to contain an increased rate of pinocytosis. 
3) Differences between intra lysosomal pH of tumor cells and nonnal cells. 4) Both 
apoptotic and necrotic cells in tumorigenic tissue may secrete or expel lysosomal 
enzymes in the interstitium of the tumor, resulting in an averal increase in extracellular 
enzyme activity. Other physiological, cell proliferative processes are also accompanied 
by an increase in the activity of lysosomal enzymes, such as tissue regeneration (119), 
bone resorption and remodelling (13, 33, 165) and the involution of the utems after 
partus (43). 
Finally, lysosomal enzymes, and in particular lysosomal proteases, have been 
implicated in different immunological reactions. Cathepsin D apparently plays a role in 
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T-cell cytotoxicity (61,144), antigen processing (126, 191,231) and inflammation (4), 
while cathepsin B is secreted by macrophages during an inflammatory response (159). 
Cathepsin L and, most likely, cathepsin S control the processing of the invariant chain 
(Ii) in cOllical thymic epithelium and bone marrow-derived antigen presenting cells, 
respectively (27, 125, 164,237). In contrast to these ill vitro obtained results (111, 164, 
237), it was shown recently that, although required, both cathepsin Band D are not 
essential for the MHC class II mediated antigen processing (34). In the case of PPCA, 
thrombin-activated human platelets release the lysosomal enzyme into the extracellular 
space. This secreted fonn, active as deamidase at pH 7.0 could participate in the local 
inactivation of peptides implicated in inflammatory processes, like substance P and 
some of the bradykinins (this thesis, 79). Lysosomal N-acetyl-a-neuraminidase 
modulates immunological reactions by controlling the sialylation status of specific cell 
surface molecules. These studies will be discussed in depth in chapter 6. 
In conclusion, although the majority of the lysosomal enzymes are encoded by 
genes containing promoters with typical features of housekeeping genes, a number of 
them have characteristics and activities, which suggests a more specialized mode of 
regulation: like (in) activation of bioactive peptides and pro-enzymes, immunological 
reactions and cell-proliferative mechanisms. In spite of the fact that some lysosomal 
enzymes are implicated in additional non-lysosomal functions, no clear phenotypic 
manifestations related to these functions have been described yet in patients deficient for 
one of these enzymes. These phenotypic abnommlities may be difficult to recognize, 
unless they can be mimicked and studied in animal models. 
1.4 Lysosomal storage disorders 
Lysosomal storage diseases comprise a group of over 40 human disorders of the 
metabolism caused by genetic lesions in one of the genes encoding lysosomal proteins. 
With the exception of two X-linked disorders, Fabry disease (a-galactosidase) and 
Hunter syndrome (a-L-iduronate-2-sulfatase), all lysosomal storage disorders are 
inherited as autosomal recessive traits. Although individual diseases can be very rare, as 
a group they have an incidence in the humau population of 1:1500 life birth (1, 55,128, 
163). Some disorders are found at higher frequency in specific eHmic groups, because 
of their genetic isolation, like the Ashkenazi Jews (Gaucher disease, Tay-SacllS disease 
and Niemann Pick disease, 55), the Japanese (adult fomls of galactosialidosis and GMI 
gangliosidosis, 29, 186,203) and the Finns (aspartylglucosaminuria, 216). Lysosomal 
diseases are subdivided into glycolipidoses, glycoproteinoses and 
mucopolysaccharidoses, depending on the major type of substrate that is accumulated. 
In addition, the routing of normal enzymes towards the lysosomal compartment or the 
export of the hydrolytic products to the cytosol can be affected (reviewed in 1, 55, 128). 
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The substrate(s) in the pathway of the affected enzyme is (are) progressively 
accumulated in the lysosome. In time, numerous and enlarged lysosomcs will populate 
a cell, leading to cellular malfunction and eventually to deterioration of the organ/tissue. 
Lysosomal hydrolases are active towards a variety of substrates, because they recognize 
linkages between sugar moieties, rather than a single compound. Therefore, the storage 
products in a diseased cell or tissue can be very heterogeneous. 
The genetic basis of lysosomal disorders can be relatively simple, but the 
presence of lysosomes in virtually evelY cell type makes the clinical phenotype of 
affected individuals rather complex. In general, these diseases display a wide range of 
clinical manifestations that include eNS involvement, skeletal malformations, eye 
abnonnalities, cardiovascular problems and organomegaly. Patients can be grouped into 
clinical subtypes depending on the age of onset of the disease and the severity of the 
symptoms: early infantile, late infantile and juvenile/adult (55, 128). The discrimination 
between the three subtypes is not absolute and they often overlap, making the exact 
clinical outcome difficult to predict. In general, however, one can apply the Olle that the 
earlier the onset of the disease, the more severe the symptoms and the shorter the life 
expectancy (55). Moreover, the increasing knowledge of affected genes and the 
screening of mutations allow for a careful correlation between genetic mutations and 
clinical phenotypes, and in some instances a better diagnosis (56, 99, 185,206,259). 
17 
Table: Overview of mouse models for lysosomal storage disorders 
Pari A: Naturally occllrillg mOllse IIIl1tallls 
Affected gene Human disease References 
Galactosylceramidase (Twitcher Krabbe (85,86, 174) 
mouse) 
ll-glucuronidase Sly-syndrome (MPS VII) (8, 100, 178, 238) 
Npc I Niemann-Pick type C (105) 
N-acetyl-a-neuraminidase (SM/J) mild sialidosis (this thesis 
chapter 5, 20) 
Cathepsin L (furless) ? (125) 
Part B: MOllse lIIodels generated by targeted gene disYllption 
Affected gene Humall disease References 
ll-hexosaminidase A Tay-Sachs disease (24, 145,254) 
ll-hexosaminidase B Sandhoff disease (145,182) 
GM2 activator GM2 activator deficiency (103) 
Protective proteinl Cathepsin A (PPCA) Galactosialidosis (chapter 3) 
ll-galactosidase GM1 gangliosidosis (62, 113) 
a-galactosidase A Fabry disease (137) 
acid sphingomyelinase Niemann-Pick type AlB disease (74, 141) 
Arylsulfatase A Metachromatic leukodystrophy (67) 
Glucocerebrosidase Gaucher disease (222) 
Glycosylasparaginase Aspartylglucosaminuria (80, 82) 
a-L-iduronidase HurlerlScheie syndrome (MPS I) (23) 
Arylsulfatase B Maroteaux-Lamy syndrome (MPS VI) (44) 
a-glucosidase Pompe disease (7) 
acid lipase Wolman's disease/choiesteryl ester (39) 
storage disease 
sphingolipid activator (prosaposin) total sphingolipid activator deficiency (48) 
a-N-acetylga Iactosamini dase Schindler disease (243) 
acid phosphatase ? (171) 
cathepsin D ? (172) 
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1.5 MOllse models/or lysosomal storage disorders 
Both the low incidence of the individual diseases and the ethical implications 
limit the access to patients' specimens and material. Therefore, animal models that 
closely resemble the concspondillg human conditions can be extremely useful to study 
the pathogenesis of the diseases in more detail, which is cmcial for the development of 
therapeutic strategies. FurthemlOre, these models could answer important biological 
questions about the different pathways in which the affected enzyme is involved. The 
mouse is the most widely used animal model, since its biology and genetics are close 
enough to humans. with short reproduction cycles and multiple, large litters. Only a few 
naturally occuring murine models for lysosomal storage disorders have been identified 
(see table, part A 8, 85, 86, 105, 174, 178), but the possibility to generate targeted 
dismptions in the mouse genome has given scientists a powerful tool to manipulate and 
develop models of virtually every disease (19, 37, 110, 195,217,218). In addition, 
mouse mutants can be generated and studied that are either not paralelled by a human 
disease because of a high lethality, or are unlikely to exist, like double knockout mice. 
In general, the majority of these knockout mice resemble the most severe fOInlS of the 
human diseases. Several mouse models for lysosomal storage disorders have been 
generated, primarily to test the feasability of different clinical treatments, like bone 
marrow transplantation and enzyme replacement (see table, part B). I will briefly 
discuss a number of the murine models that have led to surprising obsetvations and 
unveiled discrepancies with the human disease. 
The p-hexosamindase isoenzYl11es A, B and the minor fonn S are heterodimers 
of the a and p subunits, or homodimers of the p - or a subunits, respectively. These 
isoenzymes degrade various glycolipids, but the catabolism of GM2 ganglioside in 
humans is controlled exclusively by p-Hexosaminidase A and the OM' activator protein, 
which promotes the solubilization of the substrate (59). Deficiencies in the genes 
encoding either the a subunit, p subunit or the activator protein result in the impaired 
degradation of Ow ganglioside and other glycolipids, which fonn the molecular basis of 
three diseases known as OM' gangliosidoses: Tay-Sachs (a subunit deficiency), 
Sandhoff (p subunit deficiency) and G,,, activator deficiency (g1l/2a). The OM' 
gangliosidoses share conml0n clinical manifestations, a massive accumulation of G~i2 
ganglioside and other glycolipids in neurons, and are characterized by a rapidly 
progressing neurological deterioration (55, 59). Mouse models have been generated for 
Tay-SacilS (hexa-I -, 24, 145, 208, 254), Sandhoff (hexb-I-, 145, 182) and the activator 
protein deficiency (g1l/2a-I-, 103), but, unlike the human diseases, their phenotypes 
differ considerably. Despite the detected storage of 0,,, ganglioside in some of the 
cortical neurons, the ltexa-I - mice do not show neurologic disturbances in their 
behaviour, are fertile and have a Bonnal life span. In contrast, the ltexb-I- mouse 
resembles the human phenotype and is severely affected displaying progressive 
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neurodegeneration, tremor. spasticity, hind limb rigidity. ataxia and muscle wasting, 
leading to paralysis and death. An alternative metabolic pathway solely present in the 
mouse causes the different phenotypic appearance in comparison with human. The 
"exa'/' and "exb'/' mice both accumulate G", ganglioside through the block in 
hexosaminidase activity, although the latter stores four times more of this substrate as 
well as an asialo derivative of G," ganglioside, GAl glycolipid, which is generated by a 
sialidase activity. This GAl glycolipid can further be degraded by p,hexA «(I. and p 
subunit heterodimer) and p-hexB (P subunit homodimer) isoenzymes, but not by p-hexS 
«(I. subunit homodimer). So, the "exa'/' mouse, which still has p-hexB activity, is able to 
catabolize considerable levels of GM2 ganglioside through the de-sialylation pathway, 
whereas the hexb-I - mouse, which solely has p-hexS activity, intracellularly stores both 
gangliosides (103, 182,201). The gIl/2a'/' mouse has a subtle neurological dysfunction, 
because it accumulates GM2 ganglioside at comparable levels as the he.ta-I - mouse, as 
well as low levels of GAl ganglioside. The catalysis of G A2 js hampered, but not 
completely blocked, which results in a more severe phenotype than the "exa'l- mouse, 
but less severe than the "exb'/' mouse. In conclusion, only the "exb'/' mice resemble the 
early-onset Sandhoff disease patients, whereas the "exa'/' and gll/2a'/' mice display a 
milder phenotype in comparison with the human disorders. The analysis of the three 
different GM2 gangliosidosis mice unexpectedly unraveled the importance of an 
altemative pathway in mice which catalyzes GM2 ganglioside using sialidase activity. 
Crossbreeding of the "exa'/' and the "exb'/' mice resulted in a double knockout 
mouse that completely lacked p-hexosaminidase activity, resulting in a neurovisceral 
storage disorder (181, 202). The phenotype of this double knockout mouse was more 
severe and extensive than that of the individual. single knockout mice and manifest at an 
earlier age. Interestingly, biochemical, clinical and pathological features of the double 
knockout mouse paralelled the mucopolysaccharidosis phenotype of the p-glucuronidase 
deficient mouse (MPS VII or Sly syndrome). This finding suggested that the lack of all 
three hexosaminidase isoenzymes, A, Band S, interferes with the catabolism of 
glycosaminoglycans as well. Although no patients have been described who completely 
lack all three isoforrns, the double knockout mouse turned out to be a valuable model for 
studying the biological processes involved in the degradation of glycosaminoglycans 
and the consequences of excessive accumulation of these compounds. 
Similarly to what was observed in the mouse models for the GM2 gangliosidoses, 
knockout mice lacking lysosomal acid p-D-galactosidase show phenotypic differences 
with the human disease. This disorder is characterized by the excessive accumulation of 
G," ganglioside, especially in the CNS. Patients with the early infantile type 1 fonn of 
GM [ gangliosidosis present with developmental arrest, progressive neurologic 
deterioration, facial dysmorphism, hepatosplenomegaly and generalized skeletal 
dysplasia (203). Dislllption of the p-galactosidase gene to generate a model for G"l-
gangliosidosis results in mice with a severe neuropathological phenotype, which 
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resemble the early infantile patients (62, 113). Neurons throughout the cerebrum, 
cerebellum, brainstem and spinal cord store excessive amounts of OMI ganglioside as 
well as its asialo derivative, GAl. The latter feature is not observed in patients and 
results from the activity of a sialidase that converts G," ganglioside into GAl. This is 
likely the same sialidase that desialylates GM2 ganglioside into GA2 in the G"2 
gangliosidoses mice. Patients with either OMI - or GM2 gangliosidosis primarily store 
sialylated glycolipids, and hardly the desialylated fonns, suggesting that the sialidase is 
less active towards these substrates in humans. In contrast to the human disease, a 
minimal involvement of the visceral organs was observed in the G/'o.[l-gangliosidosis 
mouse, which could be due to either partial redundancy in the catabolism of p-
galactosidase substrates in mice or a difference in the type of substrates converted (62, 
113). Absence of hepatosplenomegaly was also observed in other mouse models for 
lysosomal storage disorders, like in one of the two Niemann-Pick A models (74), in the 
Gaucher mouse (222), in the MPS I mouse (23) aud iu the naturally occuring twitcher or 
MPS VII mouse, which only displays splenomegaly (100, 238). On the other hand, 
hepatosplenomegaly is observed in other murine models for lysosomal storage disorders, 
like in galactosialidosis (this thesis) and in the second Niemann-Pick A mouse (141). 
Another unexpected finding emerged from the analysis of the Gaucher mouse 
model, which dies within 24 hours after birth, whether it completely lacks 
glucocerebrosidase activity through disruption of the gene (222), or it contains point 
mutations corresponding to mutatiOlis found in human patients (104). The extent of the 
storage in these mice was not sufficient to explain their rapid deterioration and short 
lifespan, but the mutant mice apparently succumbed through a compromised epidennal 
penneability barrier caused by defective glucosylceramide mctabolism (104, 222, 246). 
In addition, the glucocerebrosidase locus tumed out to be very complex, since a gene 
called melaxill overlaps with the 3' end of the lysosomal gene and is responsible for 
cmbryonal lethality when inactivated (12). Other genes that fall into this chromosomal 
region are Ilzl'ombospolldill 3, elk2, propill 1, cole 1 and the pseudogenes for 
glucocerebrosidase and lIletaxi" (247). So, the genetic complexity of the 
glucocerebrosidase locus may contribute or add to the phenotypic abnonnalities of the 
mouse. 
The model for metachromatic leukodystrophy, generated by disruption of the 
arylsulfatase A gene, closely parallels the human disease, although no widespread 
demyelination could be detected (67). The latter would explain the absence of 
devastating neurologic deficits in the mouse, which are present in the advanced stages of 
the human disease. Two possible explanations could explain this difference between 
man and mouse: first, the murine pathology is compared with the final stage of the 
human disease; secondly, an alternative metabolic pathway in the mouse, able to clear 
sulfatide, may result in a reduced accumulation of lipid compared to humans. 
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Two murine models have been made of which no human counterparts are 
known: lysosomal acid phosphatase (LAP, 171) and cathepsin D (172). In spite of the 
fact that acid phosphatase led De Duve to the discovery of Iysosomes, neither the 
physiological substrates, nor the function of this protein is known (3,31,32). The LAP-
deficient mouse displays progressive storage in podocytes and tubular epithelium of the 
kidney, conspicuous bone abnonnalities aud CNS storage in the microglia, epenedymal 
cells and astroglia. There is only one report on a patient who completely lacked acid 
phosphatase activity, but the molecular basis still remains speculative especially since 
no other cases have been described (124). The dismption of the tartrate-resistant acid 
phosphatase (TRAP, Acp5), an enzyme also found in the Iysosomes, generated mice 
with defective enchondral ossification and delayed mineralization of the cartilage (66). 
The cross mating of the LAP and TRAP mice resulted in a severe phenotype, which 
displayed excessive lysosomal storage in cells that were devoid of storage in the 
individual knockouts, for instance Kupffer cells, suggesting that LAP and TRAP may 
have overlapping activities (171). Mice lacking the aspartic protease cathepsin D (172) 
have reduced locomotion, progressive ataxia and die within 4 weeks after birth as a 
result of intestinal necroses accompanied by thromboemboli. The phenotype suggest 
that cathepsin D is important for limited proteolysis of specific proteins involved in cell 
growth or homeostasis, while its activity in bulk proteolysis is non-critical. However, 
no human patients have been described lacking cathepsin D, or any other lysosomal 
protease, like PPCA, which suggests a crucial physiological role of this protease ill vivo. 
It is also not known whether the absence of cathepsin D makes these mice less 
susceptible to metastatic types of cancer. 
In general, mouse models for lysosomal storage disorders, either naturally 
occurring or generated by gene-specific targeted dismption, have improved our 
knowledge about the biology of these diseases. Most of these models have proven to 
parallel the human disorder, although few discrepancies were observed, which relate to 
specific differences in biochemical pathways between man and mouse. Mouse models 
are better accessible to examine phenotypic changes at any given time during 
progression of the disease. This is particularly true for studying brain pathology, which 
would only be possible, if at all, at the final stages of the disease in humans. Mouse 
models can also be used to generate and develop new therapeutic protocols and curative 
agents. For this purpose, knowledge of the distribution of affected cells in different 
organs will be instrumental to understand and explain the benefits of treat men!. 
1.6 Treatmellts of lysosomal storage disorders 
Treatments to reduce or correct the clinical manifestations, like enzyme 
replacement therapy, allogeneic bone marrow transplantation and somatic cell therapy, 
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are based on the capacity of soluble lysosomal enzymes to be secreted by one cell type 
and recaptured by neighboring or distant cells (for review see 14). The process of 
internalization occurs through the interaction of the matillose-6-phosphate moiety 
(M6P), present on the precursor enzyme, and the cation-independent M6P-receptor at 
the cell surface (69). One can anticipate that if sufficient amounts of normal enzyme 
were administered to affected individuals, it would be endocytosed by deficient cells in 
different organs and ameliorate the phenotype. Treatment of eNS pathology remains, 
nonetheless, a real challenge and the availability of animal models closely resembling 
the Imman conditions has facilitated the experimental trials. 
Different animal models have been exploited to develop and implement 
therapeutic approaches in order to revert or diminish the deleterious effects of lysosomal 
storage disorders. I will describe a number of examples of experimental treatments that 
appeared velY promising. Bone marrow transplantation on fucosidosis dogs resulted in 
a gradual improvement of the eNS lesions, a slower progression of the neurological 
symptoms and a milder phenotype (210, 211, 213). Although bone marrow 
transplantation ofmucopolysaccharidosis type 1 dogs gave only 1-3 % of control values 
of ct-L-iduronidase activity in the brain, significant reductions of stored 
glycosaminoglycans in cerebrospinal fluid and meninges were noted, as well as 
improvements of ultrastructural lesions (189, 190). Treatment of ct-mannosidosis cats 
with allogeneic bone marrow seemed to improve the eNS pathology, except for the 
Purkinje cells in the cerebellum, and showed the presence of a-mannosidase positive 
staining in neurons, glia and endothelial cells (242). However, the absence of a detailed 
map of the affected regions in the brain of these animal models, makes the interpretation 
of these results difficult. The twitcher mouse, a model for globoid cell leukodystrophy 
or Krabbe disease, had a prolonged survival and improvement of locomotor ability after 
receiving congenic bone marrow before the onset of clinical symptoms (72, 257). 
Donor-derived foamy macrophages were present in the eNS at identical sites where 
brain lesions and globoid cells occur in the untreated animals, which resulted in an 
increase of galactosylceramidase activity and an improvement of myelination (72). 
Bone matTOW transplantation (131) or enzyme replacement (25) in feline 
mucopolysaccharidosis type VI resulted in an improvement of the skeletal development, 
in spite of the persistent presence of vacuolation in the cartilage. Newbom acid 
sphingomyelinase deficient mice, model for Niemann-Pick types A and B, received 
nomlal bone marrow, which resulted in a delayed onset of ataxia and a reduction of lipid 
storage in the eNS, aside from the complete correction of the reticuloendothelial system 
(117). In certain areas of the cerebellum the presence of Purkinje cells, which are 
completely absent in the non-treated animals, was noted, but eventually all the treated 
animals developed severe ataxia and died approximately four months older than the nOI1-
treated animals. Since it is difficult to assess precisely by histopathologic analysis what 
level of correction is necessary to regain or maintain eNS function, behavioral tests are 
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important to evaluate the effect of specific therapies. Although BMT of newbom MPS 
VII mice improved their biochemical, clinical and pathological abnomJalities, it did not 
ameliorate their behavioral abnonnalities (5). Recently, Sands ef al. showed that BMT-
treated MPS VII mice had less severe histologic alterations in the ear and auditory tests 
evoked nonnal brainstem responses (179). Weekly injections of recombinant Jl-
glucuronidase initiated at birth had comparable results, showing a less severe phenotype 
and histopathological improvements in brain and ear, as well as a better perfonnance in 
a spatialleaming test (133). However, since minute amounts of enzyme may already 
lead to improvement, functional tests seem to be required to assess the success of a 
particular treatment. For instance, although no Jl-glucuronidase activity could be 
measured in osteocytes, BMT on MPS VII mice reduced many of the bone 
abnonnalities (177). I will discuss in detail in chapter 4 our encouraging findings on the 
therapeutic approach we have chosen to treat our mouse model of galactosialidosis. 
In spite of these somewhat promising data, it is still necessary to optimize the 
current protocols or develop new methods, in order to be able to treat human patients. 
The major problem encoutered in the treatment of lysosomal storage disorders is the 
involvement of the eNS. The search for cells or drugs that have the capacity to pass the 
blood-brain barrier, the temporal dismption of the blood-brain barrier or the use of brain 
invasive teclmiques for the delivery of the corrective enzyme to the appropriate site may 
be extremely valuable. Since complete bone marrow engrafiment takes 4~6 weeks, 
substantial improvement of the long tenn therapeutic benefits of BMT is achieved by 
enzyme replacement both prior to and immediately after transplantation (180). To 
increase the efficiency of uptake by neuronal cells, the atoxic proteolytic fragment of 
tetanus toxin may be conjugated to the enzyme. This method has successfully been 
tested for Jl-hexosaminidase A ill vitro (36). An alternative could be the inseliion of 
overexpressing cells into a patient as a continuous source of corrective enzyme, which 
would act locally. Human p-glucuronidase overexpressing primary mouse skin 
fibroblasts were engrafled into .nco-organs and implanted in the peritoneal cavity of 
recipient mice, where they functioned for at least three months (122). Transplantation of 
either primary fibroblasts or a fibroblast cell line overexpressing p-glucuronidase into 
MPS VII brains only gave expression of the enzyme in the vicinity of the graft, and 
expression ceased after six months (214). Injection of murine neuronal progenitor cells, 
overexpressing either Jl-glucuronidase or Jl-hexosaminidase A, into the cerebral 
ventricles of newborn mucopolysaccharidosis type VII mice (196) or Tay-SacllS mice 
(92), respectively, resulted iu the presence of donor cells throughout the brain and the 
subsequent reduction of storage in neurons and glia cells. The application of this 
method is limited, because these neuronal cells were shown to engraft in a safe and 
efficient manner in the cerebmm when injected into the ventricles, but no migration of 
donor cells occurred into the cerebellum or brain stem (212). Other methods are also 
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tested, like the use of adenovirus-based therapies, but succes so far is limited (35, 134, 
135). 
It is uncertain whether damage to the brain is reversible or not, but therapies to 
treat or prevent CNS lesions are more successful when applied at early stages of the 
developing brain, while bone abnonnalities can be prevented and, if necessary, corrected 
through surgery. The main challenge remains the treatment of the CNS aud multiple 
approaches are currently being tested to target any therapeutic protein at those sites, 
provided of course that the protein is secreted, is stable in the interstitial space, and is 
efficiently internalized by different deficient cells. 
1.7 IlItl'OIluctioll to the e.\perimelltal work 
Lysosomal storage disorders can be classified into several groups, 
glycoproteinoses, glycolipidoses and mucopolysaccharidoses, depending on the 
substrates that are accumulated. Furthermore, few diseases comprise defects in protein 
biosynthesis (I-cell disease, pseudo-Hurler polydystrophy) and membrane transport 
(cystinosis, Salla disease). Galactosialidosis is a member of the glycoproteinoses and is 
biochemically characterized by a combined deficiency of acid p-D-galactosidasc and N-
acetyl-a-ncuraminidasc, resulting in the accumulation and/or excretion of primarily 
sialylated oligosaccharides and - glycopeptides in human tissues and body fluids 
(reviewed in 29). The primary deficiency is the serine carboxypeptidase PPCA, which 
foons an active complex in the lysosome with these two hydrolases (reviewed in 29). 
The clinical phenotypes can be classified into three subtypes: the early infantile, late 
infantile and the juvenile/adult fonn. In addition to the typical features of lysosomal 
storage disorders, such as coarse facies, cherry-red spots, vertebral changes, foam ceUs 
in the bone marrow and vacuolated lymphocytes, the early infantile ronn is 
characterized by hepatosplenomegaly, kidney failure, edema, heart involvement, ascites, 
mental retardation, fetal hydrops and a short life span. The late infantile group has 
hepatosplenomegaly, growth retardation, cardiac problems and absence of mental 
retardation, whereas the juvenile/adult subtype has mental retardation, ataxia, 
angiokeratoma, myoclonus and absence of visceromegaly (29). Regardless of the 
clinical subtype, the residual poD-galactosidase activity is between 5 and 15%, whereas 
the neuraminidase activity is usually reduced to less than 1 %. 
Cocuitivation studies of patients' fibroblasts demonstrated that acid P-D-
galactosidase and N-acetyl-a-neuraminidase activities could be restored by a cOlTective 
factor, secreted into the medium of noonal cells (30, 73). The exact nature of the 
primary defect responsible for galactosialidosis was then elucidated and the human and 
mouse cDNAs were cloned and characterized. They encode a 452 and 454 aminoacid 
precursor molecule, respcctively, that share 87% identity (30, 49, 51). The co-
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translational removal of the signal seqnence (239) yields an N-glycosylated precursor 
molecule of 54 leDa with an intramolecular "linker" domain of 2 leDa. The three 
dimensional structure of the human PPCA precursor homodimer has been elucidated by 
a combination of molecular replacement and two fold density averaging (169). The 
structure reveals an unusual inactivation mechanism of the zymogen. It is divided into a 
"core" domain, homing the active site, and a "cap" domain, encompassing the "linker" 
subdomain that covers the active site (169). The proteolytic removal of the "linker" in 
the endosomal/lysosomal compartment generates two subunits of32 and 20 IeDA, which 
remain associated through disulfide bridges (11, 51,121). Each subunit contains one N-
linked glycosylation site: the one on the 32 leDa subunit receives the mannose-6-
phosphate marker necessary for correct routing to the lysosome, whereas the one on the 
20 leDa subunit seems to be necessary for protein stability (121). The homodimeric 
precursor PPCA associates with the precursor p-galactosidase and neuraminidase shortly 
after their synthesis (121, 228, 258). The existence of this complex ill vivo has been 
biochemically demonstrated previously by copurification studies using affinity matrices 
specific for either p-galactosidase or PPCA (147, 152, 183,235,253). It is likely that 
this association is mandatory for stabilization and correct routing of the glycosidases to 
the lysosomal compartment. The half-life of acid p-D-galactosidase in fibroblasts from 
galactosialidosis patients is significantly reduced as a result of enhanced proteolytic 
degradation (229, 230). This is only partially true for neuraminidase that is retained in 
an endosomallprelysosomal compartment in the absence of PPCA. Recently, our group 
unravelled a new function of PPCA, that of a transport protein, which is required for 
neuraminidase to reach the lysosomal compartment (228). 
The primary structure of the protein shares homologies with yeast and plant 
serine carboxypeptidases and has a conserved catalytic triad, Cys-Ser-His, in the active 
site (49,51). Jackman ef al., and more recently Ostrowska ef al., showed that a protein 
isolated from thrombin-activated platelets resembled PPCA and had cathepsin A activity 
at acidic pH and esteraseldeamidase activity at neutral pH (79, 140). The 
carboxypeptidase activity of PPCA was shown to inactivate a selected number of 
bioactive peptides, like substance P, oxytocin and endothelin I (63, 77-79). By site 
directed mutagenesis, we have demonstrated that the cathepsin A activity is fully 
separable from the protective function ofthe protein (51). 
The isolation of the PPCA gene and cDNA has facilitated the identification of 
mutations present in patients with different clinical phenotypes (29, 55). We were able 
to correlate specific mutations with clinical phenotypes by analyzing the level of 
functionality of the mutant protein(s) in relation to its post-translational processing, 
subcellullar localization and stability (259). FurthemlOre, a number of aminoacid 
substitutions found in defective PPCA from different galactosialidosis patients with 
varying clinical severity have been modelled into the three dimensional stmcture of the 
PPCA precursor (170). A remarkable correlation appeared to exist between the impact 
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of the mutations on the molecular integrity of PPCA structure and the severity of the 
disease caused by the same mutation. The availability of the three dimensional stmcture 
facilitates mutagenesis and biochemical studies to probe the function of PPCA alone or 
in the context of the multi-enzyme complex. 
The already mentioned lysosomal storage disorder, sialidosis, also belongs to the 
group of glycoproteinoses. It is an autosomal recessive disease characterized by lesions 
in the N-acetyl-a-neuraminidase structural gene (216). There are two distinctive clinical 
types of sialidosis based on the age of onset and the severity of the symptoms. Type I is 
a mild fonn presenting in the teenage years, while the type II has severe symptoms with 
progressive CNS involvement and an early onset. Type I is characterized by cheny-red 
spots, progressive visual problems and generalized myoclonus. Type II is distinguished 
from type I by the presence of abnonnal somatic features, like coarse facies and 
dysostosis multiplex, progressive neurologic deterioration and mental retardation. The 
residual activity of the neuraminidase in affected individuals is between 0-10%, leading 
to the progressive storage of sialylated compounds (216). Sialidosis has a number of 
clinical features in common with galactosialidosis and in order to discriminate between 
the two disorders, enzyme activity assays need to be done. As mentioned previously, 
neuraminidase is in complex with PPCA and Jl-galactosidase, which can be co-purified 
in a high molecular weight complex (151, 152, 235, 253). Although this complex 
contains only a small percentage of the total pool of Jl-galactosidase and PPCA, it 
consistently contains all the neuraminidase activity. This implies that active 
neuraminidase can not be isolated separately from the complex (225-227, 232-235). 
The dependency of neuraminidase activity on PPCA was already known from the 
analysis of galactosialidosis patients. Adding exogenous PPCA to galactosialidosis 
fibroblasts resulted in a correction of the lysosomal storage, suggesting that 
neuraminidase resides in a pre-lysosomal compartment in order to associate with PPCA 
(49,50). 
Recently, we were the first to isolate and characterize the cDNA encoding 
human lysosomal neuraminidase using the computer database search programs 
available, soon followed by others (10, liS, 153). The isolation and characterization of 
the human gene showed that it is expressed as a 1.9 kb mRNA, resulting in a 43 kDa 
protein after cleavage of the signal peptide, which contains a "FRIP"-domain and five 
Asp-boxes (10, 115, 153). The primary sequence showed extensive homology with 
other members of the sialidase superfamily, including bacteria, rodents. protozoa and 
influenza virus. In spite of the homology, mammalian neuraminidase requires PPCA to 
be active, whereas the bacterial proteins function without the need for accessory 
proteins. The question remains whether mammals acquired the need for additional 
proteins, or bacteria may have lost this restriction. Furthennore, the three~dimensional 
structure of bacterial and viral sialidases revealed a common catalytic core with a 
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characteristic six-bladed Jl-propeller fold (26, 52). Since a number of critical aminoacid 
residues are conserved, it may be anticipated that the human neuraminidase has a 
comparable stmcture. The availability of the human cDNA has enabled the 
identification of several mutations in patients with different clinical phenotypes (l0, 
153). The responsible gene is mapped to the HLA region ou chromosome 6, which 
confinned an earlier assignment done after a family study of a patient with a combined 
neuraminidase and 2 I-hydroxylase deficiency (10, 64,138, 153). 
A naturally occurring mouse strain, SMlJ, was originally selected for its small 
body size, but biochemical analysis demonstrated an abnonnal sialylation pattem of at 
least four lysosomal glycoproteins (148, 250). The responsible gene was designated 
lIell-1 and was mapped by linkage analysis to the H2 locus on chromosome 17, which is 
the syntenic region to the human chromosome 6 (175, 249). In addition, these mice 
appeared to have specific immunological abnonnalities, which are thought to occur due 
to an altered processing of cell surface molecules present on a subset ofT-celis. (22, 94-
96, 205, 252). The lysosomal storage in these mice has no drastic impact on the 
phenotype, so this mouse could reveal interesting characteristics of neuraminidase, 
which would otherwise be overshadowed by storage in a full knockout. 
'rVe have isolated and characterized human and mouse PPCA genes with the 
intent to pinpoint regulatory elements that control the human and primarily the murine 
gene. The knowledge of the genomic organization of the murine gene was applied to 
develop a targeting vector to generate a mouse model for galactosialidosis. This model 
is a reliable phenocopy of the severe human condition and has been useful for studying 
the pathogenesis of the disease and the exploration of novel therapeutic approaches. 
Finally, given the dependence of neuraminidase on PPCA and the fact that 
galactosialidosis and sialidosis share similar features, we have isolated the lllurine 
neuraminidase gene. The cDNA enabled us to identify the mutation impairing the 
neuraminidase activity in the natural occuring 8M/J strain. Our findings and main 
conclusions are given in chapters 2-7. 
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Genomic organization of the murine protective protein/cathepsinA (PPCA) gene 
ABSTRACT 
The primary defect in the human lysosomal storage disorder galactosialidosis is 
protective protein/cathepsin A (PPCA). PPCA associates with acid-p-D-galactosidase 
and N-acetyl-a-neuraminidase and protects these hydrolases from degradation in 
Iysosomes. The lack of PPCA results in the combined deficiency of the two 
glycosidases, determining the nature of the storage products. Human and murine 
cDNAs have been cloned and the corresponding proteins extensively characterized. 
Recently, the genomic organization of the human gene has been reported. Here we 
describe the organization of the murine gene. The gene consists of sixteen exons, one 
more than the human, since the first two exons represent alternatively used 5'UTRs. 
Aside from exon Ia and 15, all exons are relatively small, ranging in size from 51 to 
179 nucleotides, and the introns vary in length from 88 to 830 nucleotides. The gene 
has been mapped to chromosome 2H4 and all exons are located in a 6.5 kb region. 
The characterization of the murine PPCA gene has been important for studying its 
expression pattern in different tissues and for the generation of the mouse model for 
galactosialidosis. 
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The human protective protein/cathepsinA (PPCA) is a lysosomal carboxypeptidase involved 
in the inherited metabolic storage disorder galactosialidosis (for review see I). The clinical 
phenotypes of the disease can be grouped into three subtypes, depending on the age of onset and the 
severity of the symptoms: early infantile, late infantile and juvenile/adult. Galactosialidosis is 
biochemically characterized by the combined deficiency ofacid-p-D-galactosidase and N-acetyl-a-
neuraminidase, which are in complex with PPCA in the lysosome. The interaction with PPCA 
protects the two glycosidases from degradation in the acidic environment of the lysosome. Aside 
from the protective function and fully separable from it is the cathepsin A activity ofPPCA which 
is able to cleave bioactive peptides, like substance P, endothelin I and oxytocin (6, 7, 4, 5). The 
human and murine cDNAs have been cloned and characterized (2, 3) and the chromosomal 
localization of the respective genes have been mapped to chromosome 20q13.1 and 2H4 (10, II). 
Recently the genomic organization of the human gene was published (9), and we now report on the 
murine counterpart. 
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Figure 
Genomic organization orthe mouse PPCA gene, showing the position or the exons and introns. The hvo 
alternatively used 5'UTR-encoding exons and the 3'UTR part of exon XV are represented as gray boxes. 
TIle two lambda phage inserts, L 1 and L2, and the eDNA probes used to characterize these inserts are 
shown below the genomic organization. Each probe is designated on the basis of the eDNA sequence they 
span. 
A mouse genomic library. derived from inbred strain 129, was screened with a full length 
mouse cDNA probe. Two independent phage inserts were isolated and analyzed with restriction 
enzymes, followed by hybridization of Southem blots with different PPCA specific cDNA probes 
(Fig. I). The inserts, with estimated sizes of about 13 kb, appeared to partially overlap and together 
encompassed the 5' and 3' ends of the cDNA, indicating that we had isolated the complete mouse 
PPCA gene. The inserts were subcloned using the unique flanking Sail sites and sequenced with 
exon specific oligonucleotides. 
The murine gene consists of 16 exons (Fig. 1). one more than the human gene, since it is 
transcribed from two different promoters. The distal promoter contains a typical TAT A-box, while 
the proximal one is GC-rich. The two promoters give rise to the alternative usage of the first two 
exons, exon la and lb, representing different 5'UTRs (8). The exons of the murine gene are localized 
in a 6.5 kb region, which excludes the promoter region and other putative upstream and/or 
downstream regulatory sequences. The sizes of exon Ia and lb have been deduced from RNase 
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pratection assays. Exon Ia has a well-defined length of231 bp, being initiated from the TATA-box 
containing promoter. In contrast, exon Ib has multiple start sites varying in size between 25 and 45 
bp, a feature common to other GC-rich, TATA-Iess pramoters (8). In spite of the high degree of 
sequence similarity, the mouse exon Ia has no functional human counterpart. In contrast, exon Ib 
is the murine homolog of the human exon I, which is at least 26-27 nucleotide long (8, 9). The 
variation in size of murine exons 7, 8, 9 and II compared to their human counterparts is the result 
of a calculation error by Shinunoto (9). The differences in exon 2 and 10 represent genuine changes: 
the murine exon 2 is 15 nucleotides shorter than the human resulting in a predicted signal peptide 
of only 23 amino acids compared to 28 in the human precursor protein; exon lOis 3 nucleotides 
shorter in the mouse, explaining the absence of the lysine 265 present in the human pratein sequence. 
As shown in Table I, all exon/intran boundaries comply to the gtJag rule, and the splice sites 
have the consensus for correct splicing. The exon/intran boundaries share a considerable degree of 
homology between the human and mouse genes, although the intran sizes are not entirely conserved. 
However, the overall organization afthe two genes is identical, with illtrons 7, 8,11 and 12 being 
relatively large compared to the other intrans. Intran II is the only one that has a significant size 
difference, being 1.84 kb in the human and only 0.58 kb in the mouse sequence. Comparison of a 
number of the murine introns with the conesponding human illtrons, revealed that some of them 
share homologous sequences, which may imply important regulatory features of these introns in 
transcriptional regulation or splicing. Knowledge of the organization of the murine gene has been 
important for the creation and analysis of the PPCA knockout mouse (12). The structural 
organization is facilitating the analysis ofthe endogenous expression of the PPCA gene in different 
tissues of the adult mouse. Future research may enable us to localize intronic regions that are 
important for the regulation ofthe two genes. 
Sizes and locations of exons and introns and the sequences at the exon·lntron boundaries 
Exc= Introns 
number and size eDNA position 5' splice site 3' splice site intron size 
Ia 231 -231 - -1 ~ gtaggtgccc .... cctcctgcag ATGCCC B30 (la) 
Ib 22-40 -22 - -1 GCAGAG gtacggagat. ..• cctcctgcag ATGCCC 179 (lb) 
II 179 1-179 Cl'ACIG gtgcttggct •..• tccttcccag G'ITIGT 112 (2) 
III 112 180-291 'l"I'I'C'l'G gtgagttgac .... tcctccccag ATCCAG 259 (3) 
IV 51 292-342 AACCTG gtactcctgg •... cctcccccag ATI"GCC Be (4) 
V B7 343-429 N.:.l;QlJJ, gtgag tctgt. •.. gcatcctcag Gl'GGCG 222 (5) 
VI 156 430-585 Cl'TCAG gtgcagggca .... tgtttcgcag GGGCI'G 316 (6) 
VII 92 586-677 &>N:NJ gtaaaggaag .••. tgatccacag 1\C'lTl"G 488 (7) 
VIII B5 678-762 llACAAT gtgagctcct ..•. gtcttcacag C'l'CCIG 474 (B) 
IX 92 763-854 M:ATAG gtaggtgctg .... tttctgacag ~ 104 (9) 
X 76 855-930 CC'I'G.\G gtatgcgggg .... ccccccccag GCACI'G 101 (10) 
XI 140 931-1070 GTGCM. gtgagcttcc •..• tccccggcag CTl"CI"I' 5BO (11) 
XII 76 1071-1146 'I:CN:1IG gtatgtgtgc •... cctattccag MATAC 4BB (12) 
XIII 90 1147-1236 CAGAAG gtaaagttgc .... gatgggacag ATGGAG 115 (13) 
XIV 105 1237-1341 A'ICMG gtaggacttt .•.. ttgctcccag OOIGCC 199 (14) 
xv 433 1342-1774 CTl'CCA 
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Identification of the Promoters for the Human and Murine 
Protective Protein/Cathepsin A Genes 
ROBBERT J. ROTTlER and ALESSANORA 0' AZZO 
ABSTRACT 
Protective protein/cathepsin A (PPCA) is a lysosomal serine carboxypeptidase that forms a complex with p. 
galactosidase and neuraminidase. Its deficiency in humans leads to the lysosomal storage disorder galae-
tosialidosis (GS). The pathologic manifestations in patients relate primarily to the severe deficiency of neu-
raminidase, and the physiological significance of cathepsin A activity remains unclear. The mouse model of 
GS, which closely resembles the human phenotype, shows that cells from numerous tissues, especially the cen· 
Iral nervous system (eNS), arc affected by this disease. To study the site and le'\'el of expression of PPCA 
mRNA in murine and human tissues, we analyzed the promoter regions of the: corresponding genes. Their 5' 
genomic regions were strikingly similar in both organization and sequence. A single 1.8~kb PPCA transcript 
is present in humans, whereas mouse tissues have a major 1.8~kb and a minor 2.0·kb transcript, both of which 
are differentially expressed. These two mouse mRNA species differ only in their 5' untranslated region (UTR). 
The larger mRNA, unique to mouse, is transcribed from an upstream TATA-box-containing promoter, which 
is absent in the human gene. The downstream promoter, which transcribes the 1.8-kb mRNA common to hu-
man and mouse, has characteristics of housekeeping gene promoters and contains putative Spl binding sites 
and three USFfl\.fLTF sequences. III vitro studies demonstrated that expression from the downstream pro-
moter is higher than that from the upstream mUl'lne-speclfic promoter. III sihl hybridization of mouse tissue 
sections identified regions of the brain that preferentially express the 2.0-kh transcript. Our results imply that 
PPCA mRNA distdbution and regulation in murine tissues differs fI'om that in human tissues. 
INTRODUCTION 
HUMAN PROTECIlVE PROTEIN/CATHEPSIN A (PPCA) is a lyso-somal carboxypeptidase whose deficiency in humans re-
sults in the lysosomal storage disorder galactosialidosis (OS; 
for review, see d'Azzo et at., 1995). Three clinical phenotypes 
are distinguished, depending on the age of onset and severity 
of the symptoms: early infantile, late infantile, and 
juvenile/adult. The biochemical hallmark of this autosomal re-
cessive disease is a secondary combined deficiency of two gly-
cosidases: ,B-D·galactosidase (EC 3.2.1.23) and N-acetyl-a-neu-
raminidase (EC 3.2.1.18). These deficiencies cause excessive 
accumulation and excretion of sialylaled oligosaccharides in pa· 
tients' tissues and body fluids. PPCA associates with the two 
glycosidases, fonning a stable and active three~enzyme com-
plex in the Iysosomes. In addition to its protective function, 
PPCA exerts carboxypeptidase activity at acidic pH apd es-
terase/carboxyl terminal deamidase activity at neutral pH; both 
activities are absent in galactosialidosis patients (Galjart et at., 
1991; Itoh et at., 1993). The catalytic activity of PPCA is 
thought to be responsible for the local inactivation of selected 
bioactive peptides, including substances P, endothelin I, and 
oxytocin (Jackman et at., 1990, 1992; Hanna et af., 1994; Itoh 
e/ al., 1995). 
The human PPCA mRNA and its mouse homolog share 85% 
identity in their coding regions and 72% identity in their 3' un-
translated region (UTRs) (Galjart et al., 1988, 1990. 1991). The 
human gene localizes to chromosome 20 and the murine locus 
is found on the synthenic chromosome 2 (Wiegant et al., 1991; 
Williamson et at., 1994). The genomic organization of the hu-
man gene was recently reported (Shimmoto et al., 1996). Pre-
viously, we showed that the major PPCA mRNA species in 
Department of Genetics, St. Jude Children's Research Hospital. Memphis. TN 38105. 
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mouse is ubiquitously, but differentially, expressed (Galjart et 
al., 1990). Here, to gain further insights into the regulation of 
human and mouse PPCA expression, we characterized and com-
pared the promoter regions of these genes. We found two dif-
ferent promoter regions within a 1.5-kb fragment of the mouse 
PPCA gene: one proximal, with characteristics of a "house· 
keeping" gene promoter, which gi\'es rise to a 1.8-kb transcript, 
and one distal, which contains a consensus TATA box and gen-
erates a longer 2.0·kb transcript. These mouse PPCA mRNAs 
have different 5' UTRs. which are spliced to yield the same fi-
nal protein product. The short 1.8-kb transcript is expressed 
more abundantly than the 2.0-kb species, which ill \'jvo appears 
only in specific regions of the brain. Despite the high degree 
of homology between the murine and human 5' genomic se· 
quences, the human gene has apparently lost its distal promoter 
activity, and, therefore, may not be subject to the Same type of 
transcriptional regulation as the murine gene, 
MATERIALS AND METHODS 
Materials 
A MEG-Ol eDNA library was a gift of Dr. Hans C. Clevers 
(University Hospital, Utrecht, The Netherlands). Restriction en-
donucleases and DNA modifying enzymes were purchased 
from Bethesda Research Laboratories, Inc., Boehringer 
Mannheim. New England Biolabs, Inc., and Promega Diolec. 
The RACE-5'-amplifinder kit was supplied by Clontech. Inc., 
the BCA protein assay reagents by Pierce Chemical Co" and 
the fmol sequencing kit by Promega Biotec. All enzymes and 
kits were used according to the directions provided by the man-
ufacturers, (a-32PJdATP (3.000 Cilmmole), {a_32p]UTP (800 
Cilmmole), (y-32p]ATP (3,000 Cilmmole), (a-35S1dATP 
(>1,000 Cilmmole), [a_3SS]UTP (>1,000 Cilmmo!e), and 
[14C]chloramphenicol (55 mCifmmole) were provided by 
Amersham Corp. and Dupont NEN Research Products. All 
other reagents were obtained from standard commercial sup-
pliers. 
RNA isolation and NOrlhem blotting 
Total human RNA from MEG-Ol and XP-2 cell lines and 
mouse tissue RNA were isolated with the LiCVurea method as 
previously described (Auffray and Rougeon, 1980). 
Poly(A)+RNA was isolated according to Promega's polyAtract 
system, A total of 1-2 p.g of poly(A)+RNA was run on a 1% 
agarose gel containing 0,66 M formaldehyde, transferred onto 
a Zeta·Probe membrane (Dio-Rad), and hybridized under stan-
dard conditions (Sambrook et at., 1989). Human multiple tis-
sue Northern blots were purchased from Clontech and hy-
bridized according to the manufacturer's protocol. 
Cell cll/tltre and traflSfectiolls 
The megakaryoblast cell line MEG-OI, kindly provided by 
Dr. Hans C, Clevers (University Hospital. Utrecht, The Nether-
lands), was obtained from Dr. Saito (Nagoia Uni\'ersity, Japan). 
The XP·2 SV40·transfonned cell line was from a Xerodenna 
pigmentosum patient (European Cell Bank, Rotterdam, The 
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Netherlands, Dr. \V.J. Kleijer). ~1EG-OI cell line was cultured 
in RPMI·I640 medium supplemented with 20% fetal bovine 
serum (FBS) and antibiotics. XP-2 and NIH-3T3 cells were cui· 
tured in Dulbecco's modified Eagle's medium (DMEM) sup-
plemented with 10% FRS, glutamine, and antibiotics. COS· I 
cells were cultured under the same conditions except the 
medium was supplemented with 5% FRS. Both cell lines were 
seeded at 5 X lOS cells/lO·cm dish 12-24 hr prior to transfec-
lion as described previously (Graham and Eb, 1973). Protein 
extracts of transfected cells were prepared 36 hr post transfec-
tion and were tested for chloramphenicol acetyl transferase 
(CAT) activity (Gorman et al., 1982) and p·galactosidase (p. 
Gal) activity (An et at., 1982). The protein concentration in 
each extract was also detennined (pierce Chemical Co.). The 
ratio of converted [14C]chloramphenicol to the tolal input 
[14C]chloramphenicol was detennined with a Phosphorimager 
(Applied Diosystems). 
Rapid amplification of cDNA ends polymerase 
cIJain reaction and reverse transcriptase polymerase 
chain reaction 
First-strand PPCA eDNA was prepared using total RNA 
from several mouse tissues and human fibroblasts nnder stan-
dard conditions. We used an antisense oligonucleotide, primer 
R. located at human eDNA position 286-305 (5' -GGGCCAT-
GCTCTGTGAGGAG-3') or at mouse eDNA position 501-520 
(5'-CACCATCTGGCTGGATCAGA-3'), Rapid amplification 
of eDNA ends polymerase chain reaction (RACE-PCR) of this 
eDNA was performed according to the manufacturer's direc· 
tion using a PPCA-specific, antisense oligonucleotide con-
taining an Eco RI site (primer I, human eDNA position 
200-181, 5' ·GGAA TICAGT AGTGGAGGTGCITGGA·3'; 
mouse cDNA position 412-393, 5'-GGAATICGTICTGC-
GACTCCACAAAC-3') and the RACE ampJifinder, sense 
primer provided by the manufacturer. 
The re\'erse transcription (Rn-PCR mix contained the anti-
sense primer 1 and a transcript specific, sense primer, the se-
quence of which comes from exon la (primer 2, human genomic 
region 6-25, 5'-GGAATICTGCTCAATGCGCAGATATGG-
3'; mouse exon Ia position 11-30, GGAATICGATGCGCA-
GATAGGGITCAA-3'), The other primer sequence comes 
from exon Ib (primer 3, human, 5'-GGAATICGGCAAG-
GACGCGGGGGAGCAG-3', mouse, 5'-GGAATICAAGGA-
AGACGCAAGGAAGCAG-3'). The PCR products were elec· 
trophoretically separated on 1.5-2% agarose gels, blotted. and 
hybridized. If we omitted the first-strand eDNA synthesis step, 
we got no PCR products, which indicates that our RNA sam-
ples did not contain genomic DNA. 
Construction of CAT vectors 
The backbone of all CAT vectors was the pBLCA TI, which 
had been slightly modified to create pBLCAT6 (SchtiJer et 01., 
1989). Most constructs were made by subcloning PCR-ampli-
fied genomic fragments, which contained a 5' Sal I restriction 
site and a 3' Bam HI restriction site, upstream of the cat re-
porter gene. Cloned DNA fragments were sequenced to exclude 
mutations. Antisense clones were created by subcloning the 
PeR-amplified genomic promoter fragments into the Bam HI 
and Xlw I restriction sites of the pBLCAT6 vector. Each pro· 
moter construct (10 Ilg) was transiently transfected with a Rous 
sarcoma virus (RSV) promoter-driven lacZ reporter gene con-
struct (2 Ilg) to check transfection efficiency. 
RNase protection and in situ hybridization 
The RNase protection assays were performed using the RPA 
II kit from Ambion by following the manufacturer's protocol. III 
siflt hybridization and signal detection was performed according 
to the method of Simmons et af. (1989). Eight- to 12-week·old 
FVB mice were perfused with 4% paraformaldehyde in phos-
phate buffer pH 7.2, and brain specimens were isolated and sat-
urated in 25% sucrose. Cryosections from these brains were hy-
bridized for 16-20 he at 50PC. The washed slides were then 
dipped in Kodak NTB-2 autoradiography emulsion and exposed 
for 8 days (cDNA probe) or 21 days (Exla probe), at which time 
they were processed by using Kodak developer D-19 and fixer. 
The slides were counterstained with 0.1 % toluidine blue. 
RESULTS 
Idelltijication of a new 5' exoll in the human alld 
murine PPCA gelle 
The human PPCA eDNA, isolated from a testis library, and 
its murine homolog, isolated from a brain and testis library, 
shared close homology throughout their coding regions (85%) 
and 3' UTRs (72%) (Galjartetaf., 1988, 1990). However, com-
parisons of the murine and human 5' VTRs could not be done 
because the human clone lacked a 5' VTR. Therefore, we cloned 
a new full-length PPCA cDNA from a human megakaryocyte 
library. ThIs cDNA was identical to the clone derived from the 
human testis library (Galjart el of., 1990) with two exceptions. 
It extended 5' into a short UTR of 22 bp that shared no ho-
mology with the murine 5' UTR. And, instead of the original 
8 CTG codons (Leu) in the 5' sequence coding for the signal 
peptide, the new clone only contained 7 leucine codons. This 
difference appeared to be a polymorphism, because a group of 
50 nonnal individuals had either 7, 8, or 9 CfG triplets in this 
region (unpublished data). 
To ascertain whether the human and murine sequences do 
indeed diverge in their 5' UTRs, we amplified additional 
mouse 5' sequences from brain, kidney, and liver total RNA 
by using RACE-PCR. We isolated nOYeI murine cDNA clones 
containing short 5' UTRs that were homologous to the 22-bp 
UTR of the human cDNA. Curiously, all of our amplified 
clones contained this short 5' UTR, although some differed 
slightly in the length of their 5' extension. None of the clones 
included the 213-bp·long 5' UTR oflhe original murine PPCA 
cDNA clone that was isolated from a mouse brain library (Gal-
jart el al., 1990). This could be attributed to either tissue-spe-
cific expression or low expression of this transcript in differ-
ent tissues (see below). In contrast, RACE-PCR on human 
fibroblast RNA generated cDNA clones that exclusively con-
tained the 22·bp 5' UTR. Thus, both human and mouse PPCA 
mRNAs Contain the short 22-bp 5' UTR, but only certain 
mouse tissues contain a small pool of transcripts with the 
longer 213·bp 5' UTR. 
Sequence analysis of the human and mouse PPCA 
promoter regions 
To define the origin of the two 5' VTR sequences, we cloned 
and analyzed these regions from the human and mouse 
genomes. The two PPCA genes shared slriklng similarities in 
the organization and sequence of their 5' genomic regions (Fig. 
I). Both the human and mouse 5' UTR sequences were encoded 
by a single exon, called exon I in human and Ib in mouse. This 
exon was located 0.18 kb upstream of the first coding exon 
(exon II in both species). The long 213·bp murine 5' UTR se-
quence comprised an exon, located 0.8 kb upstream of exon II 
and shared 78% sequence homology with the human gene se-
quence at the corresponding positions. Our results strongly sug-
gested the presence of two promoters in the mouse gene. 
Direct sequence analysis of the putative promoter regions of 
both the human and mouse PPCA genes revealed that the mouse 
distal promoter contained a TAT A box and two imperfect 
CAAT boxes: one at position -95 (CCAAG) and one at -125 
(CCCAT). A putath'e glucocorticoid-responsive element 
(TGTCCf; Karin et of., 1984) was found at position -150, and 
two AP-2 boxes (CCCAfCNG/CG/CG/C; Williams el 01., 1988) 
at positions -90 and -174, respecth·ely. Although the human 
sequence was highly homologous in this area (Fig. I), it did not 
encode either the TATA box or the imperfect CAAT boxes. 
The proximal promoter had all the features of a typical house· 
keeping gene promoter (Dynan, 1986): it lacked TATA and 
CAA T boxes, was G/C rich, and had two Spl-binding sites (Fig. 
I). This promoter also contained three USF/MLTF motifs (Hen 
et af .• 1982; Carthew el af., 1985; Sawadogoand Roeder, 1985), 
which were conserved between human and mouse. 
PPCA trallScripts in mouse and humall 
The identification of two different 5' UTRs in murine PPCA 
cDNAs led us to analyze the extent to which the mRNAs de-
rived from these cDNAs is expressed in different tissues. Pre-
vious studies of total RNA from human fibroblasts identified 
only a single PPCA transcript of 1.8 kb when a human PPCA 
eDNA lacking a 5' UTR was used as a probe (Galjart et af., 
1988). Here, we analyzed multiple human tissues on Northern 
blots hybridized with a full-length cDNA probe that included 
the 22-bp 5' VTR. A single, ubiquitously expressed transcript 
of 1.8 kb was detected in all tissues (Fig. 2A). Because the 
mouse exon la·containing cDNA was isolated from a brain Ii· 
brary, we also analyzed different human brain regions; how· 
ever, only a single PPCA mRNA species was detected (Fig. 
2B). A human genomic probe containing the mouse exon la-
homologous region did not hybridize to any tissues tested (data 
not shown). 
Although every mouse tissue we tested contained the 1.8-kb 
PPCA mRNA, the levels of this transcript varied considerably 
from tissue to tissue, suggesting that PPCA expression is reg-
ulated either at the level of transcription or by mRNA turnover. 
In addition, the probe recognized a 2-kb transcript that was pre-
sent in variable amounts and only in some tissues (e.g., brain, 
spleen, heart, liver and kJdney). 
To explain these results, we hybridized a mouse multiple tis-
sue, poly(A)+RNA blot with an exon la-specific probe. This 
probe detected exclusively the larger of the two transcripts (Fig. 
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FIG. 1. Schematic representation of the human and mouse 5' genomic regions (top), and sequence comparison of their 5' VTRs 
and adjacent promoter regions (bottom). Percentage of homology is indicated. The 5' UTR exons are in boldface and putative 
transcription factor binding sites are indicated. Two imperfect CAAT boxes arc underlined in the murine distal promoter (bot-
~om, left). The transcriptional start sites, found by using RNase protection assays, are marked with an arrow above (human) or 
below (mouse) the sequence. 
2C), and identified it as the exon la-containing mRNA. An exon 
lb-specific oligonucleotide probe recognized only the ubiqui-
tous l.S-kb transcript (Fig. 20). These experiments unequivo-
cally demonstrated that exon la and exon lb do not occur to-
gether in the same molecule, but specify different PPCA 
transcripts. Rehybridization of the blot with a murine cDNA 
probe to part of the coding region (bp 777-I,ISO) confinned 
that both transcripts were genuine PPCA InRNAs (Fig. 2E). The 
exon la-specific probe also detected a LO-kb transcript in 
murine heart poly(A)+RNA (Fig_ 2C). This species did not rep-
resent an alternatively spliced PPCA mRNA, because it was not 
recognized by a cDNA probe devoid of exon la (Fig. 2E). Hy-
bridization of the human multitissue Northern blot with the ho-
mologous human probe also identified a 1.O-kb RNA transcript 
in heart and skeletal muscle. The nature orthis I.O-kb transcript 
is currently under investigation. 
The apparent lack of the 2.0-kb mRNA in some mouse tis-
sues could represent the limited sensitivity of Northern blot 
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analysis. Therefore, we reassessed the distribution of this tran-
script by using the more sensitive method ofRT-PCR (Fig. 3A). 
Analysis of the amplified products by Southern blot hybridiza-
tion with human or murine cDNA probes, confinned the North-
ern blot results: The two human cell lines expressed exclusively 
exon I-containing mRNA (Fig. 38), whereas the mouse tissues 
expressed both exon la- and exon lb-containing mRNAs (Fig. 
3C). Sequence analysis of these hybridizing products confinned 
their identity and further revealed RT-PCR products that were 
longer than expected (Fig. 3C), being derived from unspliced 
pre-mRNA. 
Transcription of human and mouse PPCA gelles 
The transcriptional start sites of the three mRNAs were iden-
tified by using RNase protection assays. The human start site 
was mapped with a riboprobe containing 412 bp of the pro-
moter, exon I, and 30 bp of intron I (Fig. 4A). Using total RNA 
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FIG. 2. Expression of PPCA mRNAs in human and mouse tissues. Northern blots containing 1-2 11& of poly(A)+RNA from 
sc\'cral human tissues (A) and from different brain regions (B) were hybridized with a human eDNA probe. A Northern blot con-
taining 1-2 p.g of poly(A)+RNA from different mouse tissues was hybridized with a 194-bp exon la-specific probe (C; expo-
sure 14 days), a 20-bp oligonucleotide-spanning excn lb probe (0; exposure 7 days), and a mouse 400-bp eDNA probe (E: ex-
posure I day). Am, Amygdala; Br, brain; Ce, corpus callosum; Cn, caudale nucleus; He, hippocampus; He, heart; HI, hypothalamus; 
Ki. kidney; Li, liver; LU t lung; Pa, pancreas; PI, placenta; Sm, smooth muscle; So, substantia nigra; Sp. spleen; Su, subthalamic 
nucleus; Te. testis; Th, thymus; TI, thalamus; Ut. uterus. 
isolated from a human megakaryocyte cell line, a single pro-
tected fragment of 26 bp was detected (Figs. I and 4B). 
The mouse distal promoter start site was identified by using 
a riboprobe spanning 226 bp of the promoter and 190 bp of 
exon Ia (Fig. 4A). We found one major protected fragment of 
211 bp in both kidney and liver poly(A)+RNA, indicating a sin-
gle site. 25 bp downstream of the TAT A box (Figs. 1 and 4C). 
Primer extensions with two different primers located in exon 
Ia confimled the position of the start site (data not shown). To 
map the start site of the proximal promoter, we used a ribo-
probe containing 140 bp of the promoter linked to exon Ib (Fig. 
4A). Total mouse kidney RNA or kidney and liver 
poly(A)+RNA showed two major protected fragments of 42 
and 45 bp, and two minor fragments of 25 and 26 bp, indicat~ 
ing two major start sites, 3 bp apart. and two minor ones, 20 
bp further downstream (Figs. 1 and 4D). 
To assay the transcriptional activity of the two mouse pro-
moters and the human promoter, different fragments of their se+ 
quences were linked to a chloramphenicol acetyl transferase 
(CAT) reporter gene (cal). Figure SA shows a schematic rep-
resentation of the various CAT constructs used for this analy-
sis. A 7-kb genomic fragment from the murine gene (Mo-CAT), 
which included exons Ia and Ib, had very high promoter acliv-
ity in both NIH-3T3 and COS-I cells (Fig. 5C). Truncation of 
this fragment to an 1.7-kb fragment that contained only the dis-
tal promoter region and 17 bp of exon Ia (1\.10·CAT5.1, Fig. 
5B), se\'erely reduced but did not suppress promoter activity. 
To minimize further the region required for distal promoter ac-
ti\'ity. we generated progressive 5' deletions of the 1.7-kb frag-
ment, which resulted in constructs 1\'fo-CAT5.2, 5.3, 5.4, and 
5.5 whose fragment sizes were 0.9, 0.7, 0.5, and 0.25 kb. re-
spectively (Fig. 5A). Reducing the distal promoter fragment to 
0.9 kb did not significantly alter its activity (Fig. 5D). Further 
5' deletions appeared to up-regulate transcriptional activity 
four- to five-fold for fragments of 0.7 and 0.5 kb and an addi-
tional four- to five-fold for the 0.25-kb fragment (Fig. 5B). 
These results suggest that two transcription suppressing se-
quences lie in the distal promoter region. one located between 
-0.9 and -0.5 kb, and the other between -0.5 and 0.25 kb of 
the cap site. 
The proximal promoter was analyzed using a genomic frag-
ment that included exon Jb and 600 bp of 5' sequences linked 
to the cal reporter gene (Mo-CAT 3.1; Fig. 5A). This fragment 
had a high, unidirectional promoter activity identical to that of 
construct r-.-fo-CAT, which suggests that Mo-CAT activity was 
mainly derived from the proximal promoter (Fig. 5C). Pro-
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FIG. 3. RT·PCR showing the presence of different PPCA transcripts in human and mouse. A. Outline of the RT-PCR strat-
egy, indicating the location of the different primers used to generate the rust-strand eDNA and the PCR products. B. Southern 
blot analysis of the human derived RT-PCR samples run on a 2% agarose gel and hybridized with a probe homologous to the 
murine exon Ia (top) or an exon I probe (bottom). C. Southern blot analysis of the mouse-derived RT-PCR samples hybridized 
with an exon Ia probe (lOp) or an exon Ib probe (bottom). Lanes marked I contained PCR products amplified with primers I and 
3, and lanes marked 2 contained products amplified with primers 1 and 2. Br, brain; Ki, kidney; Li. liver; Mu. skeletal muscle; 
PI. placenta, at day 18 of gestation; Uf, uterus, at day 18 of gestation; Te, testis; Th. thymus; MEG, megakaryocyte cell line; 
XP2, Xerodenna pigmentosa fibroblast cell line. 
gressive 5' deletions of Mo-CATJ.1 demonstrated that the se-
.quences necessary for maximal promoter activity were located 
within a 298·bp fragment (Mo-CATJ.3; Fig. 5A.C), which ex-
cluded the two SPI binding sites. Further 5' truncation of this 
298-bp fragment to 125 bp resulted in a dramatic loss of pro-
moter activity (Mo-CA TJ.4; Fig. 5A.C). despite the fact that the 
three conserved USFIMLTF motifs were retained in this frag-
ment. Deletion of exon Ib from the 3' side of Mo·CA 1'3.1 did 
not diminish the promoter activity of this fragment (Mo-CA D.5; 
Fig. 5A.c); however. deletion of an additional 105 bp from the 
3' side of Mo-CAD,S. which eliminated the three USFIMLTF 
motifs. completely abolished activity (Mo-CAT3.6; Fig. SA.C)_ 
Taken together, these results indicate that the promoter elements 
necessary to drive transient expression of the mouse exon Ib 
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PPCA transcript are located in two regions: one between ~298 
and -125. and one between -lOS. and ~ I_ 
To compare the activity of the mouse distal promoter with 
that of the corresponding region in the human gene, two hu-
man genomic fragments homologous to the mouse distal pro-
moter, were subcloned into the cat reporter plasmid and trans-
rected into COS-I and NIH-3T3 cells (Fig. SA; Hu·CAT5 and 
Hu-CATSA). As expected, these two constructs completely 
lacked promoter activity (Fig. SB). In contrast, a human prox-
imal promoter fragment. Hu-CAT3.S, displayed a very high, 
unidirectional activity. comparable to that of its mouse coun-
terpart, Mo·CAT3.S (Fig. SC), Overall the activity of these pro-
moters reflect the mRNA levels detected on mouse and human 
Northern blots. 
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FIG. 4. RNase protection analysis of the human and mouse PPCA promoter. A. Genomic location of the fragments used to 
generate the riboprobes. The indicated fragments were subcloned into pBluescript, linearized, and ;11 vitro-transcribed using ei-
ther T3 or 17 RNA polymerase. B. The human promoter was analyzed using 10 p.g (lane I) or 30 p.g (lane 2) of total RNA from 
a human megakaryocyte cell line. C. Mapping of the mouse distal promoter, using 15 p.g (lane 4) or 30 p.g (lane 5) of total kid-
ney RNA, and 2 p.g of poly(A)+RNA from kidney (lane 6) or liver (lane 7). D. Mapping of the mouse proximal promoter using 
15 p.g (lane 9) or 30 p.g (lane 10) of tolal kidney RNA. and 2 p.g of poly(A)+from kidney (lane II) and liver (lane 12). For each 
probe, a negative control containing 15 p.g of yeast tRNA was used (lanes 3, 8, and 13). A sequence marker lane was run next 
to the samples (lane M). The arrows indicate fragments of interest. 
The mllrine exoll fa transcript is expressed in vivo 
To validate the in vim occurrence of the two murine 
mRNAs. we perfomled ill situ hybridizations on mouse brain 
cryose<:tions using two PPCA cDNA fragments to generate 35S_ 
labeled antisense riboprobes: ExIa, specific for exon Ia~ 
containing transcripts and eDNA, which recognizes both exon 
Ia and Ib transcripts (Fig. 6, bottom panel). The eDNA antisense 
probe showed high expression of PPCA mImAs in the choroid 
plexus, the hippocampus, and the dentate gyrus (Fig. 6A,D,G). 
Subsequent sections hybridized with ExIa showed specific and 
discrete expression of the exon Ia transcript in only the hip-. 
pocampus and the dentate gyrus (Fig. 6B,E,H). This finding sug-
gests that the two murine transcripts may be differentially dis-
tributed ill v;m and that their regional expression may not o\'er~ 
lap. Moreover, these data indicate that the exon Ia mRNA is 
genuinely transcribed;1l v;\'O and is not an artifact of the ill \'i(ro 
systems used. Hybridization of similar mouse brain regions us~ 
ing the sense control of either riboprobe is shown for the choroid 
plexus. the hippocampus, and the dentate gyrus (Fig. 6C,F,I). 
DISCUSSION 
To understand better the transcriptional regulation of the 
PPCA gene, we have analyzed the human and mouse PPCA 5' 
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FIG. 5, III ~,itro promoter activity associated with the human and mouse promoter regions. A. Schematic representations of the 
human and mouse constructs. B. Relative CAT activity of the distal promoter fragments driving the cal gene. C. Relative CAT 
activity of the proximal promoter fragments driving the cat gene. All activities are relative to the pBLCAT6 empty vector. 
genomic regions and have identified their promoter elements. 
Although transcription of the human gene is controlled by a sin-
gle promoter, there are two promoter elements in the murine 
gene that generate two PPCA transcripts with alternative 5' ex-
ons. Multiple promoters occur in a number of genes from dif-
ferent species, ranging from bacteria to humans (for review, see 
Schibler and Sierra. 1987). Such genes can be grouped in four 
different classes. Classes I and II contain the most common 
types of gene, which either have one constitutive and one tis-
sue-specific promoter (Izzo e( af., 1988; Stauffer and Ciejek-
Baez. 1992; Strahle et af., 1992; Saitta and Chu, 1994; Chotani 
et af., 1995; Salminen et al., 1996), or they have two tissue-
specific promoters (Fraser et al., 1989; Visvader and VernIa, 
1989; Neuhaus et al., 1995; Jahng et af., 1996; Mutoh et al., 
1996). Class ill genes use differential promoters to create pro-
teins with alternative amino tennini (Libri et al., 1990; Rath-
jen et al., 1990; Snijders et af., 1993; Banville et af., 1995), and 
class IV consists of genes that use differential promoters to con-
trol developmental switches (Cartwright, 1987; Tautz el ai., 
1987; Corbin and Maniatis, 1989; Podgorski et af., 1989; 
Takadera et af., 1989; Allen et al., 1992). Besides PPCA, two 
other lysosomal genes have dual promoters. The human f3-glu-
curonidase gene is driven by a constitutive and a tissue-specific 
promoter (Shipley et al., 1991). However, the expression from 
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the latter promoter has only be shown in transfonned cells. In 
the human lysosomal cathepsin D gene, the same promoter 
seems to have dual activity----driving constitutive expression of 
the mRNA, and sensitivity to estrogen in breast cancer cells 
(Cavailles et al .• 1993; May et af., 1993; Augereau et af., 1994). 
Our data suggest that, although developmental regulation can-
not be excluded at present, the murine lysosomal PPCA gene 
is a class I multiple promoter gene. The function of the addi-
tional, tissue-specific promoter is, as yet, unclear. One expla-
nation could be that the distal promoter is substrate sensitive 
and also induced by high local substrate concentration. For in-
stance, this promoter could regulate PPCA transcription in spe-
cialized cells that require the enzyme to inactivate and clear 
bioacth'e peptides (Jackman el a/., 1990, 1992); at high bioac-
live peptide levels, more PPCA would be expressed. 
The two alternative 5' exons might also generate mRNAs 
that differ in their stability or translation efficiency (Kozak, 
1989), Which, in tum, may inOuence the PPCA protein con-
centration in specific cells. We have not analyzed other mam-
malian species and, therefore, we are unable to detcnnine 
whether the mouse has gained the distal promoter or the human 
has lost it. In either situations, the presence of the distal pro-
moter in the mouse could indicate differences in local meta-
bolic needs between the two species. Alternatively, the mouse 
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FIG. 6. In vil'o expression of the murine PPCA transcripts in adult mouse brain. An outline of the two rihoprobes used for the 
ill situ hybridizations is shown at the bottom of the figure. The indicated fragments were subcloned into pBluescript, linearized, 
and subsequently ill vitro-transcribed using either the T7 or T3 RNA polymerase. A-C. The choroid plexus hybridized with the 
eDNA (A). the ExIa (B), and the sense control (C) riboprobes. D-J. The hippocampus and the dentate gyrus hybridized with the 
eDNA (D,G), Exia (E,H), and the sense control (F,l) riboprobes. 111e hippocampus and the denlate gyrus are clearly positive 
with both probes. whereas the choroid plexus is only recognized by the eDNA probe. 
may have kepi this nonessential remnant promoter that is 
nonetheless still active. in an evolutionary step analogous to 
that involving the human S-globin gene promoter (Wood et 01 .• 
1978), 
Despite the high level of homology between the human up-
stream sequences and the mouse distal promoter. the human re-
gion completely lacks transcriptional activity. It has lost the 
TATA box (TGTAGA vs. TATAAA) and the two imperfect 
CAA T boxes (CCAGG vs. CCAAG and OeCAT vs. eeCAT). 
Site-directed mutagenesis of these sites in either gene could ver-
ify their involvement in transcription regulation. OUf prelimi-
nary data suggest that mutating the mouse TATA box to the 
human counterpart (TATAAA into TOTAOA) increases rather 
than decreases promoter activity ill vitro, which implies that the 
TATA box is not the principal transcriptional activator of the 
upstream murine promoter (data not shown). It is evident from 
our Northern blot analyses that expression of human PPCA 
mRNA is less variable than that of the murine exon Ib tran-
script. This could represent a compensatory effect for the loss 
of the second human promoter. 
The sequence of the human promoter has several features in 
common with that of the murine proximal promoter. BoUt lack 
conventional TAT A and CAA T boxes. and both are ole rich. In 
addition. the mouse gene has multiple transcriptional start sites. 
These characteristics are shared by housekeeping genes, which 
encode proteins that perfoml essential metabolic functions and 
have a wide tissue distribution (Dynan, 1986). Several other lyso-
somal genes are members of tbis gene family (Hocfsloot et of., 
1988; Neote et 01., 1988; Proia, 1988; Geier et of., 1989; Kreysing 
et 01 .• 1990; Martiniuk et 01 .• 1991; Morreau et 01.. 1991; Re-
decker e/ al., 1991; Shipley et al., 1991). We demonstrate that 
the human and mouse proximal promoter fragments fXlssess max-
imal transcriptional activity in transient transfections, and dele-
tion analysis of-the mouse promoter confined the necessary reg-
ulatory elements for maximal transcription ill vitro to a 298-bp 
fragment. These findings correlate well with what has been de-
scribed for the human J3-galactosidase ~1orreau et 01 .• 1991}, the 
human fJ-hexosaminidase A and B (Norflus el of., 1996), the 
mouse hexosaminidase A (\Vakanlatsu et of., 1994), and the hu-
man J3-glucuronidase (Shipley et al., 1991) genes. 
The most striking homology between the human promoter 
and the mouse proximal promoter is the presence of USF/ML TF 
57 
sequence motifs (Hen et al., 1982; Carthew et af., 1985; 
Sawadogo and Roeder, 1985), also known as E boxes (Murre 
et al., 1989; Blackwell et a/,. 1990) or adenovirus 2 major late 
promoter upstream element factors (Ad2 MLP VEl"; Hen et al., 
1982). Transcription factors like MyoD, kE2-binding protein. 
and c-Myc are known to bind to these elements (Murre et al .• 
1989; Blackwell el al., 1990; Blackwell and Weintraub. 1990). 
Moreover, a number of cellular genes involve UEF in their ac-
tivation (Carthew et al., 1987: Chodosh et af., 1987; Peritz et 
al .• 1988). This sequence motif is also found in the promoter 
of the lysosomal human and mouse cathepsin D (Augereau et 
at., 1994; Hetman el aI" 1994) and p-hexosaminidase A, genes 
(Proia and Soravia, 1987; Wakamatsu et al., 1994), where it is 
thought to regulate transcription. Howe"'er. the importance of 
the USl"lML TF motifs in regulation transcription of the murine 
PPCA gene is not yet clear. Deletions from the 3' side of the 
proximal promoter identified sequences between -100 and + 1 
that are necessary for transcription. 
In GS patients. the activities of lysosomal p·galactosidase 
and neuraminidase are reduced because the enzymes are unable 
to complex with PPCA. This leads to lysosomal storage of pri-
marily sialylaled otigosaccharides and oligopeptides, Patho· 
logic manifestations in GS patients include the vacuolation of 
predominately reticuloendothelial cells in most organs. We have 
recently generated a OS mouse model (Zhou et al .• 1995) that 
closely resembles the human phenotype, The storage pattern 
observed in these mice may reflect the differential expression 
of PPCA mRNAs in specific cells of affected organs, Indeed. 
our in situ hybridization experiments clearly demonstrated a lo-
cal distribution of the two mRNAs in the adult mouse brain. It 
will be of interest to analyze further the need for differential 
expression of the PPCA transcripts in mouse tissues and to cor-
relate these findings with the pleiotopic functions of the pro· 
tein in both mice and humans. 
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Mouse model for the lysosomal disorder 
galactosialidosis and correction 
of the phenotype with overexpressing 
erythroid precursor cells 
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The lysosomal storage disorder galactosialidosis results from a primary deficiency of the protective 
proteln/cathepsin A (PPCA), which in turn affects the acth'ities of j3.galactosidase and neuraminidase. Mice 
homozygous for a null mutation at the PPCA locus present with signs of the disease shortly after birth and 
de\'elop a phenot)'pe closely resembling human patients with galactosialidosis. Most of theh tissues show 
characteristic vacuolation of specific cells, attributable to lysosomal storage. Excessive excretion of 
sialylollgosaccharides in urine Is diagnostic of the disease. Affected mice progressively deteriorate as a 
consequence of severe organ dysfunction, especially of the kidne)'. The deficient phenotype can be corrected 
by transplanting null mutants with bone maHOW hom a transgenic line overexpressing human PPCA in 
erythroid precursor cells. The transgenic bone marrow gives a more eHicient and complete correction of the 
visceral organs than normal bone marrow. Our data demonstrate the use(ulness of this animal model, very 
similar to the human disease, for experimenting therapeutic strategies aimed to deliver the functional protein 
or gene to affected organs. Furthermore, the)' suggest the feasibility of gene therapy for galactosialidosis and 
other disorders, using bone marrow cells engineered to overexpress and secrete the correcting l}'sosomal 
protein. 
[Key Words: Mouse model; galactosialidosis; lysosomal diseasej protective proteinj erythroid expressionj BMTJ 
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Galactosialidosis (for review, see d'Azzo et al. 1995) is a 
lysosomal storage disease, inherited as an autosomal re· 
cessive trait and characterized by a combined deficiency 
of I3'D-galactosidase and N-acetyl-a-neuraminidase, sec-
ondary to a defect of the protective protein/cathepsin A 
(PPCA) (Wenger et al. 1978/ d'Azzo ct al. 1982). This 
serine carboxypeptidase (Galjart et al. 1988; Rawlings 
and Barrett 1994) has at least two distinct functions. 
First, as demonstrated by copuTification experiments 
(Verheijen et al. 1982) Yamamoto and Nishimura 1987; 
Potier et a!. 1990; Scheibe et al. 1990; Hubbes et al. 
1992), it associates with the two glycosidases, thereby 
modtllating their intralysosomal stability and aetivity 
(Hoogeveen et al. 1983) van der Horst et al. 1989/ Galjart 
et al. 1991). Second, the protein is catalytically active as 
a lysosomal cathepsin at acidic pH, as well as a deami-
8Corresponding author. 
dase/esterase at neutral pH, and has been shown to par-
ticipate in the inactivation of selccted neuropeptides like 
substance P, oxytocin, and endothelin I (fackman et al. 
1990; Galjart et al. 1991; Jackman et al. 1992 j Hanna et 
al. 1994). Mammalian and avian protective proteins are 
highly conserved and share homology to yeast and plant 
serine carboxypeptidases (Galjart et al. 1988; Gaijart et 
al. 1991). The murine and avian enzymes can even sub-
stitute for their human homolog to stabilize and activate 
human l3-galactosidase and neuraminidase (Galjart et al. 
1991). 
Patients with galactosialidosis have clinical manifes-
tations indicative of a lysosomal disorder, including 
coarse facies, ocular cherry red spots, vertebral changes, 
foamy cells in the bone marrow, and vacuolated lympho-
cytes in peripheral blood. Based on the age of onset of the 
symptoms, three clinical phenotypes arc distinguished: 
early infantile, late infantile, and juvenile/adult vari-
ants. The most severe early infantile form is associated 
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with fetal hydrops, diffuse edema, ascites, hepatospleno-
megaly, psychomotor delay, bone deformity, and severe 
heart and kidney involvement. Death occurs within the 
first year of age, likely as a result of renal failure. Late 
infantile and juvenile/adult patients have a later onset 
and slower progression of the disease; however, whereas 
adult patients have central nervous system (CNS) in-
volvement, the late infantile types are not mentally reo 
tarded or only mildly so. In spite of the triple enzyme 
deficiency, the storage products isolated from tissues and 
urine of galactosialidosis patients are primarily sialy-
lated oligosaccharides {Okada et al. 1978} van Pelt et al. 
1988a,b, 1989J. The 'characteristic pathology of the dis-
ease includes vacuolation of cells in the central, periph-
eral, and autonomic nervous systems, retina, liver, kid· 
ney, skin, and peripheral blood {d'AzZQ et al. 1995}. 
There is currently no effective therapy for galactosial-
idosis or for other lysosomal disorders with CNS in-
volvement. Transplantation of allogeneic hone marrow 
as a source of normal enzyme has proven of limited ben-
efit in hum all studies with other lysosomal diseases (for 
review, see Krivit et al. 1992; Hoogerbrugge et al. 1995), 
but has never been tried for galactosialidosis. Also in 
naturally occurring animal models with these disorders, 
the effect of bone marrow transplantation (BMT) has 
been variable {for review, see Haskins et al. 1991}. Im-
provement of the pathology was observed after BMT in 
cats with «-mannosidosis (Walkley et al. 1994a). but 
only partial correction was obtained with this procedure 
in mice with mucopolysaccharidosis VII (Birkenmeier et 
al. 1991) and no amelioration was detected in treated 
GM2-gangliosidosis cats (Walkley et al. 1994b). This dif-
ference may depend on the number of perivascular 
monocytes/macrophages originating from the graft but 
also on differential secretion of the correcting enzyme by 
donor-derived cells, as seems to be the case for a-man-
nosidase and p-hexosaminidase, at least in in vitro stud-
ies {Dobrenis et al. 1994J. Other novel approaches, like 
intraperitoneal implant of fibroblasts organoids (Moul-
lier et al. 1995) or direct transfer of neuronal progenitor 
cells (Snyder et al. 1995), have been employed recently 
for the local delivery of exogenous functional enzyme to 
the liver and the CNS, respectively. Overall, these stud-
ies establish the validity of suitable animal models, 
which closely resemble the human disease, to evaluate 
therapeutic strategies for the correction of disorders like 
galactosialidosis. Although sheep with a combined j3-ga-
lactosidase and neuraminidase deficiency have been 
identified (Ahem-Rindell ct al. 1988), both the localiza-
tion of severe storage only to neurons and the enzymatic 
characteristics differentiate this model from the human 
disease. Recently, a disease with pathology similar to the 
adult form of galactosialidosis was described in a Schip-
perke dog {Knowles et al. I993}, but the biochemical data 
were insufficient to verify the diagnosis. To produce an 
animal model for galaetosialidosis we have generated 
mice carrying a null mutation at the PPCA locus. Defi-
cient animals are viable and fertile but exhibit severe 
abnormalities soon after birth that closely resemble 
those found in galactosialidosis patients. They also de-
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velop the characteristic histopathology of the human 
disease. Thus, this mouse model provides an attractive 
opportunity to study the pathogenesis and pathophysiol-
ogy of the disease and to evaluate experimental thera-
pies, including gene therapy_ In this report we have 
tested the hypothesis that substantial secretion of PPCA 
by genetically modified bone marrow cells could trans-
late into a more timely and effective correction of the 
lesions in affected mice. We demonstrate that treatment 
of the (-/-) phenotype with transgenic bone marrow 
overexpressing the human PPCA in erythroid precursors, 
which also secrete the protein at high levels, can im-
prove the pathological conditions better than normal 
bone marrow cells. These results give the first indication 
of the potential of overproducing and secreting he-
matopoietic cells for the treatment of galactosialidosis 
and possibly other similar disorders. 
Results 
Generation of PPCA-deficient mice 
A targeting vector for homologous recombination at the 
murine PPCA locus was constructed as outlined in Fig-
ure lAo The position of the positive selectable marker 
prevents translation of the polypeptide and thus the tar-
geted replacement constitutes a genuine null mutation. 
Targeted E14 embryonic stem (ES) cells were obtained at 
a frequency of 13%-15%. Chimeric males derived from 
two independent clones {28 and 139) yielded germ-line 
transmission of the null allele. Interbreeding of hcteroz}'-
gates (+ /- J from both clones readily generated homozy-
gous (-/-) mice. Offspring were genot}'ped by Southern 
blotting and hybridization with a 5' external probe (Fig. 
lB). Combined data from crosses between clone 28 and/ 
or clone 139 heterozygotes showed a distribution of 24% 
(+/+),20% {-/-j, and 56% (+/-) in 292 offspring 
analyzed, suggesting that an intact PPCA gene is not 
required for normal embryonic development of homozy-
gous null mice. Northern blot analysis (Fig. Ie) of total 
RNA isolated from PPCA (-/- J tissues confirmed the 
lack of a PPCA transcript in deficient mice. 
Biochemical analysis of PPCA-deficient mice 
The engineered mutation rendered (-/-) mice unable 
to encode the PPCA protein, as established by assaying 
cathepsin A activity in cultured fibroblasts and tissues 
from (+ / +), (+ /-), and (-/-) mutant animals of dif-
ferent age (Table 1). This catalytic activit}' either was 
absent or reduced severely in tissues of homozygous mu-
tant mice, with the levels ranging from nondetectable in 
bone marrow to ~8% of normal in liver. The small, re-
sidual activity measured in some of the samples may be 
attributable to the presence of catalyticall}' related pro-
teins that have a low affinity for the Z-phe-Ala substrate. 
Heterozygous mice showed clear intermediate values 
(Table I). Because direct biochemical evidence of galac-
tosialidosis in human patients is the combined defi-
ciency of neuraminidase and p·galactosidase in fibro-
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blasts and leukocytes {d'Azzo et al. 19951, we assessed 
these parameters in the mutant mice. The deficiency of 
cathepsin A in {-I-} tissues directly influenced the ac-
tivity of neuraminidase, which was severely reduced, es-
pecially in fibroblasts and kidney samples (Table 1). 
However, p-galactosidase levels varied considerably for 
the different tissues from deficient mice, being -20% of 
normal levels in fibroblasts, as found in human galacto-
sialidosis {IO%-lS%J, but even higher than normal in 
liver. These results suggest that murine p-galactosidase 
may be less dependent for its stability and activity on 
complex formation with PPCA than is murine neur-
aminidase. 
A second parameter used in clinical diagnosis is the 
overexcretion of undegraded sialyloligosaccharides in 
the urine of affected individuals (van Pelt et al. 1989). 
The total content of these metabolites in PPCA ! -/-) 
mice thus was determined for urine from PPCA (-/-), 
~ ) " f 
I I II 
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Figure 1. Targeted disruption of the PPCA locus by homolo· 
gous recombination. {AI Structure of a portion of the PPCA 
gene, the targeting construct, and the predicted structure of the 
targeted PPCA locus following homologous recombination. 
Only the relevant restriction sites are shown: lEI EcoRI; IN] 
NdeT. The numbered solid boxes represent exons. The labeled 
boxes indicate the position of the respective 5' and3' hy probes. 
Horizontal single arrows indicate the direction of transcription 
of the hyglO and TK cassettes. Two·headed arrows show the 
position and size of Nder restriction fragments diagnostic for 
proper targeting of the locus. (BI Southern blot analysis of NdeI· 
digested genomic DNA of nine mice from one litter resulting 
from a cross between two PPCA (+ I-I mice. The blot was 
hybridized with the 5' Ndel-EcoRl probe. The wild·type and 
mutant alleles are indicated by 12- and 5·kb NdeI fragments, 
respectively. (q. Northern blot analysis of PPCA mRNA from 
mouse tissues. Total RNAs: (20 j.lg) from brain lBI, kidney {KI, 
and liver {Ll of a wild·type I + I + I mouse and two mutant {-/ 
- I mice derived from ES clone 28 and 139 were analyzed by 
Northern blotting with the PPCA mouse eDNA probe. The 
expected 2-kb mRNA, detected in normal tissues, is absent in 
tissues from the mutant mice. 
(+ /-), and (+ / +) mice. Twenty·one affected mice, 
tested between the age of 2 and S months excreted 3-10 
times more sialylated oligosaccharides in urine than 
their normal and heterozygous littermates {Table 2}. The 
amount of accumulated products increased progressively 
with time, eventually reaching levels 2S times higher 
than controls and heterozygotes in seven {-/ - J mice 
tested at the age of 6-8 months. These biochemical data 
clearly mirror the situation for humans with galactosial-
idosis and establish the validity of this model as an ex-
perimental substrate. 
Phenotypic characterization and histopathology 
of deficient mice 
PPCA (-/-) mice are viable and fertile, and die at -12 
months of age. At birth and during the first 6 weeks of 
Ufe their gross appearance was normal, except for an ap-
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Table 1. Lysosomal enzyme activities in cultured fibroblasts and tissues from PPCA (-/-) mice 
Cathepsin A Neuraminidase p·galactosidase 
(mmole/mln/mg) (nmole/hr/mg) (nmole/hr/mg1 
+/+ +/- -/- +/+ -/- +/+ -/-
Fibroblast 159:!: 9 98:!: 17 1.3:!: 0.9 23.00:!: 0.10 0.43 ::!: 0.17 812:!: 82 263 ::!: SO 
Kidney 135::!: 14 61 ::!: 8 1.8 ::!: 0.9 40.00 :!: 6.40 0.57 :!: 0.09 275:!: 72 176 :!: 25 
Buin 20::!: 3 lO::!: 2 0.7 ::!: 0.3 3.06 ::!: 0.36 0.98:!: 0.19 68:!: 21 59:!: 9 
Spleen 114:!: 16 43:!: 18 5.5:!: 2.3 4.00 :!: 1.92 0.94 ::!: 0.21 291 :!: 51 240 ::!: 46 
Liver 77:!: 19 31 ::!: 13 3.8:!: 1.1 3.78 ::!: 0.66 0.42 :!: 0.07 68:!: 8 144:!: 22 
Bone marrow 163::!: 27 N.D. O.O::!: 0.0 3.66 ::!: 0.36 0.19:!: 0.02 119:!: 11 106 ± 25 
Fibroblast celllysates and total tissue homogenates in HlO from PP normal I +1+), heterozygous I +1 ), and homozygous 1 / J mice 
we-re assayed for cathepsin A activity, using the acylated dipeptide Z-Phe-Ala, and for neuraminidase and p·galactosidase activities, 
using synthetic 4·methylumbelliferyl substrates. Values represent means:!: S.DI. of measurements done on 4{ +1+), 2{ +1 -), and 7 
1-/-) mice. All mice were between 2 and 8 weeks of age and were derived from ES cell clones 28 and 139. (~.D.) Not done. 
parent flattening of the face. However, the majority of 
young {-/- J mice weighed 25%--40% less than (+ / + J 
and! + /-) !ittermates and were identified readily by 
size. Two of the smallest mice died spontaneously at 3 
weeks of age and were found to have hepatic and splenic 
enlargement. No distinguishable skeletal deformities 
were observed in the young (-/- J mice, but their phys· 
ical condition overall worsened with age. Progressive 
and diffuse edema was accompanied by apparent ataxic 
movements and tremor. The characteristic broad face, 
rough coat, and extensive swelling of subcutaneous tis· 
sues, limbs, and eyelids are obvious in the lO·month·old 
(- 1-) mouse shown in Figure 2. 
Visceromegaly is a specific clinical abnormality asso· 
ciated with the early and sometimes late infantile forms 
with galactosialidosis. This feature was also found in 
PPCA (-/-) mice with enlargement of both the liver 
and the spleen being prominent at autopsy {not shown}. 
Morphological studies of tissues from {-/- , mice were 
carried out on either paraffin, cryosections, or epoxy-
resin sections examined both by light and electron mi· 
croscopy. Affected mice were sacrificed at the age of 14 
days, 1 month, 3--4 months, 6 months, and 10 months. 
Signs of metabolic storage were found primarily in the 
reticuloendothelial system of most organs, already no-
ticeable in the first mouse analyzed 14 days after birth. 
Thirty percent of the lymphocytes in peripheral blood 
had translucent vacuoles in their cytoplasm. In the skin, 
foamy macrophages, sometimes clearly perivascular, 
were visible between collagen bundles of the dermis. 
The presence of stored material was confirmed by posi-
tive cytoplasmic staining with periodic acid-Schiff {PAS} 
and diastase treatment {pAS +). The kidney appeared to 
be the earliest and most severely affected organ in young 
mutant mice, analogous to the situation for severe hu-
man disease. Electron microscopy of ultrathin sections 
of kidney from a 14·day·old (-/-) mouse demonstrated 
vacuolation of the tubular epithelium, most evident in 
the proximal tubules (Fig. 3A), whereas distal tubules 
and glomeruli were less or minimally affected at this 
stage (Fig. 3B). The numerous membrane· bound vacuoles 
representing secondary lysosomes appeared either empty 
or filled with sparse fibrillar structures, reflecting lysos· 
omal accumulation of low molecular weight compounds 
(e.g., oligosaccharides or glycopeptides). 
This spectrum of pathological changes worsened pro-
Table 2. Total urinary sialyloligosaccharides in affected and BM·lransplanled mice 
Mice 
Controls 
Heterozygotes 
Homozygotes 
BMT·N 
BMT·TG 
Number 
4 
14 
21 
7 
1 
4 
Ag, 
2-8 months 
2-8 months 
2-5 months 
6-8 months 
5 months 
5 months 
5 months 
5 months 
2.S months 
nmole NANAfmg creatinine 
I906::!: 15S (range 1663--2310) 
1905 ± 117 (range 993-2923) 
7215 ± 647 (range 5305----19362) 
27368 ± 4845 (range 111200-45763) 
1812 {5 weeks} 3months p.t.) 
2114 {5 weeks} 8 weeks p.t.) 
2106 (8 weeks 3 months p.t.) 
179918 weeks} 9 weeks} 3 months p.t.) 
2011 18 weeks} 9 weeks; 3 months p.t.) 
Total sialyloligosaccharides were measured after acid hydroloysis of urine samples with thiobarinturic acid and were expressed in 
nmoles of released neuraminic acids per milligram of creatinine.jBMT·N) PPCA (-/-) mice transplanted with bone marrow from a 
normal donor. !BMT·TG) PPCA (-I -) mice transplanted with bone marrow from a transgenic mouse, overexpressing human pro· 
tective protein in the erythroid Hne.:lge. Mice were transplanted at either 2.5 or 5 months of age. Sialyloligosaccharide determinations 
were performed .:It various time points post·transplantation (p.t.), as specified in parentheses. The values represent the mean of 
Independent measurements. 
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Figure 2. Gross phenotypic appearance of a PPCA ! -/- I 
mouse (middle) at 10 months of age, compared to a wild·type 
! + 1+) littermate (light), and a (-/- ) littennate (leftl trans· 
planted 5 months earlier with transgenic BM. The affected 
mouse has a broad face, disheveled coat, and swollen limbs and 
eyelids. In contrast, the BMT mouse clearly has improved in 
appear<lnce. Evidence of edema has disappeared, and the coat is 
shiny and full. 
gressively with age. The toluidine blue· and PAS·stained 
histological sections shown in Figure 4 were derived 
from a {-/-) mouse at 6 month of age. In the affected 
kidney the epithelial cells of the proximal tubules were 
filled with swollen lysosomes. The glomeruli also were 
severely impaired by abundant vacuolation of parietal 
and visceral epithelium, endothelium and mesangial 
cells at this stage of the disease. Accumulation of unde-
graded material again was not apparent in the distal tu-
bules. These abnormalities were not observed in control 
specimens, except for small resorption vesicles present 
normally at the apical side of the tubular epithelial cell 
surface (Fig. 4A). No evidence of storage was detected in 
the adrenal glands {not shown). In the {-/- J liver, he· 
patocytes contained numerous, small membrane-bound 
vacuoles, whereas the Kupffercells in the sinusoids were 
more affected and acquired the characteristic foamy ap· 
pearance {Fig. 4A). Both hepatocytes and Kupffer cells 
stained positive with PAS+ {not shown). The spleen of 
the diseased mouse showed extensive congestion of the 
sinuses and the marginal zones with foamy macro· 
phages, which were also slightly PAS-positive. Further-
more, large cytoplasmic vacuoles were found in the lym-
phoid cells. Megakaryocytes were devoid of storage, de· 
spite their extensive lysosomal system {Fig. 4A). 
The histopathology of the brain was examined in par-
affin sections, and portions of the cerebrum and cerebel· 
lum were processed for frozen sections stained with PAS 
or for epoxy-resin sections stained with toluidine blue. 
Finely vacuolated storage cells similar to those found in 
the visceral organs also were observed in the brain. They 
often were located around neurons or blood vessels (Fig. 
4B, a--c). Neuronal storage was rather inconspicuous on 
paraffin sections even in older mice. However, on frozen 
sections stained with PAS, affected neurons were iden· 
tified easily by a brilliantly red storage material {Fig. 4B, 
dJ. Although frozen section study was carried out on lim-
ited portions of the brain, there was a significant regional 
variation in the distribution of PAS'positive neurons. 
Entorhinal cortex and hippocampus appeared to be more 
involved !Fig. 4B, d) than the somatosensory cortex (Fig. 
4B, e). In the cerebellum, there was a loss of Purkinje 
cells and some of the remaining Purkinje cells contained 
storage material in their perikarya !not shown). The 
granular cells were well preserved. Extensive storage was 
apparent in the epithelial and stromal cells of the chor-
oid plexi {Fig. 58, below}. Finally, vacuolated cells were 
present in the trigeminal ganglia and the pituitary gland. 
The pituicytes also showed fine vacuolation !Fig. 4C). 
Examination of other organs {Le., pancreas, small and 
large intestine, lymph nodes, testis, ovaries, uterus, 
heart, bone marrow, and eyeJ confirmed the presence of 
membrane-bound vacuoles primarily in macrophages 
and cells of epithelial/endothelial origin {not shown}. No 
evidence of lysosomal storage was detected in the lungs 
and skeletal muscles. The distribution and type of accu-
mulating cells remained similar in lO-month·old mutant 
mice. 
Rescue of the galactosialidosis phenotype 
in the mouse model 
The rationale for using allogeneic BMT to treat lysoso· 
mal storage disorders is that progenitor bone marrow 
{BMJ cells will repopulate the transplanted host and sup· 
ply the missing enzyme to deficient cells in the tissues of 
the recipient. Correction takes place when the therapeu-
tic enzyme secreted from normal BM cells is reinternal-
ized b}' deficient cells, with restoration of lysosomal 
A B 
Figure 3. Electron microscopy of kidney from a 2·week·old 
(-/- I mouse. {Al Micro· and macfOvacuolation of the proximal 
tubules is apparent.jB1 Distal tubules and glomeruli are less, if 
not at all, affected at this stage of the disease. Magnification, 
2000x IAI and 2500x for (B). 
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function. It is conceivable that higher levels of the caf-
recting protein will relate directly to more timely and 
effective treatment. We have shown previously that both 
human and murine PPCA precursors, selectively se· 
creted by overexpressing cells, undergo endocytosis by 
cultured galactosialidosis fibroblasts via the rnannose-6-
phosphate receptor and correct both p-galactosidase and 
neuraminidase activities (Galjart et al. 1991). Having a 
suitable animal model for galactosialidosis, we now 
could test whether transplantation of affected mice with 
8M cells overexpressing and secreting a functional PPCA 
protein could correct the lysosomal storage better than 
normal bone marrow. Therefore, four transgenic mouse 
lines were generated in which expression of a human 
PPCA transgene was driven by the p-globin promoter 
and locus control region ILCR} of the p-globin gene 
{Grosveld et al. 1987}_ The transgenic mice synthesized 
the heterologous human protein at high levels in cells of 
the erythroid lineage. Prior to transplantation, we ascer-
tained that the product of the transgene also was se-
creted by 8M cells to the extent that the high uptake 
precursor form of the protein was detectable in plasma 
and would undergo endocytosis by recipient cells. For 
this experiment, total 8M cells derived from either trans-
genic or normal mice were cultured in the presence of 
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Figure 4. Histopathological analysis of a 6·month·old PPCA 
(~I ~) mouse compared to a (+ I +) littermate. Semithin tis· 
sue sections from kidney (Kid.), liver (tiv.), spleen (Sp1.), brain 
(Br.), and pituitary (Pit.) were stained with toluidine hlue, 
whereas cl)'osections from the brain were stained with PAS. 
Morphological changes and extensive vacuolation of numer-
ous cell types were detected, reflecting massive lysosomal 
slOrage. (A) (Odginal magnifications 400x). In the kidney, ar-
rows 1 and 2 indicate the vacuolation in glomeruli and prox-
imal tubules, respectively; in the liver, 1 and 3 point to bal· 
looned Kupffer cells, whereas 2 indicates microvacuolation of 
the hepatocyte. In the spleen, 1 and 2 show a vacuolated mac-
rophage and lymphocyte, respecth'eiy, hut a megakaryocyte is 
not affected (arrow 3). (B,a) (Magnification, 400x). Some of the 
large neurons in the cerchral cortex have storage vacuoles (ar-
row 2) and endothelial and glial cells show extensive vacuo' 
lation (arrows 1 and 3, respecth'el)'). (B,b) A greater magnifi· 
cation Oooox) of a selected area of B,a whereas B,c shows an 
enlarged perivascular cell OOOOx! with extensive storage vac-
uoles. IB,d) IMagnification, 440x). Neurons in the entorhinal 
cortex contain abundant PAS + stora.ge material in their 
[lerikarya. IB,e) (Magnification, 400x). Only rare neurons con-
:aining PAS+ storage materials (arrows) are identified in the 
iomatosensory cortex. {q {Magnification, 880X), PituitaI)' 
~land of the (~I ~ I mouse shows vacuolation of pituicytes in 
addition to foamy macrophagcs. 
cytokines for 5 days. The conditioned mcdium from 
these cultures, as well as serum from the same animals, 
was first assayed for o.-galactosidase, a-glucosidase, and 
p-hexosaminidase activities Inot shown) to ensure that 
overproduction of PPCA did not lead to aspecific release 
of other lysosomal proteins. Similar values for the three 
enzyme activities were measured in normal and trans-
genic samples, indicating that oversecretion of human 
PPCA was selective, Neuraminidase, being membrane 
bound, was not secreted and extracellular PPCA activity 
could not be tested because the precursor form of the 
protein is a zymogen, activated only in lysosomes, Con-
ditioned media and sera then were added separately to 
deficient galactosialidosis cells from an early infantile 
patient {Galjart et a!. 1988), As shown in Table 3, cathep· 
sin A, p-galactosidase, and neuraminidase activities 
were clearly enhanced upon uptake of the human PPCA 
precursor from either 8M-conditioned medium or di-
rectly from transgenic mOllse serum. No significant in-
crease in activity was detected in deficient fibroblasts 
treated with serum or BM·conditioned medium from 
normal mice. These results suggested that transgenic 
BM cells might achieve similar correction in vivo in af-
fected mice. 
Homozygous (-/-) mice, ranging in age from 2.S to 5 
Table 3. Uptake of BM-secreted human PPCA precursor by galaclOsialidosis fibroblasts and restoration of enzyme activities 
Cathepsin A Ii-galactosidase Neuraminidase 
(nmole/minlmg) (nmolelhr/mg) (nmole/hrfmg) 
No addition 2.1 66 0.05 
Normal serum 3.3 78 0.1 
Normal BM-CM 5.5 71 3.1 
TG serum 31.2 186 14.5 
TGBM-CM 51.2 216 13.5 
Conditioned media (CM) from cultured BM cells and serum samples, both derived from either normal or transgenic (TC! mice, were 
added to PPCA (-/- ) human galaeto,ialidosis fibroblasts. After uptake, celllysates were assayed for exogenous cathepsin A activitiy 
using the acylated dipeptide Z·phe-Ala and for endogenous neuraminidase and Ii-galactosidase activities using synthetic 4·methyl-
umbelliferyl substrates. 
months, were lethally irradiated and transplanted, six 
with bone marrow from transgenic mice and six with 
bone marrow from normal mice. Both donor mouse lines 
were T cell depleted and were H-2B compatible with the 
affected recipients. The repopulated mice were moni-
tored for the level of storage material excreted in urine 
ITable 2). At S weeks after transplantation the total ex· 
eretion of sialyloligosaccharides already was reduced to 
normal values, indicating that the PPCA provided by 
both transgenic and normal BM cells was sufficient to 
correct the accumulation of these storage products in 
urine. Furthermore, gross examination of transplanted 
animals, starting at 3 months post-BMT, showed com-
plete reversal of the diseased phenotype, as exemplified 
by the lO-month-old mouse shown in Fig. 2 [left}, trans-
planted 5 months earlier with transgenic bone 
marrow. 
Histopathology of transplanted mice 
Tissue sections from kidney, liver, spleen, intestine, 
heart, lymph nodes, and brain of two (-/-) mice trans· 
planted with bone marrow from either transgenic {BMT-
TgJ or normal donors {BMT-N} were compared with sim-
ilar sections from normal and untreated littermates 3 
months after transplantation. As shown in Fig. SA, the 
abnormalities in the proximal tubular epithelium in the 
kidney of the BMT-N mouse were resolved practically, 
whereas storage vacuoles were still abundant in the glo· 
merular epithelium. These aberrant features still per-
sisted in similarly treated mice examined 2 months 
later. In contrast, kidney specimens of the BMT-Tg 
mouse showed complete reversal of the diseased pheno-
type, even within the glomeruli, indicating that a higher 
dose of normal enzyme had a more beneficial and imme-
diate effect on this severely affected tissue. Clearance of 
storage material and normalization of cellular morphol· 
ogy was apparent from the liver of mice treated either 
with normal or transgenic bone marrow (Fig. SA). How-
ever, Kupffer cells with some vacuoles were encountered 
infrequently in liver sections of the BMT-N mouse, but 
not in corresponding sections of the BMT-Tg mouse. As 
expected, spleen !Fig. SA) as well as bone marrow spec-
imens appeared completely normal. Most of the abnor-
malities in the colon, jejlmum, and duodenum were cor-
Tected, though the autonomic ganglia still showed a 
lesser degree of storage. In the heart vacuolated endothe-
lial cells and foamy histiocytes were no longer encoun-
tered. The lymph nodes of both types of transplanted 
mice had a normal appearance with no evidence of ac-
cumulation of foamy macrophages, although storage in 
occasional lymphoid cells was seen only in the speci-
mens from the BMT-N mice (not shown}. In the brain of 
8M-transplanted mice storage neurons and perivascular 
as well as perineural vacuolated cells still could be iden-
tified lnat shown). However, further quantitative assess-
ment is necessary to evaluate the effect of the BM trans-
plant in the brain. On the other hand, vacuolated cells in 
the choroid plexi {Fig. SB}, the trigeminal ganglia, and the 
pituitary had disappeared completely in both trans· 
planted mice. 
In conclusion, reversal of the diseased phenotype 
clearly was significant in BMT-N mice but was more 
complete in Bi\1T-Tg animals, supporting the idea that 
the release of a higher level of enzyme by overproducing 
donor BM cells is likely to be more effective for treat-
nlent. 
Discussion 
Molecular and biochemical characteristics of PPCA 
{-/-} mice correlate well with the most severe form of 
galactosialidosis in humans. Although viable and fertile, 
deficient mice present signs of illness very early in life 
with clear evidence of metabolic storage in cells from 
different organs. The edema, visceromegaly, and coarse 
face noticed in {-/- J animals are abnormalities charac-
teristic of the human disease phenotype. Nephropathy, 
which is a major complication and cause of death in 
early infantile patients {d'Azzo ct al. 1995}, is also the 
most apparent cause of physical deterioration in affected 
mice. Discrepancy in the severity of the disease between 
early infantile patients and young affected mice may be 
attributed simply to the much shorter gestation period of 
mice because the pathology of lysosomal disorders is 
targely associated with progressive accumulation of un-
degraded products in Iysosomes, leading eventually to 
cellular dysfunction. The greater longevity of affected 
mice relative to human patients could also relate to the 
observed higher levels of ~-galactosidase in some of the 
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Figure 5. Histology of BMT mice. {AI Sections from the kidney 
(Kid.), liver (tiv.l, and spleen (SpI.J of a (-/-) mouse trans-
planted with either BMT-N or BMT-Tg were stained with to-
luidine blue (magnification, 400xJ. In the BMT-N kidney, stor· 
age vacuoles still are apparent in the glomerular epithelium. In 
contrast, the BMT - Tg kidney shows complete correction of the 
lesions. In both BMT-N and BMT-Tg mice, the !h-cr and the 
spleen show normal cellular morphology. However, in the 
BMT -N mouse, some of the Kupffcr cells still are slightly vac· 
uolated. IB) Haematoxylin/eosin·stained paraffin sections (mag-
nification, 400Xj of the choroid plexus from normal, affected, 
and transplanted mice. Storage in the epithelial cells of the {-I 
- J animal is signified by the dispersed staining of the cyto· 
plasm. This aberration is reversed completely by transplanta· 
tion with normal or transgenic BM. 
affected mouse tissues. Alternatively, but not exclusive 
of the first two, the difference may be caused by species-
specific variation in substrate metabolism. Similar ex-
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planations may aCCOUlH for divergence in time of devel-
opment of the diseased phenotype for mice and humans 
with hexosaminidase A deficiency (Yamanaka et al. 
1994). Thus, in spite of the longer survival, galactosiaU-
dosis mice are affected severely and can be considered a 
faithful model for the human disease. 
The deficiency of PPCA in tissues of mutant mice is 
accompanied by an equivalent loss of lysosomal neur-
aminidase activity, whereas Il-galactosidase values are 
variable. Although in murine (- / -) fibroblasts the re-
sidual Il·galactosidase activity is consistent with that 
measured in patients' cells (d'Azzo et al. 1995J, in other 
tissues the activity is either only slightly reduced or 
higher than normal levels. This finding may again reflect 
dif(erences between species, although equivalent data for 
galactosialidosis patients are scarce, as autopsies are lim-
ited to a few cases from adult Japanese patients (Amano 
et al. 1983; Suzuki et oil. 1984). The mouse results may 
be in line with earlier purification and coprecipitation 
studies, indicating that only a fraction of the Il·galactosi-
dase and PPCA in mammalian tissues exists in the as-
sociated mode, whereas all neuraminidase activity is de-
tected in complex with the other two enzymes jVerhe-
ijen et al. 1985; Galjart ct a1. 1991; Hubbes et oil. 1992). 
Thus, it is possible that in different murine cell types, 
Il-galactosidase is stable whether or not associated with 
PPCA, whereas the interaction of neuraminidase with 
PPCA clearly is essential for its activity. The conse-
quences of the severe neuraminidase, rather than Il-ga-
lactosidase, deficiency are reflected in the type of storage 
products present in urine of the (-/-) mice, which arc 
mainly sialylated oligosaccharides, as observed in hu-
man patients {Amano et al. 1983 j van Pelt et al. 1989). 
The pathological findings in the PPCA-deficient mice 
are consistent with those reported for galactosialidosis 
patients. Epithelial cells, endothelial cells, and macro-
phages are the first to show lesions in most organs, and 
the distribution of storage appears similar to that ob-
served in the Gaucher and Nieman Pick mouse models 
(Tybulewicz et al. 1992; Horinouchi et al. 1995; Otter-
bach and Stoffel 1995). The type and number of vacuo· 
lated cells in galactosialidosis mice gradually increase 
with age. However, not all cells become affected and the 
extent of the damage is variable, even in older (-/-) 
animals. The profiles may depend on the metabolic state 
of the cells and the type of substrates to be catabolized, 
in particular by neuraminidase. Alternatively, it may re-
flect a microheterogeneity in the distribution of the nor-
mal protein in different cell types. We have shown pre-
viously that the protective and catalytic functions of 
PPCA are fully separable {Galjart et a1. 1991), but the 
physiological significance of the cathepsin A activity is 
still unclear. We can speculate that in certain cells the 
protein exerts its activity outside the lysosomal com-
plex. In this case,loss of catalytic activity may not result 
in lysosomal storage. Perhaps evidence of a functional 
lesion will be found when knockout mice are screened 
for symptoms associated with loss of cathepsin A activ-
ity on peptides (e.g., substance P, oxytocin, or endothelin 
1), which may be substrates of the protein in vivo. 
The most striking results of this study are those ob· 
tained with BMT. The main aim for generating a mouse 
model for galactosialidosis was to evaluate therapeutic 
strategies that could be applicable to genetic correction 
of this and other similar disorders in humans. The pos· 
sibility of manipulating autologous hematopoietic pro· 
genitor cells in vitro that will express constitutively the 
correcting enzyme at high levels in the repopulated reo 
cipient has important implications for somatic gene 
therapy of lysosomal disorders with CNS involvement. 
Transfer and expression of foreign genes into animal and 
human hematopoietic cells, as well as other cell types, 
has been achieved using different viral vectors {for reo 
view, see Kay and Woo 1994}. In designing a therapeutic 
approach for our galactosialidosis mouse model, we 
started with the supposition that the amount of normal 
enzyme (supplied by BM cells) would be crucial for ef· 
fective correction. Thus, we have analyzed the conse· 
quences of transplanting PPCA /-/-) mice with BM 
cells, derived from a transgenic line overexpressing the 
normal protein in a specific hematopoietic lineage. By 
analogy with other heterologous genes (van Assendelft et 
al. 1989) Needham et at. 1992), the LCR and fl·globin 
cassette (used in this study) promote high expression of 
PPCA in erythroid precursor cells in a copy number·de-
pendent, position·independent fashion. Overexpression 
of the transgene results in the extracellular release of 
PPCA precursor that is readily taken up by deficient hu· 
man cells via a mannose·6·phosphate·mediated endocy· 
tosis. Hyper secretion is selective for the product of the 
transgene, as observed previously for other lysosomal en· 
zymes overexpressed in various cell types (Ioannou et al. 
1992) Grubb et al. 1993; Kakkis et al. 1994}. BMT has 
proven to be very effective for improvement of the dis· 
eased phenotype. Treated PPCA (-/-) animals look 
completely normal and outlive the affected mice. Anal· 
ysis of their tissues demonstrates that transplantation of 
the overexpressing bone marrow clearly is more effective 
than normal bone marrow for clearing storage in cells of 
visceral organs that undergo complete reversal of the Ie· 
sions. The most plausible explanation of these data is 
that erythroid precursor cells secrete sufficient amounts 
of a stable PPCA precursor into the plasma to permit its 
ready uptake by cells in distant organs. Correction in the 
CNS, which mostly excludes plasma proteins because of 
the blood-brain barrier, is less evident but still notice· 
able, especially in the epithelial cells of the choroid 
plexi. This is likely attributable to internalization of the 
heterologous human protein from the plasma via the 
mannose·6·phosphate receptor (Nilsson et al. 1992) and/ 
or the murine protein from donor-derived monocytes 
and perivascular macrophages. Detailed evaluation of 
the degree of CNS correction awaits fine mapping of the 
affected cells in different regions of the brain, which is 
currently in progress, and the analysis of a larger number 
of treated mice. Our findings conform in part with the 
results obtained with BMT in cats with the lysosomal 
storage disorder a·mannosidosis (Walkley et al. 1994a), 
another disorder of glycoprotein metabolism. These in· 
vestigators report a clear improvement of the CNS Ie· 
sions, but its extent is unclear, as no detailed spatial 
mapping of the storage neurons was presented. To im· 
prove the correction of the CNS, we currently are testing 
whether transgenic bone marrow with targeted expres-
sion of PPCA in the monocyte/macrophage lineage 
would be more effective, Transplantation of young ani· 
mals with such transgenic bone marrow is expected to be 
more beneficial because donor-derived monocytes and 
macrophages can become part of the microglial popula· 
tion (Perry et a1. 1985) Hickey and Kimura 1988}. 
Although galactosialidosis affects only a small propor· 
tion of the population, it has devastating consequences 
in children, with the early infantile form of the disease 
resulting in early death, multiple organ dysfunction, and 
mental retardation. There are, however, a limited num· 
ber of patients, some of them diagnosed recently, in 
which the disease does not impairtheCNS. Our findings 
indicate that somatic gene therapy approaches using au· 
tologous human 8M cells, which continuously express 
the correcting enzyme at high levels, may be feasible in 
the future as a cure of galactosialidosis, especially in 
mildly affected children. Moreover, they set the stage for 
the use of this approach in other lysosomal storage 
diseases. 
Materials and methods 
Construction of the PPCA targeling vec/or 
A mouse genomic clone encompassing the entire coding region 
of the PPCA gene was isolated from an EMBL-3 X phage library 
construCled with DNA from the CCE ES cell line derived from 
mouse strain 1 29Sv. PPCA DNA sequences contained in a l4-
kb SaIl fragment were identified by restriction mapping and 
paIlial sequencing of exons, From this done a lO·kb EcoRI-Sall 
fragment was subdoned into pTZIS and used to generate the 
targeting vector. The hygro caSsette ( ... an Deursen and Wieringa 
1992) was inserted into exon 2 of the PPCA gene, 6 nucleotides 
downstream of the ATG start codon (see Fig. 1). In the resulting 
targeting vector, the hygro gene was flanked 5' and 3' by 3 and 
7 kb of homologous sequences, respectively. A 2.0·kb SaIlfrag· 
ment of the herpes simplex \'irus thymidine kinase (HSV-TK) 
cassene was positioned 3' of the conStruct, outside the region of 
homology. Both positive and negative selectable markers were 
inserted in the antisense orientation with respect to the tran· 
scriptional orientation of the PPCA gene and were dri ... en by the 
TK promoter and PyF441 polyoma enhancer. 
Gene targeting in ES cells 
The 12910Ia·deri ... ed ES cell line El4 (a gift of Anton Berns, The 
Netherlands Cancer Institute, Amsterdam) was maintained in 
60% Buffalo rat liver (BRL)·conditioned Dulbecco's modified 
Eagle medium (DMEM)140% fresh DMEM, 15% fetal bo ... ine 
serum (FBS), 0.1 m~\ 2·mercaptoethanol, 2 m.\\ glutamine, and 
1000 U/m! of leukemia inhibiting factor (GIBCO). The cells 
were Irypsinized, resuspended at a concentration of 107 /ml in 
PBS, and eleclroporated at room temperature with 25 )lg of Sail 
linearized vector DNA at 117 Vand 1200)lF for 10 rosec, using 
a Progenetor II gene pulser (HoeUer). After electroporation, cells 
were kept on ice for 10 min and transferred onto lO·cm culture 
dishes coated with 0.1% gelatin in above medium. After reco ... • 
ery for 24 hr, cells were put on selection medium containing 188 
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J.lg/ml of hygromycin B {Calbiochem] and 0.2 J.lM FIAU {H2-
deoxy, 2-fluoro-Jl-o-arabinofuranosyIJ-S iodoutacil, a kind gift of 
BrislOl Myers] for 7-10 days. Resisunt colonies were expanded 
in 24-well plates; half of the cells in each well was cryopre-
served, and the other half was expanded for genotype analysis. 
Positive dones were slOred in liquid nitrogen and thawed at 
least 3 days before blastocyst injection. 
Generation of mutant mice 
Blastocysts were isolated at day 3.5 postcoitum by flushing the 
uterine horns of naturally mated C57BLl6 pregnant females 
with DMEM plus 10% FB5. Approximately 10-15 ES cells from 
each homologous recombinant done carrying 40 chromosomes 
were microinjected into recipient blastocysts, and 9-14 em-
bryos were transferred into the uterine horns of (C57BLI 
6xCBAlCa] FI pseudopregnant fosters IBradley 1987J. Chimeric 
males were mated with C57BLl6 or FVB/T females, and germ-
line transmission of the mutant allele was verified by Southern 
blot analysis of tail DNA from FI offspring with either agouti or 
gray coat color. F2 offspring from interbred heterozygotes was 
genotyped by Southern blotting to identify homozygous null 
mutants. The phenotypic alterations in PPCA {-1-1 mice, as 
presented in this paper, were uniform and showed complete 
penelrance, irrespective of their genetic background. 
Southern and Northern Blo/ Analyses 
Genomic DNA isolated from ES cells or mouse tails was di-
gested with NdeI, resolved on a 0.8% agJrose gel, and Irans-
ferred onto Hybond-N + membranes {Amershaml_ The 5' junc-
tion was checked by hybridization with a l-kb EcoRI-NdeI 
probe positioned immediately 5' of the targeting construct, and 
the 3' junction was checked with aO.5-kb PCR probe positioned 
immediately3' of the targeting construct. Absence of additional 
random integrations of the targeting construct was checked 
with a hyglO probe. Clones that contained the expected S-kb 
NdeI fragment, diagnostic for homologous recombination, were 
obtained at a frequency of 1 in 7. For genotype analySiS of tail 
DNA, only the 5' probe was used. Total RNA was isolated from 
brain, kidney, and liver tissues of 4-to 6-week-old mice as de-
scribed (Auffray and Rougeon 1980). RNA {15--20 J.lgl was sep-
arated on a 1 % agarose gel containing 0.66 M formaldehyde. 
After electrophoresis, the RNA was blotted onto a Zeta-probe 
membrane (Bio-Rad) and hybridized with the mouse eDNA 
probe. 
Enzyme activity assays and urine 
oligosaccharide determillations 
For enzyme activity assays, primary cultures of skin fibroblasts 
and tissues from affected and normal mice were homogenized in 
double-distilled water. Cathepsin A activity was measured with 
the synthetic dipeptide substrate Z-Phe-Ala, according to the 
procedure described earlier {Galiart et a119911. The activities of 
p-galactosidase and neuraminidase were assayed with artificial 
4-methylumbelliferyl substrates {Galjaard 1980J. Total protein 
concentration was determined using the method of Smith et aL 
{19851. Total sialic acid content in urine was measured in 10 J.lI 
samples after hydrolysis inO.l N H1 S04 by a modification of the 
method of Aminoff (1961J, as described in Wenger and Williams 
(1991). N-acetylneuraminic acid was used as a standard. Creat-
inine was measured in a fraction of each sample by the central 
diagnostic laboratory of Thomas Teffersoll University jPhiladel-
phia, PA). 
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Histopathological analyses 
Tissues isolated from affected and BM-treated mice as well as 
normal or heterozygous littermates were fixed with 2% glut-
araldehyde in 0.2 M phosphate buffer, postfixed with 1 % os-
mium tetroxide in 0.2:-'1 phosphate buffer, dehydrated in graded 
ethanol (70% through absolute), en bloc stained with 4% uranyl 
acetate in absolute ethanol, and embedded in Spun resin ILadd 
Research Industries, Inc., Burlington, VTJ. Semithin sections 
were cut at 470 nm and stained with toluidine blue for light 
microscopy_ Sections for electron microscopy were cut at 85 nm 
and stained with 2% uranyl acetate/lead dtrate and screened 
with lEOL 1200 EX II HEOL USA Inc., Peabody, MAJ. For prep-
aration of paraffin sections, dissected tissues were fixed over-
night in 10% formalin_ After dehydration and paraffin embed-
ding, 6·p.m sections were made, mounted on slides, and stained 
vdth haematoxylin/eosin. For the analysis of the brain, affected 
and BM.-treated mice were perfused through the left cardiac ven-
tricle with 4% paraformaldehyde in PBS. The cerebrum was 
sectioned coronaUy at the level of the optic chiasm_ The ante-
rior half of the cerebrum, cerebellum, and brainstem were pro-
cessed for paraffin embedding, sectioned 6 J.lm thick, and 
stained solochrome/eosin and luxol fast blue JLFBII PAS. The 
posterior half was cryosectioned serially at 10 J.lm thick and 
stained with PAS. The trigeminJI ganglia and pituitary gland 
were postfixed with osmium and processed for epoxy-resin em-
bedding as described above. 
Uptake in galactosialido5is fibroblasts 
BM cells from three normal and three transgenic mice were 
han'cstcd by flushing the femurs with DMEM and 15% FB5. 
Cells were washed once with the same medium and seeded at a 
concentration of 1.5x 106/ml in three 30 mm dishes. Then they 
were cultured for an additional 5 days in the above medium 
supplemented with 10 U/ml of erythropoietin (Amgen, IncJ. 
The conditioned medium from each culture then was pooled 
and added to confluent galactosialidosis fibroblasts from an 
early infantile patient, seeded S days in advance in six-well 
plates. In parallel, serum samples from the same mice were also 
pooled, concentrated, and added to the deficient cells. Uptake 
was carried out for 4 days. Treated fibroblasts then were har-
vested by trypsinization and homogenized for enzymatic assays 
as above. 
BM transplantation 
The recipient galactosialidosis mice at 2.5--S months of age 
were lethally irradiated with 9.25 G}' from J cesium irradiator, 
24 hr before transplant. Normal BM was derived from two 
C57BL/6 ThyLl mice. Transgenic BM was derived from two 
mice of a (C57BI/6xCBA) FI transgenic line in which the hu-
man protective protein precursor is overexpressed in the ery-
throid lineage under the conlrol of the jl-globin promoter and 
LCR. BM cells were han'ested by flushing the femurs with 
Hanks medium with 5% FBS. Prior to BMT, donor cells were 
incubated with HO-22-I and AT 83 antibodies for IS min to 
deplete the T-cell population. A cell suspension {0.5 mlJ con-
taining 2x 101 cclls/ml was injected intravenously into the tail 
vein. Starting at 3 months post-transplantation, tissues from 
both normal and transgenic BM-treated mice were isolated and 
prepared for light microscopy, as dcscribed above. 
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Protective protein/cathepsin A (PPCA) Is a pleiotropic ly-
sosomal enzyme that complexes with jl-galactosldase 
and neuraminidase, and possesses serine carboxypepti-
dase activity. Its deficiency in man results in the neurocle-
generative lysosomal storage disorder galactoslalldosis 
(GS). The mouse model of this disease resembles the 
human early onset phenotype and results In severe 
nephropathy and ataxia. To understand beHer the patho-
physiology of the disease, we compared the occurrence 
of lysosomal PPCA mANA and protein In normal adult 
mouse tissues with the Incidence of lysosomal storage 
In PPCA(-/-) mice. PPCA expression was markedly vari-
able among different tissues. Most sites that produced 
both mANA and protein at high levels in normal mice 
showed extensive and overt storage In the knockout 
mice. However, this correlation was not consistent as 
some cells that normally expressed high levels of PPCA 
were unaffected in their storage capability in the 
PPCA(-/-} mice. In addition, some normally low expres-
sing cells accumulated large amounts of undegraded 
products in the GS mouse. This apparent discrepancy 
may reflect a requirement for the catalytic rather than the 
protective function of PPCA andlor the presence of cell-
specific substrates in certain cell types. A detailed map 
showing the cellular distribution of PPCA In nomal 
mouse tissues as well as the siles of lysosomal storage 
In deficient mice is critical for accurate assessment of 
the effects of therapeutic Interventions. 
INTRODUCTION 
Lysosomal protective protein/cathepsin A (PPCA) is a serine 
carboxypeptidase that fonns a high molecular weight multi-
enzyme complex with acid p-o-galactosidase and 
N-acetyl-«-neuraminidase (1---6). PPCt\'s role in this complex is 
to facilitate the intracellular routing, lysosomal localization and 
activation of neuraminidase (7,8), and to stabilize p-galactosidase 
in the lysosomal environment (5,9). Genetic lesions in thc PPCA 
gene that abolish its protective function cause severe loss of 
neuraminidase activity, and render fl-galactosidase susceptible to 
rapid intralysosomal proteolysis (10, II). The resulting combined 
enzyme deficiency is the basis of the lysosomal storage disorder 
galactosialidosis (GS), which is characterized by the primary 
accumulation of sialylated oligosaccharidcs and glycopeptidcs in 
patient tissues and body fluids (12-15). Patients with as present 
clinically with one of three fonns of the disease (early infantile, 
latc infantile or juvenile/adult), depending on their age at onset 
and the sewnt)' of their symptoms (16). The early onsct patients, 
who completely lack PPCA activity, die within the first months 
of life from heart and kidney failure. The mouse model of GS 
closely resembles the phenotype of early infantile patients (17). 
Extensive vacuolation of certain cells in most orgalls is caused by 
the abnonnal accumulation of undigested metabolites that result 
primarily from the severe secondary deficiency of lysosomal 
neuraminidase. 
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As n member of the serine protease family, PPCA exerts 
cathepsin A activity at acidic pH and esteraselC-terminal 
deamidase activity at neutral pH. The catal)1ic activity ofPPCA, 
which is fully separable from its protective function (18), is 
apparently important for the initial catalysis of selected bioactive 
peptides, iricluding substance P, oxytocin and endothelin I 
(19-22). However, the physiological significance of this enzyme 
activity has 1I0t yet been proven. Recently, we identified the 
minimal promoter regions of the human and mouse PPCA genes 
(23). Transcription of the murine gene, unlike that of the human 
gene, gives rise to two differentially expressed transcripts that 
contain the same protein-encoding region. The more abundant 1.8 
kb species is expressed in all tissues and originates from a 
promoter with features characteristic of housekeeping gene 
promoters (23). A minor murine-specific 2.0 kb mRNA is 
transcribed from a TATA box-containing promoter and is 
expressed at lower levels in specific tissues. 
Here, we studied the ill l'il'O expression of PPCA in adult 
murine tissues by using ill situ hybridization and immunocyto-
chemistry. Our aim was to correlate the distribution pattern of 
PPCA mRi\'A and protein in normal mice with the disease 
pathology in the knockout mouse. Our findings demonstrate that 
PPCA expression is not ubiquitous in normal adult tissues, but 
rather is confined preferentially to specific cells, especially those 
that ure metabolically active. ~-lost regions that express PPCA at 
high levels develop overt morphologic changes in the knockout 
mouse. Interestingly, however, there are also cell types where the 
correlation between gene expression and the occurrence of 
lysosomal storage is not maintained. We discuss how this result 
could suggest a role for the catalytic rather than the protective 
function of PPCA. 
RESULTS 
111e distribution of PPCA mRNA and protein in the tissues of 
normal adult mice was analyzed using ill silll hybridization and 
immunocytochemistry, respectively. The presence of lysosomal 
storage materi[ll in defined cell populations of GS mice was 
cvidenced by periodic acid Schiff (PAS) staining and lysosomal 
vacuolation. 
Urain 
Despitc a generalized expre£sion of PPCA in the brain, regional 
and cellular differences were obvious. The frontal, parietal and 
occipital lobes of the cortex displayed a moderate signal 
throughout the inner five layers, whereas the extemallayer, which 
contains unmyelinated axons, was devoid of PPCA-specific 
signal (Fig. IA). The inferior colliculus and cells within the 
meningeal layers also contained PPCA transcripts and protein. 
The expression in the cortex and the diencephalon was confined 
primarily to neuronal cell bodies rather than to nerve fibers. 
Sustained expression of PPCA mRNA was detected throughout 
the olfactory bulb, being most prominent at the level of the mitral 
cell layer (Fig. IB). This was paralleled by strong punctated 
PPCA staining in the large mitral cells (Fig. I C). Weak expression 
was present in the granular cells and the periglomerular neurons. 
The axons of the mitral cells are in contact with the olfactory 
cortex, which consists of five defined regions: the anterior 
olfactory nuclei, the tuberculum olfactorium, the pyrifoml 
cortical neurons, the amygdala and the entorhinal cortex. All of 
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these areas, which belong to the limbic system, and in particular 
the tuberculum olfactorium and the pyriform nuclear cells, 
expressed PPCA mRNA and protein at high levels (not shown). 
The pyramidal neurons of the hippocampus and the granular cells 
of the dentate gyrus were also highly positive for both mRNA and 
protein (Fig. IE and F). Only basal expression levels were 
detected in the caudate putamen, the thalamic and hypothalamic 
regions, and the substantia nigra (not shown). In the cerebellum, 
a strong positive signal was confined to the Purkinje cells, 
whereas the molecular and granular layers had significantly lower 
expression (Fig. I H and I). The large neuronS of the cerebellar 
nucleus also stained strongly. Like the cerebrum and the 
cerebellUm, the brain stem expressed PPCA primarily in gray 
mailer nuclei, containing the cell bodies of the different neurons. 
Both PPCA transcripts and protein were very prominent in the 
epithelial cells of the choroid plexus, whereas expression in the 
ependymal cells that line the cerebral ventricles was low (Fig. 1 K 
and L). Strong expression was detected in the perivascular and 
leptomeningeal macrophages. 
In general, PPCA expression in the brain correlated well with 
the distribution of vacuolated cells with lysosomal storage in the 
PPCA(-I-) mome. PAS-positive cells appeared early in life. At 
2 months of age, they were detected only in the anterior olfactory 
nucleus, the amygdala and the entorhinal cortex (not shown). 
Occasional Purkinje cells were also positive. As the disease 
progressed, the number of accumulating cells became more 
conspicuous in these regions; other neurons also appeared 
positive, including mitral cells (Fig. lD), neurons of the 3rd-4th 
cerebral cortical layer, scattered cells of the thalamus and 
hypothalamus, and the large neurons of the cercbellarnucleus and 
brain stem (not shown). Interestingly, PAS-positive staining 
differed in different vacuolated cell types, probably reflecting 
variation in the composition of storage prodUCts. The choroid 
plexus, for example, showed clear morphological changes 
without evident PAS staining (Fig. 1~'1). Contrary to what might 
be expected from the high PPCA expression in the pyramidal 
neurons of the hippocampus and the granular cells of the dentate 
gyrus, very few PAS-positive or vacuolated cells were detected 
in these areas (Fig. IG). This apparent inconsistency could be 
attributed to differences in the metabolic state of these cells or to 
the type of macromolecular substrates. Furthermore, there 
appeared to be a variable effect of the storage products on cell 
viability. Purkinje cells display few large PAS-positive granules 
prior to cell death (Fig. IJ), whereas cerebellar basket cells, and 
cells of the amygdala and anterior olfactory nucleus, become 
filled with PAS-positive material prior to obvious signs of cellular 
deterioration (not shown). It should also be noted that the 
undegraded products accumulate first in the Purkinje cells of the 
more anterior lobules which also die earliest. As the disease 
progresses, however, Purkinje cells in more posterior regions 
store and die. Loss of these cells contributes to the progressive 
ataxia seen in these mice (17). Interestingly, a similar feature was 
obser.ed in other mouse models of lysosomal storage disorders 
such as Niemann-Pick A and C (24-27). 
Visceral organs 
PPCA mRNA expression was distributed throughout the liver 
(Fig. 2A). ImnlUnocytochemistry clearly demonstrated that the 
protein expression was moderate in hepatocytes and high in 
Kupffer cells (Fig. 28), reflecting the storage pattern detectcd in 
FIgure I. Comparison of PPCA mRNA and protein expre.;sion in ""i1d-t)pe mouse brain with !)'SOsomalstorage in PPCA{-I-) mouse brain. Sagittal brain ~ctions 
demonllrate the localization of mouse PPCA mRNA expre.;sion by i" Silll RNA h}'bridiution (A. B, E, H and K) and protein distribution by immuooc)to<:hemhtl)' 
with PPCA antibodies (C, F, I and L) in re!atioo to the accumulation of undegra&:d Iy~osomal producls in the PPCA(-/-) mouse (D. G, J and M). (A) An o\"ef\'iew 
of a dark-field image of a mouse brain; the asterish mark the regions of high PPCA mRNA npression. Representative areas show PPCA expression and accumulated 
storage in the mitral ceHlayer of the olfactory bulb (B-O), the hippo:amp<.ls and denlate gyrus (F ..... G), the Purkinje cell layer of the cerebellum (ll-J) and the choroid 
ple.\us (K-:\I). Note the PAS-positive storage granules in the mitral (D) and Purkinje cells (1), the !:lck of storage in the hippocamp<.ls anddenlate g)"J\lS (0), and the 
PAS-l1i!galjve storage \acuoles in the choroid pinus (M). Mice of age 2-6 months ""ere used for ill Jim RNA h)bridization and immunoC}tochemistry, and mice of 
11}-13 months were used for PAS staining although storage was visible in some cells earlier. All in Jim RNA h,bridiu.1ionand PAS slaining ""ere performed on froun 
sections, and immUIl<X)lOChemistry was performed on PJIaffin ~tions. Scale bJI '" J mm (A), 250 Jlm (E, G and H), 50 Jlffi (B-D, F and I-M), 
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Figufl,' 2. Comparison of PPCA mRNA and protein npression in wild·type moose tissues with lysosomal storage in PPCA{-I-) mOllse tissue5. PPCA mRNA 
Hpression \l'as arlJlyzed in wild·type mice (2-4 months) by iii Jim RN A h)'bridization (A, D, G and J), rne distribution of protein wasdelecled by immunoc) tocliemistry 
\\ith PPCA ilI\tibodies (B. E, H and K) and lysosomal storage prodU(i5 were \"isualizetl in PPCA{-I-)mice (2--4 months) by PAS staining (C, F, I and L). Uvcr{A-C), 
sple~n (O-F), kidney (G-I) and small intestine (J-L) are ~hown. Note rnat mmt \'is,~ral organ storage prodocts are PAS·negaliye and appear as vacooles. SC.:lle 
b~r '" 50 11m (A-I), 150 11m (J-L). 
the knockout mouse, where Kupffer cells arc more affected than 
hepatocytes (Fig. 2C). The red pulp of the spleen showed higher 
protein and mRNA expression than the white pulp, probably 
because ofthc numerous macrophages thai express high levcls of 
PPCA (Fig. 2D and E). Consistent with this,lhe pathology of the 
splecn in the (....f-) mouse showed macrophages filled with 
vacuoles, whcrca~ lymphoc}1es and megakaryocylcs displayed 
little or no signs ofstorugc. As a result of accumulating products 
in the livcr and spleen, the affected mice develop hepatosple-
nomegaly, a clinical feature associated with the early and 
sometimes late infantile fomlS of the human disease (16). 
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In the kidncy of wild· type mice, PPCAexpression was high in 
the cuboidal epithelium of the proximal convoluted tubules and 
s.omewhat lower in the distal convoluted tubules of the nephron 
(Fig. 20 and H). The epithelial cells of Bowman's capsule were 
highly positivc, whereas the glomerulus expressed very low 
levels that could be seen only weakly by immunocytochcmistry 
(Fig. 2H). No expression was detected in the renal medulla. The 
epithelia of the proximal convoluted tubules and the Bowman's 
capsule were the first sites to store overtly ill PPCA(--/-) mice 
(Fig. 21). Intcrestingly, although the expression was very low in 
the glomerulus of the wild·type mouse, tltis region of the deficient 
FIgure 3. Comp.uison of PPCA mRNA and protein e_\pre~ion in wHd-t)1'¢ mouse ""ith lysosomal storage in PPCA(---/-) mouse male reprodu,ti\"e organs. PPCA 
mRNA eXj1fusion was analyzed in w Hd-Iype mice by in si/ll RNA b) bridil.ltion (A and 0), the distribution of the protein I'i as detected by immunoc),tochemistry with 
PPCA antibodies (B and E) and lysosomal storage produm were \-isualireJ in the PPC'A(-/-) mouse by PAS staining (C and FJ. Shown are til<' seminiferous tubules 
llild interstitial tissue oflhe testis (A-C) and the caput of the epidid)Tnis (D-F). Mke ranged in age from 2 to 4 months. Scale bar '" 90 !-1m (A-C), 35 /.1m (D-f.). 
mousc displayed high levels of storage (17). This severe renal 
pathology in knockout mice resulted in diffuse edema and closely 
paralleled the nephrotic syndrome seen in OS patients (16). 
In the duodenum and jejunum of the small intestine, the crypts 
of Lieberkuhn expressed high levels of PPCA mRNA. but little 
protein, whereas the mucosal layer of the microvilli expressed 
moderately (Fig. 21 and K). In (-/-) mice, storage products or 
vacuolation were not detected in these cells (Fig. 2L). However, 
foamy macrophages were seen in the inlerstitial space of the 
mucosa, submucosa, muscular outer layer and the lymphoid 
Peyer's patches (not shown). 
Heart and skeletal muscle appeared to have an overall, low 
PPCA expression. In muscle fibers, the knockout mouse dis-
played vacuolation only within endothelial cells and macro-
phages, but showed no signs of storage. The adrenal gland 
showed high expression in a specific rim of cells, probably the X 
zone, which is loosely defined between the cortical and the 
medullar cell layers (not shown). Cells in this layer secrete 
glucocorticoids and androgens, and are only present in sexually 
immature male and virgin female mice (28). PPCA(-I-) mice did 
not show detectable levels of storage products in the adrenal 
glund. 
Reproduclh'e s~'slem: t~slis and epididymis 
Within the seminiferous tubules of the testis, PPCA expression 
was observed in the Sertoli cells, which provide nutrients to the 
developing spemlatocytes. No expression was noted in the 
spemlatogonia or spermatocytes (Fig. 3A and B). ~-Ioderatc 
mRNA and protein levcls were also detected in the interstitial 
cells of Leydig, which surround the seminiferous tubules and 
secrete testosterone under the influence of luteinizing hormone. 
Interestingly, the PPCA signal wried along the length of the 
epididymis. ~·Iost proximal to the testis, in the caput epididymis, 
PPCA levels were very high in the columnar epithelial cells oflhe 
ducts with little or no apparent expression in the supportive 
connective tissue (Fig. 3D and E). Further along through the 
corpus of the epididymis, the number of expressing cells 
decreased to the cauda, where only a few expressed high levels 
of the protein (data not shown). 
In the (-1-) mice, extensive vacuolation occurred in all high 
expressing celis and, in addition, in the interstitial cells (Fig. 3C 
and F). Marked vacuolation of the epididymis and Leydig cells 
was already \'isible at 2 months of age, and these cells remained 
viable, but markedly affected, for the life of the animals. 
Drury and uterus 
The zona pellucida and the granulosa cells, that surround the 
developing follicle and serve as support and/or feeder cells for the 
follicle, expressed high levels of PPCA transcripts (data not 
shown). The corpus luteum, which originates from the differen-
tiated granulosa cells after follicle maturation and secretes 
estrogen and progesterone, displayed even higher levels of 
mRNA and protein, whereas expression was very low in the 
interstitial cells (not shown). High expression was also apparent 
in the coJumnarepitheIial cells and branched tubular glands of the 
uterus and, during pregnancy, within the rapidly dividing 
endometrium/trophoblasts. In the affected mouse, foamy macro-
phages infiltrated the stroma of the ovary and uterus, but the 
secretory epithelial cells appeared normal (data not shown). 
DISCUSSION 
It is becoming increasingly clear that the notion of lysosomal 
genes as simple housekeeping genes (Le. requiring little or no 
regulation) may be inaccurate. These enzymes are expressed at 
basalleve1s in virtually all cells, but are expressed differentially 
in specific cell types. For instance, murine pros[lposin mRi'IA is 
seen in Leydig, Sertoli and peritubular cells but not in the 
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spennatogenic cells of the testis (29,30). In contrast, acid 
phosphatase is detected only in the sperntatocytes of this organ 
(31). Acid lipase is expressed basally throughout the testis (32), 
while acid a-glucosidase is seen in the seminiferous tubules but 
not in the spennatogonia (33). In this study, we havc identified 
another pattern of expression in the testis, that of PPCA being 
evident in Leydig and Sertoli cells but not in spennatogenic cells. 
Similar differential expression for PPCA mRNA and protein 
exists for virtually all other tissues of the body, being highest in 
metabolically active or phagocytic cells. This is particularly 
evident in specific subpopu\ations ofneurofiS. 
The distribution pattern ofPPCA and other lysosomal enzymes 
necessitates some kind of regulation that carulOt be anticipated by 
the housekeeping characteristics of their promoters. Regulation 
of each of these genes could occur at the transcriptional and/or 
post-lmnscriptional levels. It has been reported that human 
H~partylglucosaminidase is regulated predominantly at the 
translational level (34). Moreover, the activity of lysosomal 
enzymes that rely on other proteins or cofactorslactivators for 
function may be modulated in a more complex fashion. For 
example, some lysosomal enzymes require other lysosomal 
proteins for intracellular transport and stabilil}' (neuraminidase! 
PPCA), activity (sphingolipid degradative enzymeslsaposins, 
p-hexosaminidase/G/lI2-activator) or substrate specificity 
(homo- and heterodimers ofp-hexosaminidase) (8,29,30,35~37). 
Despite differences in the expression patterns of many lysosomal 
proteins, it is noteworthy that their interacting and cooperating 
proteins are usually co-expressed in specific cells. Little is known 
uhout the physiological and pathological stimuli or molecular 
mechanisms that affect the activity of lysosomal enzymes; 
however, it is clear that steroid honnones, such as androgens and 
estrogens, have a general inductive effect on the activity levels of 
many Iysosom<ll enzymes (38-40), 
Comparing PPCA levels in nonnal mouse tissues with the 
distribution of storage in PPCA knockout mice reve<lled that, in 
most cell types, a higher level of expression correlated with more 
extensive storage. This was particularly evident in the brain 
where specific neurons, such as the Purkinje and mitral cells, and 
the cells of the am ygd<lla and entorhi nul cortex displayed the most 
extensive storage. In some neuronal cells such as those of the 
hippocampus and dentate gyrus, howe\'er, this pattern was not 
maintained. Also, the glomerulus of the kidney expressed 
virtually no PPCA and yet th<lt of the PPCA(-J-) mouse stored 
extensively. This apparent discrepancy between endogenous 
expression levels and the degree of storage in diseased mice could 
be due to a difference in the spectrum and amounts of substrates, 
derived during nonnal cellular processes. Alternatively, PPCA 
may be expressed in selected cells primarily for its enzymatic 
function on bioactive peptides, such as oxytocin, substance P or 
endothelin I (19-21), rather than for its abilil}' to protect 
neuraminidase and p-galactosidase. In this latter situation, 
undegraded products would not be expected to accumulate in the 
knockout model. It is worth noting that the substance Preceptor 
(NK-I receptor) is well expressed in the hippocampus (41,42); 
however, it remains to be seen whether the primary requirement 
for PPCA in these cells is for its role in neuropeptide inactivation. 
In PPCA(-J~) mice, we obsen'ed differences in the storage 
within different cell types. Purkinje cells accumulated only a few 
hlfge PAS-positive storage granules prior to cell death, whereas 
cerebellar basket cclis, nnd the cells of the amygdala and anterior 
olfactory nucleus, were nlmost completely full of fine storage 
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granules before they deteriorated. Epithelial cells of the choroid 
plexus, renal proximal convoluted tubule and caput epididymis 
accumulated PAS-negative material and appeared to survh'e for 
the entire lifespan of the animal. From these results, it seems clear 
that some stored internlediates have more toxic effects on cell 
viability than do others, or that certain cells may be more 
vulnerable to toxicity. In this regard, both GM2-ganglioside and 
oneofits downstream degradation products, ceramide, have been 
implicated in the induction of apoPlosis (43-47). 
The lifespan of cells may also playa role in the correlation 
between PPCA expression and storage. In the small intestine, we 
found PPCA mRt'lA transcripts in the crypts of Lieberkuhn and 
expression of the protein only in the mucosal epithelium of the 
microvilli. This is consistent with the newly dividing mucosal 
cells, differentiating in the crypts to express PPCA transcripts and 
then translating these transcripts into protein as they move toward 
the tips of the microvilli. As might be expected, in PPCA(-/~) 
mice, storage products were never apparent in these cells, 
probably because their lifespan is too short to allow for 
accumulation at detectable levels. 
The reproductive organs also differentially express PPCA, 
which is not surprising as lysosomal enzymes have been 
implicated in reproduction for many years (38,48-51). Both male 
and female mice express PPCA differentially at specific sites. In 
lhe knockout mice, the lack of PPCA considerably disturbs the 
reproductive capacity of the mice. Although fertile, they mate 
poorly, and the frequency of pregnancies is less than that for 
wild-type mice. Litter sizes and delivery, however, appear 
!lonnal. We do not know at the moment whether this reduced 
number of pregnancies, which worsens with age, is a result of 
decreased fertility or whether it is secondary to pathological 
effects on other organs, including the brain, which may affect 
perfornnnce. It is noteworthy that one of the peptide honnones 
known to be inactivated by PPCA is oxytocin (19). The honnone 
is found in the corpus luteum, which also expresses PPCA at high 
levels, and stimul<ltes growth during early blastocyst develop-
ment (52). Oxytocin and its receptor are also important for 
parturition and lactation in mflmmals (53-60). It is unclear 
whether the absence of PPCA in the knockout mouse model 
hampers processing or clearance of oxytocin in the uterus, which 
could have detrimental effects on the continuing pregnancy. 
Curiously, it has been reported that mothcrs of human GS 
patients, who have 50% PPCA activity, often suffer from 
spontaneous abortions (61). 
This detailed study highlights some important factors regarding 
the expression of lysosomal enzymes and the consequences of 
their functional loss. It is clear that there are marked differences 
in the expression levels of lysosomal enzymes in different cell 
types. Questions remain as to the specific cellular distribution of 
enzyme substrates and the differential toxicity of accumulated 
substrates in different cell types throughout the body. A detailed 
map of expression and storage will be extremely valuable in the 
accurate assessment of correction following therapeutic regimes. 
MATERIALS AND METHODS 
l\.laterials 
Chemicals were obtained from standard commercial suppliers. 
[a~3SSJUTP (>1000 Cilmmol; Amersham), was used to prepare 
riboprobcs for ill vitro transcription assays, which included either 
17 or T3 RNA polymerase (Promega Biotec). 
III situ RNA hybridization 
FVB mice (8-12 weeks old) were anesthesized sublethally with 
avertin and subsequently perfused with freshly prepared 4% 
parafonnaldehyde in 0.1 M sodium phosphate buffer, pH 7.4. 
Tissues were isolated and post-fixed for 2--4 h, before being 
processed for cryostat sectioning. Sections (10--14 pm) were 
placed on SuperfrostIPlus (Fisher Scientific) glass slides and 
h!'bridized for 16-20 h at 50"'C with a 272 bp murine PPCA 
3 S-labe1ed riboprobe (position 904--1176 bp of the mouse PPCA 
cDNA), as previously described (23,62). This probe detects both 
the predominant ubiquitous 1.8 kb and the minor 2.0 kb PPCA 
mRNA. The washed slides were dipped in photographic emulsion 
(Kodak NTB-2) and developed after 5--8 days with Kodak 0-19 
developer and fixer. The slides were then counterstained with 
0.1% toluidine blue and mounted. 
Immunocytochemical and histological staining 
Mice were perfused via the left cardiac ventricle at a rate of 
3.5 mUmin for 2 min with phosophate-buffered saline (PBS) to 
remove circulating blood cells. l1tey were perfused further for 
15 min with 4% parafonllaldehyde in 0.1 M sodium phosphate, 
pH 7.4. Tissues were removed and fixed for a further 4 h in the 
same fixative before being paraffin embedded. Tissue sections 
(10 pm for brain; 4 pm for all other tissues) were deparaffinized 
:md rehydrated and the antigen was retrieved by microwave 
boiling in 0.1 M citrate, pH 6.0, and cooling for 30 min. The 
sections were then blocked in PBS (containing 0.05% Tween-20 
and 0.1 % bovjne semm albumin) and 10% nonnal goat semm for 
30 min before being incubated overnight at room temperature 
with anti-mouse PPCA antibodies. The latter were raised in rabbit 
ugainst the native mouse PPCA precursor, overproduced in insect 
cells infected with a PPCA recombinant baculovirus eonstruct. 
The polyclonal antibody preparation was shown previously to be 
monospecific for the mouse 54 kDa precursor and mature 
subunits (63), The Vector ABC-HRP system was used for 
detection. After a secondary antibody incubation of 2 h, 
endogenous peroxidase activity was removed by adding PBS 
containing 0.3% hydrogen peroxide and 0.02% sodium azide for 
30 min. The ABC-I-IRP complex was then added for I hand 
visualized by adding a VIP substrate (Vector) for 3-8 min. Nuclei 
were counterstained with methyl green. For histological staining 
with hematoxylin/eosin, tissues were paraffin embedded (see 
above), and, for PAS staining, lissues were processed for frozen 
sectioning (17). 
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lysosomal neuraminidase (slalldase) occurs In a high 
molecular weight complex with the glycosidase 
p..galactosldase and the serine carboxypeptidase 
protective protein/cathepsin A (PPCA). Association of 
the enzyme with PPCA Is crucial for Its correct targeting 
and lysosomal activation. In man two genetically 
distinct storage dIsorders are associated with either a 
primary or a secondary deficiency of lysosomal 
neuraminidase: slal/dosts and galactoslalldosls. In the 
mouse the naturally occurring Inbred strain SMlJ 
presents with a number of phenotypic abnormalities 
that have been attributed to reduced neuraminidase 
activity. SMfJ mice were originally characterized by their 
altered slalylation of several lysosomal glycoprotelns. 
This defect was linked to a single gene, neu-1, on 
chromosome 17, which was mapped by linkage 
analysis to the H-2 locus. In addition, these mice have 
an altered Immune response that has also been coupled 
to a deficiency of the Neu-1 neuraminidase. Here we 
report the Identification In SMlJ mice of a single amino 
acid substitution (L2091) In the Neu-1 protein which Is 
responsible for the partial deficiency of lysosomal 
neuraminidase. We propose that the reduced activity Is 
caused by the enzyme's altered affinity for Its substrate, 
rather than a change In substrate specificity or turnover 
rate. The mutant enzyme Is correctly compartment-
alized In Iysosomes and maintains the ability to 
associate with Its activating protein, PPCA. We propose 
that It Is this mutation that Is responsible for the SMlJ 
phenotype. 
INTRODUCTION 
Neuraminidases (sialidases) constitute a large and important 
family of hydrolytic enzymes that cleave the terminal sialic acid 
residues from a variety of sialoglycoconjugates [for a review see 
(10)]. This event influences many cellular processes, including 
cell-cell interaction/adhesion. protection from pathogens and 
antigen recognition (10-14). Some family members share certain 
characteristic features, including the F(Y)RIP domain in the 
N-terminal region of the protein, where the arginine is part of the 
active site, and two to five evenly spaced Asp boxes (Sff-X-D-X-
G·X·T·W/F), which are located C-temlinal of the F(Y)RlP 
sequence (15,16). The three-dimensional structure of bacterial 
and viral sialidases has shown that these enzymes have a common 
catalytic core of -40 kDa with a characteristic six-bladed 
l3-propeller fold (17,18). Human lysosomal N-acetyl-((·neur· 
aminidase is deficient or defective in two distinct metabolic 
storage disorders; sialidosis, which is caused by slruclUrallesions 
in Ihe neuraminidase gene; and galactosialidosis, in which 
neuraminidase deficiency is secondary 10 a primary defect in the 
serine carboxypeptidase protective protein/cathepsin A (PPCA) 
(1,4). Recently we and others cloned the human neuraminidase 
eDNA and identified a number of independent mutations in the 
neuraminidase gene that we associated with different clinical 
variants of sialidosis (3,19,20). The neuraminidase locus maps to 
the HLA region on chromosome 6p21 (3,21,22). 
In the mouse a partial deficiency of a neuraminidase was first 
identified in the naturally occurring strain SM/J (23). These 
inbred mice had already been selected in the early 1940s for their 
relative small body size following cross matings with seven 
different inbred strains. Later, biochemical analysis demonstrated 
abnormal sialylation of at least four lysosomal glycoproleins thai 
showed an altered migration pattern on starch gel electrophoresis. 
This defect was corrected by treatment with bacterial sialidase 
[reviewed in (5)J. This hypersialylation was attributed to a 
reduction in activity of a liver-specific sialidase (5,24,25), 
although some reports suggested that other organs were also 
affected (23,26). The responsible gene was designated lIell·} and 
mapped, by linkage analysis, to the histocompatibility locus on 
chromosome 17, in the region between H·2D and H-2Eo: (6,7), 
\-vhich is syntenic to the human HLA locus on chromosome 6p21. 
Besides the abnonnal sialylation of lysosomal gl),coproteins, 
SM/J mice also have an impaired immune response, which is 
thought to result from the altered processing of sialic acids pres-
ent on cell surface molecules of subpopulations of T cells 
(8,9,27-31). An important step in the development of an immune 
r.esponse is differentiation of activated naive T cells into either 
IFN-y-producing (Thl) or IL-4·producing (Th2) cells {for a 
review see (32)]. Although Sr-,.VJ mice can stimulate a Thl-
mediated immune response, they cannot stimulate the coO\'ersion 
of naive T cells into lL-4-producing Th2 lymphocytes. This 
altered rcsponse has been auributed to reduced activity of Neu-I 
neuraminidase, which is thought to resuh in; (i) improper 
desialylation of surface antigens on Th2-commilled cells; (ij) 
rc;:duCiion in early fL-4 production; and (iii) absence of JgO I and 
IgE production by B cells after ill l'il'O immunization of SM/J 
mice with pertussis toxin (31). T cell Neu-I neuraminidase has 
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also been implicated in conversion of vitamin 03 binding protein 
into macrophage activating factor (27). Together these data 
suggest an important role for Neu-I neuraminidase in processing 
of selected sialoglycoconjugates at either the pla~ma membrane 
or within intracellular compartments. 
In this paper we describe identification of a single amino acid 
substitution, L209I, in the lieu i-encoded lysosomal neuramini-
dase ofSM/J mice. Analysis of the biochemical properties of this 
mutant enzyme demonstrates that its reduced neuraminidase 
activity is indeed caused by the presence of this mutation and not 
by improper compartmentalization of the protein, altered turn-
over or a lack of association with PPCA. 
RESULTS 
Isolation orthe murine neuraminidase eDNA and 
expression pattern or IleU-] in mouse tissues 
Two murine neuraminidase cDNAs (1.8 and 2.4 kb) were isolated 
using the human cDNA as probe. Both contained the same open 
reading frame, but the 2.4 kb clone lacked the first twocodons and 
had an extended 3'-untranslated region (UfR). The deduced 
amino acid sequence of the mouse protein is 91 % similar to its 
human counterpart: the N-temlinus begins with aeol1ventional39 
amino acid signal sequence (33) and includes a FRIP domain as 
well a~ three conserved and two degenerated Asp boxes. The 
protein has four potential N-linked glyeo~ylation site~; the first 
three arc found at identical positions in the human neuraminidase. 
wherea~ the fourth, which is close to the C-terminus, is only 
present in the mouse sequence (Fig. I). Northem blot analysis of 
multiple tissues. ming probes spanning the cDNA (Fig. I) 
demonstrated two major and two minortramcripfs. which \'aT)' in 
len!lth from 1.8 to 4.0 kb (Fig. \). The 3'-UTR probe, unique for 
the 2.4 kb cDNA, recognized only the 2.4 and 4.0 kb transcripts. 
indicating that the four mRNAs use alternative 3'-UTRs. The 
hybridization results suggest that all four transcripts contain the 
same protein encoding sequence. TIle 1.8 and 2.4 kb mRNAs 
were the most abundant and displayed a differential pattern of 
e;l;pression which closely correlated with expression of PPCA, 
which fomls a complex with the neuraminidase protein (34.35). 
The murine gene coding for the isolated cDNAs contains six 
coding exons (Table I). The gene spanned a small region of 4 kb 
and was mapped, using the 1.8 kb cDNA insert a~ probe, to the 
H~2 region of chromosome 17 (data not shown). 
Phenotypic characterization of Sl\UJ mice and 
idenfificalion of the mutation in the lleu-] gene 
All four neuraminidase tr,mscript~ di~played ~imilar pallerns of 
expression in kidney, brain, liver and spleen RNA prepamtions 
from St-.W mice (Fig. I). In addition, a single polypeptide was 
immunoprecipitated with anti-human neuraminidase antibodies 
(anti-neur) from mdiolabeled Iysates of SM/J fibroblasts; this 
immunoprecipitated protein was comparable in size with the 
nonnal murine protein (data not shown). Although we found no 
overt changes at the RNA or protein level, we did find that 
neuraminidase activity of SM/1 Neu-I differed from that of 
wild-type Neu-I. Using sodium 4-methyl-umbelliferyl-a-o-N-
acetylneuraminate (4-MU-NANA) as substrate, SM/J Neu-I 
activity was significantly reduced in lysosomal/mitochondrial 
extracts derived from several S~VJ ti~sues and this partial 
deficiency was clearly not restricted to anyone tissue (Fig. 2). 
S;\VJ neuraminidase activity in kidney and liver extracts was also 
lower than Ihat of control values when assayed with eilhera-2,3-
and a-2,6-sialyllactose (a-2.3- and a-2.6-NANA-lactose) as 
substrate, thus demonstrating that the defective enzyme did not 
show altered specificity for either of the two linkages (Fig. 2). 
However. using fibroblast extracts we could demonstrate that 
SM/J neuraminidase assayed with substrate concentrations 
ranging from 0.1 to 1.5 mi\.l4-MU-NANA had an -3-fold lower 
\' mn than the wild·type enzyme (Fig. 2). This suggests that the 
L209I substitution innuences the kinetic properties of the mutant 
enzyme. Furthermore. the mutant mice displayed an abnornlal 
pattem of urinary oligosaccharides (Fig. 2). indicative of 
oligosacchuriduria, a condition commonly observed in galaelo-
sialido~is mice (2). Histological analysis of the SM!1 mice 
showed evidence of storage products in specific cells. such as the 
Porkinje cells of the cerebellum and the glomerular epithelium. 
which appeared to accumulate o\'er time (uata not shown). 
Because these parameters are commonly used in biochemical 
dtagnosis of sialidosis and galactosialidosis patients (1,4). it is 
dearthat SM/J mice share similar phenotypic abnomlalities with 
these two human diseases. 
To identify the underlying genetic lesion responsible for these 
abnonnalities we searched fora mutation(s) in the neuraminidase 
gene. Using RT-PCR on brain and liver RNA derived from Si\VJ 
mice of different ages and from different litters we amplified four 
overlapping fragments that span the entire neuraminidase eDNA 
(Fig. 3). Three mouse strain~, BALB/c, I 29/Sv and FVB, were 
used as controls. Sequence comparison identified seven nudeo-
tide changes in the Si\I/J cDNA; four involved the wobble base 
of amino acid codons Lys93. Arg202. Thr295 and Ala316, two 
were present in the 3'-UTR and one wa~ a C~A transversion at 
nl 625 within exon IV of the gene. This tfilnsversion resulted in 
the amino acid change Leu209 to IIe (L209I). Because exon IV 
is present in all four neuraminidase transcripts (Fig. t). we 
inferred that this point l11utatiol1 must be present in all of the 
mRNAs and in the corresponding protein. 
Table I. Siu, and tlX;1ljoll\ of eWI1, and introrlS and sequence, allhe e\on!intwn boundark, of the I1t'l1-/ g~ne 
E,on, eDNA po,ilion Intron> Intron size 
Number Siu 5' splice sile 3' spli,ce ,ile 
171 -30 to 141 AGCCTGgtg3ge gegcagGTGCAG 365 (I) 
« (9(j 142t033t ACCAGGgtaacJ. ttctagGTAGCA 453 III 
«( 266 33210597 ATICAGgIHea IJ..;cJgAAACAG (200 (J) 
(V 
'" 
59310730 TGCCAGgtcJgg acgcagCCCTAC 97 (" 
V 12( 78110 lOOt AGTICCgIgJ.gI \(OJgGAGTGA 99 (5) 
V( 1365 ]002102366 
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for tile 2...1 kb dOll<: i, sho"'TI a.<; a ~malkr bbck lXH. Number> repl"(""sent nucleotide p<hitioru. The different probes used to h}bridiu til<' northern blot are: I. nt -23 
10491; II, nt 601 to ?SO; lII,nl 104910 1539; IV, nl 2[)n to 2163. {CI Northern blot anal)"sis u,ing the probe, outli/l<'d in (8) and indi(J1?d undere.Kh panel. E~JXHur~ 
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Expression of 1.2091 mulant neuraminidase In deficient 
fibroblasts 
To assess the impact of the L2091 change on biochemical 
properties of the nomlal enzyme we engineered this mutation into 
the normal 1.8 kb murine eDNA. The resulting mutant done 
(i\·to~smj) was completely sequenced toconfinn correct introduc-
tion of the mutation. This mutant eDNA was transiently 
expressed in two human sialidosis type II fibroblasts. These cells 
were chosen because. unlike Si\I/J fibroblasts, Ihey 101all), lack 
neuraminidase activit}' (3). Mo-smj cDNA only partially cor-
rected the deficient fibroblasts. generating neuraminidase activity 
of between 40 and 65% of that of the wild-type murine (~to-neur) 
enzyme. Given the strict dependence of neuraminidase on PPCA 
for full enzymatic activity (1.2), we also tested the effect of both 
mouse and human PPCA on S~I/J neuraminidase. Co·transfec-
tion of the l\to-smj and l\lo·neurcDNAs with either the mouse or 
human PPCA cDNA (Mo-ppca and Hu-ppca) resuhed in a dear 
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increase in neuraminidase activity for bolh the nomlal and mutant 
protein (Fig. 3), The induced SI\1/1 activity, howe\'er, remained 
lower than that of the wild·type. The L2091 mutation was also 
introduced into the human neuraminidase cDNA (Hu-smj), 
Expression of this mutant clone alone or in combination with 
human or mouse PPCA again resulted in reduced neuraminidase 
activity (Fig. 3). unequivocally demonstrating that the L2091 
substitution is responsible for the enzyme defect. Immuno-
fluorescence analysis of singly and doubly transfected cells 
showed that the presence of the mutation in either the mouse or 
the human neuraminidase molecule does not alter the subcellular 
distribution of the enzyme. which maintained a typical punctate 
lysosomal staining (Fig. 3). TIle lysosomal localization of the 
mutant enzyme was confimled using Percoll density gradients 
with transfected COS-I cells (data not shown). Co-expression of 
either mouse or human PPCA clearly enhanced the lysosomal 
signal. further indicating that PPCA has a stabilizing effect on the 
mutant protein, 
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Biosynlhesis of Ihe L2091 OIulanl in COS-I cells and its 
association wilh Ihe PPCA precursor 
The increase in SM/J neuraminidase activity in cells co--expres-
sing mutant Ncu-I neuraminidase and PPCA suggested that 
interaction between the two proteins was not affected by the 
L209J mutation, We tested this assumption by overexpressing the 
Smj-neul and the PPCA cDNAs in COS-l cells and then 
immunoprecipitating radiolabeIed proteins with anti-neur or 
anti-PPCA antibodies (Fig. 4), Although the anti-neurantibodies 
recognized the murine protein with lower affinity than they did 
the human protein, more SM/J protein than wild-type mouse 
protein was immunoprccipitated from equaily transfected cells 
(Fig, 4, lanes 2 and 3). Ncvertheless. neuraminidase activilY in 
singly tnlllsfected cells was again 50% of that of control values 
(data not shown), In co·transfected cclls both the mouse and 
human PPCA precursors were co-precipitated with anti·neur 
antibodies. together with the Sr..-I}J polypeptide (Fig, 4. lanes 8 
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and II). The mutant protein, the wild-type mouse protein and 
human neuraminidase all co-precipitated the PPCA precursor 
equally effidently (lanes 7, 9, 10 and 12), Therefore, the L209! 
substitution did not interfere with association between the mutant 
protein and either mouse or human PPCA, excluding the 
possibility that the S~"f/J mutation affects complex forotation, 
Sequential immunoprecipitation of all samples with anti-PPCA 
antibodies explained the difterence in the ability oflhe mouse and 
human PPCA to enhance neuraminidase activity (Fig. 3). The 
murine PPCA precursor in overexpressing cells was not as well 
processed to the mature two chain fonn as the human PPCA 
precursor (Fig. 4. lanes 7-9 and 10--12). This reduced level of 
processing could have led to a smaller pool of mature PPCA 
available for 'protection' of the lysosomal neuraminidase. 
Turnover of the SM/J neuraminidase was apparently not 
influenced by the L2091 substitution, as detemlined by pul~e-
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chase labeling of transfected COS-I cells (Fig. 4). Both the 
mutant and wild-type neuraminidase appeared to be stabilized 
upon co-expression of mouse PPCA, since immunoprecipitable 
material could still be detected at the 3-6 h time points (Fig. 4, 
middle panels). The stabilizing effect was less apparent, but still 
recognizable, when human PPCA was co-expressed with mutant 
or wild-type neuraminidase (Fig. 4, lower panels). These results 
clearly correlate with the observed increase in enzyme activity in 
cells co-expressing mutant or wild-type neuraminidase with 
PPCA. 
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DISCUSSION 
Overall the results we present here provide strong evidence that 
the subtle L2091 substitution is responsible for the altered 
neuraminidase activity in SM!J mice. Leu209 in the murine 
enzyme falls in an amino acid stretch thaI is highly consen'ed 
among the different sialidases (10,36). This residue coincides 
with Leunl and Leul99 of the Micromollospora I'iridijaciens 
and Sa/mol/ella tytJhilllllrifllll sialidases respectively, which are 
located in the three-dimensional structure of these enzymes in the 
vicinity of the active site (17,18). It i~ therefore conceivable that 
this amino acid substitution in the S~I!1 neuraminidase could 
affect substrate recognition, rate of substrate cleavage or release 
of the product, as evidenced by the altered Vrnn of the mutant 
protein. Although SMjJ mice present with some of the biochemi-
cal abnonnalities that are associated with the human lysosomal 
disorder sialidosis, the relatively high residual neuraminidase 
activity prevents the occurrence in young mice of excessive 
storage in their tissues. Older mice, on the other hand, e"cntulllly 
develop visible cellular changes. especially in the CNS. There-
fore this animal model may be regarded as a mild foml of 
sialidosis. 
The residual SM/J activity varied slightly in different tissues. 
This could be attributed to the occurrence in some tissues. like 
brain, of neuraminidase 'isoenzymes' thought to be localized in 
the lysosomal (37,38) or plasma membrane (38-42) and the 
cytosol (16.38,43-45). However, the existence of various 
lysosomal neumminidases is questionable, since in PPCA-
deficient mice no residual neununinidase activity is detected at 
acidic pI [ (2). The same holds true for human sialidosis patients 
with structural mutations in the neuraminidase gene that result in 
complete loss of neuraminidase activity (3). 
Modification of sialic acid residues, which are present as 
tenninal sugars on various types of sialoglycoconjugates, is 
essential for regulation of many cellular activities. TIle Neu-I 
neuraminidase plays a key role in such modifications, for 
example in processing of cell surface molecules that are involved 
in modulating an immune response (9,27~31). T lymphocyte 
activation is nonnally accompanied by an increase in endogenous 
Neu-I neumminidase (30,31), Which, in tum, results in hypo-
sialylation of glycoproteins on the surface of activated T cells 
(9,46-49). These surface glycoproteins are required for T cell 
differentiation [for a review see (32)] and several of them are 
known to be internalized from the plasma membr,me and 
subsequently re-e.'l:posed by a 'recycling' process. MHC class I 
and class II molecules and the T cell receplOrare examples of such 
molecules (50-53). Therefore, it may Ix that processing of the 
sialic acid residues on these and olher glycoproleins present on 
the surface of specific T cells is mediated intnlcellularly by 
lysosomal neuraminidase. If this enzyme is part of the mllin 
mechanism for sialic acid processing in T cells then the altered 
Vrna\ value ofSl>.VJ neumminidase would quite logically account 
for the abnonnal sialylation of these molecules. Our data suggest 
that the mutant enzyme retains the capacity to recognize its 
substrate but that its rate of catalysis and/or release of product is 
impaired. The type of substrates that are cleaved by the enzyme 
may determine whether or not a certain cell type can compensate 
for a reduction in activity of mutant neuraminidase. Again. this is 
best exemplified in the T cell system, where the immune response 
in SM/J mice involves differentiation of naive T cells to Tht but 
not to T h2 cells. 
Interestingly, reduced neuraminidase activity has also been 
detected in nlt strain KGH (54). The responsible gene,lIeu-J, wa~ 
mapped to the RT I locus (55), which is syntenic to the mouse H-2 
and human HLA loci. It is unclear whether this defect results in 
the same phenotypic alterations identified in S~1JJ mice. It will be 
instructive to identify the molecular basis of the defecti\'e 
neuraminida'ie activity in this rat strain and to compare it with that 
found in SM/J mice. A second gene, 1Ii'1l-2, has also been 
descrit}l:d in hath mouse and rat (54,56). However, the encoded 
enzyme is localized in the cytoplasm and does not cleave the 
tluorimetric substrate (57). Furthennore. linkage analysis dem-
onstrated that the nell-2 is not linked 10 the lle/l·llocus (54). 
Once the three-dimensional structure of the lysosomal mam-
malian neunlminidase becomes available we could gain a better 
understanding of the impact of the L2091 mutation on structure 
and function of the enzyme. Our findings on SM/J mice will 
hopefully facilitate further genetic and immunological studies on 
this animal model. 
MATERIALS AND METHODS 
Isolalion of the mouse eDNA 
A mOllse BALB/c cDNA library was screened according to the 
manufacturer's instructions (Clontech). eDNA clones were 
sequenced with the Amersham thennocycler kit and subcloned 
into the mammalian expression vector pscroP (58). 
RNA isolation and Northern blot analysis 
Ri'fA was prepared from S~I/J mouse tissues by the LiCI/urea 
method as previously described (59). TOlal RNA was separated on 
1% agarose gels that contained 0.66 M fonnaldehyde in MOPS 
buffer, was then blotted onto Zelaprobe membranes (BioRad) and 
was finally hybridized under standard conditions (60). TIle 
multiple tissue nonhem blot was purchased from Clontech and 
handled according 10 the manufacturer's instructions. 
Mutation analysis and mutagenesis 
Total Rt"lA prepanllions from different SMJJ mice and FVB controls 
were subj.."'Cted to RT-PCR (3,61). The following primers were used 
in the reactions: 5'-CCCfAGGACACCGGGCCITC+3' (antisense, 
primer R); 5'-CCTGGACAGGGATCGCCG-3' and 5'·GTA-
GAGGCCACcrGGCAG-3' (fragment I); 5'-CGGACCAGGG-
TAGCACGTGG-3' and 5'~GGGTGTCACAGGCGTCATAG-3' 
(fragment Ill; 5'-GATGACCACGGTGCCfCC-3' and 5'-GGTGT-
ACCGGTI'CAGGCC-,3' (fmgment m): 5'-CCfGGCAGAAG· 
GAGAGGG-3' and 5'-CTGTICATcrCTCCAGGG-3' (fragment 
IV). 
Amplified products were purified by phenol/chlorofornl ex-
traction, on Centricon-IOO columns (Amicon) and by ethanol 
precipitation. TIle purified products were directly sequenced with 
the fmol sequencing kit (Promega). The mutation was in~erted 
into the wild-type cDNA by combining fmgments II and III (Fig. 
3) and u~ing the StilI restriction sites at positions 377 and 1168 to 
substitute the SUIl fragment for the wild-type fragment. 
Cell culture, elcctroporation of fibroblasts and 
transfcetion of COS-I cells 
Human skin fibroblasts were cultured in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with antibiotics and 
10% fetal bovine serum (FBS). COS-J cells were maintained in 
D~IEM supplemented with 5% FRS. Fibroblasts were electro· 
pomted according to the manufacturer's instructions (BioRad) 
with the following modifications. Cells werc harvested by 
trypsinization and washed once in Iscovc's medium. TIley were 
thell cOllnted and 25 pg plasmid DNA were elcctroporated into 
I x Icf:i cells suspended in 500 )..II hcovc's medium using a 
BioRad Gene Pulser set til 0.32 kV and 500 ~tF. Electroporated 
cells were seeded in 6-well plates for 14-18 h before the medium 
W:'l~ changed. TIley were harvested 72 h later. Immullotluores-
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cence of e1ectroporated fibroblasts was perfonned as described 
previously (3). COS·, cells were transfected with Qiagen's 
Superfect according to the manufacturer's imlmclions and 
harvested 72 h posHransfection. Transfection eftidency was 
checked by inllimnofluorescence and Ihe tOlal amount of 
synthesized neuraminidase protein was estimated by western blot 
analysis of total celllysates. Comparable transfection efficiencies 
were obtained among sanlples within each experiment and 
similar Ie\'els of neuraminidase protein were synthesized, 
Lysosomatlmltochondrlal extract 
~"ice were sacrificed by cervical dislocation and their tissues 
immediately isolaled and placed in ice~cold 10 mM HEPES, pH 
7.4,250 mM sucrose. After the tissues were washed several times 
in this' buffer they were weighed and homogenized in a 
tight-fitting dounce (Konles) in 4 vols HEPES-buffered sucrose. 
A lysosomal/mitochondrial extract was prepared according to the 
procedure described by Gieselmann (62). The resulting lyso-
somal/mitochondrial pellet was dissolved in HEPES-buffered 
sucrose and analyzed for enzyme activity. 
Enzyme acti\'llics and urine analysis 
LysosomaVmilochondrial extracts and cell lysate from either 
transfccted COS-I cells or electropomted fibroblasts were assayed 
for neuraminidase activity using the artificial substrate 
4-~m-NANA according 10 Galjaard (63). Protein concentrations 
were determined using the BCA kit from Pierce Chemical Co. 
Neuraminidase activity also was ass..yed with a-2,3- and «-2,6-
NANA-Iactose as substmtes, according (0 the procedure described 
previously (64,65). Urine sanlp!es were collected and analyzed 
using a FACE® Urinary Cmbohydrate Analysis kit purchased from 
Glyko Inc. following the manufacturer's instructions. 
Immunoprecipitallon 
Transfected COS-I cells were seeded in 6-well plates and labeled 
for 16h with 50 IlCi eHJ-4,5-leucine. Radiolabeledproteinswere 
immunopredpitated with anti-neur antibodies, as described 
previously (66). For the pulse-chase experiment transfectedcells 
were labeled with 50 ~ICj eH]-4,5-leucine for I h and then chased 
in fresh DMEM over different time periods (67). 
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Discussion and future prospects 
A: Human alld murine genomic organization 
The results presented in chapters 2 to 5 have emphasized the concept that 
lysosomal proteins, until now viewed as structural enzymes merely fulfilling a digestive 
function, have characteristics that demand a level of regulation not previously 
anticipated. I have studied two mammalian PPCA genes, the human and mouse, and 
found that they are very homologous, both in organization of the exon/intron boundaries 
as well as in exon sequences (chapter 2, 51). Comparison of their genomic organization 
has enabled the identification of conserved domains that could be important in the 
regulation of PPCA expression, either by influencing the rate of transcription or the 
splicing efficiency. It was unexpectedly discovered that even sequences within intron8 
were very conserved, as we found for introns 3,4 and 5 (unpublished result). The 
homology extents into the promoter regions, which share some features of housekeeping 
genes, like GlC-rich sequences and SPI boxes (17). In addition, the murine gene has a 
unique, TATA-box containing additional promoter that could control expression of the 
gene under the influence of tissue-specific stimuli. It is noteworthy, for instance, that 
PPCA mRNA expression gradually increases in the uterus during pregnancy with a clear 
peak right before parturition after which the level drops drastically. This pattern closely 
coincides with that of oxytocin and its receptor, a peptide hormone known to be 
inactivated by PPCA (27). This, together with the observation that this promoter also 
contains a GRE half-site, is suggestive for honnone dependent Of inducible expression, 
which would ensure the generation of sufficient protein to inactivate the hornlOne at the 
proper time and target site. Another lysosomal gene, the aspartyl proteinase cathepsin 
D, has been shown to be activated by estrogens, which direct transcription from a 
TATA-box present in a mixed promoter context (3, 12,32,33). 
It was already shown that the last 58 nucleotides of the last PPCA exon are 
reverse complementary to the 3 'UTR of the Phospholipid trallsfer proteill gene (Pltp, 
51). Through our analysis of the promoter region, we have discovered that both the 
human and mouse PPCA loci are flanked by and partially overlapped by yet another 
gene of unknown function so far (chapter 3). This novel gene is transcribed from the 
opposite strand and results in a mRNA of I kb. Similar, but not identical, situations 
have been observed in other genes, like tellascill-X, erb-A and cytochrome P450c27125 
(2, 9, 30, 35, 50, 54, 63). Aside from the PPCA, two other loci encoding lysosomal 
enzymes were shown to have overlapping transcriptional units, p-glucuronidase (Gus-s) 
and glucocerebl'Osidase (Gba). Gus-s contains a complex transcriptional unit on the 
same strand, called Gig, which has its promoter within intron I of Gus-s. Although the 
two genes intermingle and partially overlap, their transcripts share little, if any, sequence 
similarity (62). The Gba gene and its adjacent pseudogene are flanked both upstream 
99 
and downstream by several other loci, that do not, however, overlap with the Gba 
transcript (64). Interestingly, the generation of the Gaucher mouse led to the 
identification of one of these genes, called metaxill (Mtx). The Mtx gene, located 
immediately downstream of the GBA pseudogene, is transcribed convergently to the 
Gba gene and shares a bidirectional promoter with another gene, encoding for 
thrombospondin 3 (Thbs 3, 7). Upstream of the Gba gene, and transcribed from the 
same strand, are at least three other genes, Clk2, Propill J, Cote J and a non-transcribed 
pseudogene of Mtx is in between the Gba gene and its pseudogene (64). 
Nonetheless, the PPCA locus is unique since it overlaps both at the 5' and 3' end 
with two other genes, both of which are transcribed from the complementary straud with 
respect to PPCA. This adds complexity to the PPCA locus and the mode of regulation 
of the three genes. It is remarkable that the human and mouse PPCA TATA-Iess 
promoters contain three conserved E-boxes to which transcription factors like MyoD, 
kE2-binding protein and c-myc bind (5, 6, 36). It is unclear at the moment, whether 
these elements are implicated in the regulation of the PPCA gene, or of the 5' 
overlapping gene, which is primarily expressed in heart and skeletal muscle. It would 
be interesting to examine severe early infantile galactosialidosis patients, who 
completely lack PPCA mRNA, for the influence of the two overlapping genes on the 
phenotypic expression of the disease. Mutations or deletions in the PPCA promoters 
may result in the silencing of the PPCA gene, but could simultaneously abolish or 
influence expression of the 5' overlapping gene, or cause mutations in the encoded 
protein. The heterogenous clinical manifestations of galactosialidosis can include the 
involvement of heart problems, consisting of cardiomegaly, thickening of the septum 
and cardiac failure. The interesting possibility arises that mutations in this 5' 
overlapping gene, which is highly expressed in heart, are responsible for these 
symptoms. Recently, it was demonstrated that in cases of severe Hunter syndrome 
mutations in the FMR2 locus, neighboring the a-iduronate-2-sulphatase gene, could 
contribute to the clinical manifestations (59). These authors showed that patients 
suffering from seizures combined with atypical symptoms had a genomic deletion that 
also involved the FMRZ locus. 
The extensive homology between the human and mouse PPCA genes could aid 
in the identification of mutations within important regulatory elements in the genes of 
patients who completely lack PPCA mRNA (chapters 2 and 3). Analysis of the 
complete PPCA locus may facilitate the understanding of the phenotypic variation 
observed in galactosialidosis patients and improve our ability to relate genotype with 
phenotype in order to provide appropriate therapies. Clinical manifestations, unusual for 
a lysosomal storage disorder, could eventually be explained by the prolonged presence 
or abnonnally high levels of active peptide-honnones, which are known to be a natural 
substrate ofPPCA. The expression of the two flanking genes and their influence on the 
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features of the disease may also be worth investigating, because it could reveal new 
clinical features in patients unknown until now. 
B: A1011Se modelfor human galaclosialidosis 
Knowledge of the genomic organization of the mouse PPCA gene has helped in 
the generation of a mouse model for galactosialidosis by targeted gene dismption 
(chapter 4). The PPCA knockout mouse, or GS mouse, displayed progressive 
nephropathy, ataxia and premature death, a phenotype that closely resembled the most 
severe fonn of the human disease. The early infantile type patients suffer from fetal 
hydrops, kidney and heart involvement, visceromegaly, psychomotor delay, skeletal 
abnornlalities, mental retardation and death occurs within the first year of life (IS). The 
mouse model provides an excellent in vivo system and has led to a better understanding 
of the development of the disease pathology. Analysis of the GS mouse unexpectedly 
revealed a remarkable regional distribution of cells with lysosomal storage in different 
tissues, in spite of the presence of lysosomes in virtually every cell type. For example, 
the epithelial cells oflhe proximal tubuli in the kidney clearly show storage, whereas the 
epithelium of the distal tubuli in the kidney is devoid of detectable storage. In brain, the 
entorhinal cortex contains more PAS positive neurons than the somatosensory cortex, 
the epithelial cells of the choroid plexus are extensively vacuolated, while the Purkinje 
cells in the cerebellum only have a few defined vacuoles before they die. The neurons 
of the hippocampus and dentate gyms do not show signs of storage at all throughout the 
lifespan of the animals. For a clearer interpretation of the GS phenotype, we have 
examined the site and level of in vivo PPCA expression in nonnal mice (chapter 5). We 
found a regional distribution of both PPCA mRNA and protein, which in general 
colocalized with the detected lysosomal storage pattern. However, also some interesting 
discrepancies were noted as cells with high levels of PPCA expression showed no 
detectable storage in the GS mouse (hippocampus, dentate gyms), whereas low 
expressing sites displayed high levels of storage (glomemlus). At this moment it is not 
clear why such differences occur, but it may reflect the importance of the catalytic 
activity of PPCA, known to inactivate specific bioactive pep tides, rather than its 
protective function in specific cell types, as discussed in chapter 5. Alternatively, since 
the glomemlar epithelium fillers the blood, it may collect blood-derived metabolites that 
cannot be cleared once internalized. Other lysosomal genes, like murine prosaposin (55, 
56), acid phosphatase (20), acid lipase (16) and acid a-glucosidase (42), show a regional 
distribution of mRNA and/or protein. However, a comparison between storage and 
nonnal gene expression has not been performed in these cases. 
A close examination of the galactosialidosis phenotype may also help in the 
identification of novel metabolic pathways in which PPCA is involved. This in view of 
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what has been discovered through the analysis of mouse models for the lysosomal 
storage disorders GMI gangliosidosis (p-galactosidase), Tay-SaellS (p-hexosaminidase 
A), Sandhoff (p-hexosaminidase B) and GMl activator deficiency (14, 22, 31, 40, 49, 57, 
58, 65). These models elucidated the importance of a parallel metabolic pathway that 
converts GMI - and GMl gangliosides into the asialo types GAi and GAl through a 
sialidase active in mice, but absent or less active in humans (see also general 
introduction, part 1.5). The asialo glycolipids could be further cleared by the remaining 
hexosaminidase isoenzyme in Tay-Sachs and GMl activator deficient mouse models. 
The slow metabolic turnover results in modest storage and a mild phenotype in 
comparison with the Sandhoff mouse, which misses sufficient residual hexosaminidase 
activity to process the asiolo derivatives and thus accumulates considerable amounts of 
GMl and GAl. It is not clear yet what the potential contribution of GAl and GA2 is in 
relation to the emerging disease patterns, but it may be responsible for significant 
differences between the human and mouse neuropathology. 
Finally, the availability of the GS mouse model may be very useful for the 
understanding of the physiological role of PPCA in the conversion of its biological 
substrates. The knowledge that the PPCA carboxypeptidase activity can be separated 
from its protective function towards p-galactosidase and N-acetyl-a-neuraminidase 
could be applied to the generation of catalytic mutants that maintain the protective 
activity (19). Analysis of these mouse mutants may lead to the identification of 
individuals with mutations that only hamper the cathepsin A activity. Those mutations 
are not noticed yet since they lack overt clinical signs typical for galactosialidosis. 
c: Experimental approaches to treatment 
The importance of a detailed expression map of the gene in relation with the 
disease pattem in the knockout mouse is crucial for the precise assessment of correction 
of the phenotypic abnormalities after treatment. In fact, one of the reasons for creating 
mouse models is the development of an ill vivo system to examine the feasibility of 
different therapeutic approaches to treat these diseases (21, 37, 57). Therapeutic 
strategies have relied on the unique capacity of soluble, lysosomal enzyme precursors to 
be secreted by one cell type and internalized via receptor-mediated endocytosis by other 
cells at distant sites (reviewed in 8). Methods such as enzyme replacement therapy 
(ERT), bone marrow transplantation (BMT), organoid implantation and gene therapy 
have been attempted in patients with moderate succes (reviewed in23, 25, 26, 43). Each 
approach presents inherent problems mainly related to the difficulty of correcting bone 
abnonnalities and the CNS pathology. ERT, which to date has been succesful for the 
treatment of humans with the non-neuropathic form of Gaucher disease, could be the 
treatment of choice, but only for non-neuropathic patients. However, it is costly and 
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requires repeated administrations of normal enzyme. BMT implies a "once-only" 
practice, and relies on delivery of enzyme from donor-derived normal hematopoietic 
cells to affected host cells after treatment. This approach has been widely used to treat 
lysosomal diseases in both human and animal studies (I, 15, 23), but the outcome has 
been inconsistent, primarily with regard to CNS correction. Other methods, including ex 
vivo gene therapy, have suffered from poor transduction efficiencies, short-term or 
silenced gene expression ill vivo and the difficulty of delivering therapeutic protein to 
target cells. To overcome these obstacles, we have used a novel approach based on the 
generation of transgenic mice, expressing a human PPCA minigene under the control of 
the p-globin promoter and the LCR. Contrary to what is achieved with ex vivo systems 
using viral vectors, these transgenic mice would mimic 100 % transduction efficiency of 
bone marrow cells, maintain high level of expression of the therapeutic gene and express 
it in a cell specific manner. It was not known, however, how the heterologous 
lysosomal protein would behave during differentiation and maturation of the 
erythrocytes. The results of the analysis of this transgenic line were very encouraging, 
since the human PPCA minigene was expressed in erythroid precursors at high levels 
and depended on the copy number of the transgene. Furthermore, the overexpressed 
precursor protein was secreted by erythroid cells in large amounts and appeared stable in 
the circulation. The synthesized protein was correctly glycosylated, since ill vitro 
uptake studies showed correction of galactosialidosis fibroblasts and thus their 
therapeutic value. So, to test whether sustained expression of corrective protein in 
specific bone marrow derived cells can revert, diminish or prevent lysosomal storage in 
all tissues affected in the as mouse, including the brain, we transplanted bone marrow 
derived from wild type and transgenic mice into deficient mice (chapter 4). The treated 
animals showed a reduction of excreted sialyloligosaccharides, correction of all the 
affected systemic organs and a prolonged lifespan (chapter 4). The brain was only 
partially corrected, showing persistent storage in neurons, but a nonnal microscopic 
appearance of the choroid plexus, the trigeminal ganglia and the pituitary. The partial 
reversal of the galactosialidosis phenotype was more pronounced with the 
overexpressing transgenic bone marrow, indicating that the level of correction is 
dependent on the amount of normal enzyme. These studies demonstrate the importance 
of cell-specific expression of the therapeutic enzyme, since it facilitates the 
interpretation orthe ilt vivo effects of overexpression. 
The correction obtained after bone marrow transplantation of as mice using our 
strategy based on this novel approach are very promising. A number of reports have 
been published describing the results of different treatments for lysosomal storage 
disorders in animals, including correction of the visceral organs and a prolonged 
lifespan, but minimal improvement of the CNS involvement and bone abnonnalities (4, 
II, 38, 44, 45, 47, 48, 52, 53). It was shown that administered p-glucuronidase through 
intravenous injection into newborn mice was taken up within one hour by many tissues, 
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including the meninges, choroid plexus and vessels (61). However, no detectable 
enzyme levels were found in eNS neurons and small amounts were identified in neurons 
in the peripheral nervous system. Bone marrow transduced with a retrovirus expressing 
glucocerebrosidase was transplanted into nom}al mice to assess the possibility of 
hematopoietic cells to contribute to the CNS. All macrophage populations, including 
CNS microglia, appeared to be partially replaced with donor cells, which continued to 
express glucocerebrosidase as long as 8 months afier transplantation (28). These and 
other studies demonstrated the possibility that donor·derived cells, most likely 
monocytes and macrophages, have the capacity to infiltrate the CNS and differentiate 
into the microglial population (24, 29, 39). In addition, it was noted that treatment 
initiated early afier birth was more effective than those started later in life, most likely 
because the blood-brain barrier is not yet fully developed in very young mice (34, 45, 
46). 
Considering the encouraging results obtained with the p-globiniLCR mediated, 
erythrocyte·specific expression of PPCA and in order to target more specifically the 
eNS, we have developed another transgenic mouse, which expressed the human PPCA 
minigene under the control of the CSF-l-receptor promoter (Hahn ef al., submitted for 
publication). These mice expressed the therapeutic protein exclusively in the 
monocyte/macrophage lineage, as well as in brain microglia. Transplantation of 
transgenic bone marrow into deficient mice resulted in a direct reversal of the 
oligosacchariduria, and an impreSSive correction of the visceral organs, even if GS mice 
were transplanted late in life. This could be relevant for future applications in human 
patients. Infiltration of expressing macrophages in the brain clearly improved 
perivascular sites, although scattered neurons still accumulated undegraded products, 
while the cerebellar Purkinje cells continued to store and die. So, either the therapeutic 
macrophages and monocytes were not introduced at an early enough stage, or the level 
of expression was not high cnough to clear the storage, as cultured bone marrow 
macrophages secreted only low amounts of PPCA. It remains to be seen whether 
enough macrophages will ever repopulate the CNS, even following BMT at an early 
age, to allow for sufficient neural correction prior to the onset of irreversible damage. 
D: The role oflysosomailleuramillidase 
The loss of neuraminidase activity in galactosialidosis patients and in the 
PPCA knockout mouse, together with the biochemical evidence that, in addition to p-
galactosidase, neuraminidase is in complex with PPCA, encouraged the isolation of the 
murine lysosomal neuraminidase gene. In chapter 6 the characterization of the mouse 
neuraminidase cDNA and gene are described, including the detemlination of the 
molecular basis for reduced neuraminidase activity in the naturally occurring mouse 
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inbred strain SM/J. The importance of lysosomal neuraminidase in the de-sialylation of 
cell-surface molecules is demonstrated by the inability of these mice to produce T h2-
cells (13). It would be interesting to investigate if the galactosialidosis mouse behaves 
in a similar fashion with respect to T-cell differentiation. If this phenotypic abnomlality 
is not present in the GS mouse, we could speculate on a novel role for lysosomal 
neuraminidase outside the complex with PPCA. In line with this, it is known that in the 
absence of PPCA, endogenous neuraminidase resides in a prelysosomallendocytic 
compartmcnt and is not transported to mature Iysosomes (60). However, it is well 
documented that exogenous addition of PPCA to galactosialidosis fibroblasts triggers 
the transp0l1 of neuraminidase to the Iysosomes and its activation (18, 19, 60). So, it 
can be postulated that a cell-surface, sialylated receptor molecule could be intemalized 
in a prclysosomal/cndocytic compartment, associate with neuraminidase and serve as 
"protective factor". This complex could then be transported to the lysosome where the 
activated neuraminidase would process the receptor molecule, which is then rerouted to 
the cell surface. Once dissociated from the "receptor", neuraminidase remaining in the 
mature lysosome would be quickly degraded due to the absence ofPPCA. 
The identification of the mutation in the neuraminidase gene of the SM!J mouse 
enabled us to link the observed phenotypic abnomlalities with a partial neuraminidase 
deficiency. However, these mice have only a partial neuraminidase deficiency, so the 
generation of a model completely lacking neuraminidase activity will be important for 
the study of the pathogenesis of the severe type of sialidosis, as well as the development 
of therapeutic strategies. The generated mouse model may resemble the 
galactosiaIidosis mouse, since the storage pattem observed in the GS mouse is primarily 
detern1ined by the absence of neuraminidase activity. Comparison between these two 
knockout mice may answer questions about the catalytic activity of PPCA, which is 
separable from its protective function. Moreover, if lysosomal neuraminidase is 
responsible for the turnover ofGMI and GM2 gangliosides into the asialo GAl and GA2, as 
previously discussed, then the neuraminidase knockout mouse may also accumulate 
these gangliosides, aside from sialylated compounds. It would be interesting to analyze 
crosses between the sialidosis mouse and GMI gangliosidosis, Tay-Sachs and Sandhoff 
mice to check whether the sialidase activity that processes the G"l - and GM2 
gangliosides into the asialo derivatives is identical to the lysosomal protein. 
E: Concluding remarks 
The work described in this thesis has contributed to the further understanding of 
galactosialidosis and sialidosis and will help to elucidate the molecular pathology of 
patients with these diseases. Furthennore, the obtained knowledge cml be used to 
generate mouse models of these diseases carrying sophisticated mutations, which in tum 
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will help in the understanding of the pathogenesis of the disorders and the exact 
biological functions ofthe proteins. The extrapolation from animal models to humans is 
very difficult and requires careful examination of the variable factors involved. For 
instance, murine models are genetically identical and live in a controlled environment, 
whereas human patients are genetically different and often their enviromnental factors 
vary as well. On the other hand, murine models for human disorders have been very 
instmctive, as has been shown in this thesis. For instance, the discovery of alternative 
biochemical pathways in animal models may be helpful in the identification of new 
therapeutic strategies for human patients. 
The results of therapeutic applications in patients with lysosomal storage 
disorders have so far been modest. One of the problems is the targeting of the normal, 
therapeutic protein to the affected cells and tissues and also the occurrence of antibodies 
against the corrective factor may cause unwanted clinical manifestations (10, 41). 
Nevertheless, both the studies of animal models and the results of several clinical trials 
are encouraging to continue our efforts to solve these problems. 
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SUMMARY 
Lysosomes are a heterogeneous population of cellular organelles involved in the 
degradation of a wide variety of intra- and extra-cellular substrates. These acidic 
compartments contain proteins that orchestrate the stepwise degradation of 
macromolecules and the emerging products are either recycled or further degraded. 
Lysosomal storage disorders are characterized by the deficiency of proteins involved in 
one ofthese catabolic pathways, leading to the accumulation of un degraded substrates in 
Iysosomes. The continuous accumulation of storage products results in cells containing 
numerous enlarged Iysosomes and ultimately to cellular dysfunctioning. Since 
Iysosomes are present in virtually every cell type, the partial or complete loss of their 
function causes multi-systemic clinical manifestations in humans, which may include 
CNS involvement, skeletal abnormalities, cardiovascular problems and organomegaly. 
These diseases can be subdivided into glycoproteinoses, glycolipidoses and 
mucopolysaccharidoses, depending on the nature of the main storage product. In 
addition, the biosynthetic pathway of lysosomal hydro lases may be affected, as has been 
demonstrated for I-cell disease and pseudo-Hurler polydystrophy, or membrane 
transport could be affected, as in Salla disease. 
The lysosomal storage disorder galactosialidosis is one of the glycoproteinoses 
and is biochemically characterized by the loss of activity of two hydro lases, acid P-D-
galactosidase and N-acetyl-o:-neuraminidase, although the primary defect is a mutation 
in the protective protein/cathepsin A (PPCA) gene. The PPCA protein associates with 
the two hydrolases and forms an active complex in Iysosomes. In the absence ofPPCA, 
sialylated oligosaccharides, the substrates for N-acetyl-o:-neuraminidase, are the primary 
storage products in the Iysosomes. In addition and fully separable of its protective 
function towards these two hydro lases, PPCA has catalytic activity towards a selective 
set ofbioactive peptides. 
Chapter 2 and 3 describe the isolation and characterization of the organization of 
the murine PPCA gene, as well as the analysis of the promoter region. The organization 
appears to be very homologous to the human, both in the position of the exon/intron 
boundaries as well as their exonic sequences. Comparison of the human and mouse 
genes may reveal important conserved domains that could facilitate the molecular 
analysis of galactosialidosis patients. The promoter regions are also highly conserved 
and contain several elements that are shared by the family of housekeeping genes. 
Family members are known to be expressed ubiquitously and encode proteins that fulfill 
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metabolic functions. Surprisingly, two promoters rather than one control the murine 
gene. This additional promoter contains a TATA-box and two imperfect CAAT boxes, 
suggesting a special regulatory mechanism for its activation. Northern blot analyses and 
reverse transcriptase coupled polymerase chain reactions revealed that both promoters 
drive transcription in every tissue tested, but the level of transcript derived from the 
"housekeeping" promoter is generally higher. These results were paralelled by ill vitro 
activity studies carried out using the CAT reporter gene, which allowed us to map the 
minimal promoter region. The ill vivo activity of both promoters was demonstrated 
using ill situ hybridization. In addition, it showed that the TATA-box containing 
promoter was not active in all cells that express PPCA from the housekeeping promoter. 
Chapter 4 describes the generation of a mouse model for galactosialidosis using 
targeted dismption of the PPCA gene by inserting a selectable marker in exon II. The 
mice appeared to be phenotypically and histologically similar to the human disease, 
displaying a high urinary excretion of sialylated oligosaccharides, nephropathy, ataxia, 
hepatosplenomegaly and a shortened lifespan. Transplantation of these -/- mice with 
transgenic bone marrow overexpressing the human PPCA in the erythroid lineage 
resulted in a complete reversal of the diseased phenotype in the visceral organs, and a 
partial correction of the CNS. It was clear that higher levels oftherapeutic protein from 
overexpressing bone marrow cells afford a more timely and complete correction of the 
disease phenotype than nonnal bone marrow. These encouraging data demonstrated the 
effectiveness of cell therapy in the treatment of galactosialidosis and fonn the basis for 
the development of new therapeutic strategies in the future. FurthernlOre, the usage of 
transgenics that specifically express the PPCA in the erythroid lineage enabled us to 
examine the effect of a single cell population after bone marrow transplantation. 
In order to understand the pathophysiology of galactosialidosis, a fine mapping 
of the storage in the PPCA (-/-) mice was perfonned, as described in chapter 5. The 
distribution was remarkably regional within different tissues, as some cell types 
displayed clear signs of storage, while others did not. This pattern did not consistently 
correlate with the expression of PPCA mRNA and protein, since some high expressing 
cells did not store at all in the affected mouse, and certain low expressing cells 
accumulated high amounts of storage products. This discrepancy suggests that at these 
sites the catalytic functions of PPCA could be more important than its protective 
function. Furthennore, a fine mapping of the storage distribution in different tissues 
allows for a more precise assessment of the results of specific therapeutic approaches. 
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Chapter 6 describes the isolation of the murine N-acetyl-a-neuraminidase, one of 
the hydro lases in complex with PPCA. The protein has many of the typical sialidase 
superfamily features and is highly homologous to the human counterpart. In addition, 
molecular analysis of the murine inbred strain SMlJ identified a point mutation resulting 
in a aminoacid substitution (L2091), which was responsible for the reduced activity 
observed in these mice. The mutation hampers the efficiency of neuraminidase to 
cleave its substrates, while its specificity remains unchanged. The isolation of the 
murine genomic region will be used to generate a mouse model for the severe fonn a 
sialidosis by inactivating the neuraminidase gene by targeted gene dismption. 
The studies presented in this thesis will eventually contribute to a better 
understanding of both galactosialidosis and sialidosis. They will facilitate studies on the 
PPCA and neuraminidase interactions and elucidate important regulatory factors 
involved in the expression of both genes. A broader and deeper knowledge on the way 
these proteins function ill vivo will be beneficial for the testing and evaluation of 
therapeutic approaches and to set up ill vivo systems for the analysis of the two separate 
functions of PPCA. 
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SAMENV ATTING 
De kleinste bouwsteen van het leven, de cel, is opgebouwd uit verscheidene 
compartimenten, die elk afzonderlijk een specifieke functie vervullen. In de kern van de 
cel bevindt zich het erfelijke materiaal, het DNA, wat onder meer verdeeld is in stukken 
welke informatie bevatten voor het aanmaken van eiwitten (codering), alsmede de 
stukken met instmcties warmeer deze eiwitten gemaakt moeten worden (regulatie). Het 
stuk DNA wat de combinatie van codering en regulatie van cen eiwit bevat, heet een 
gen. Het coderende gedeelte van een gen, de exonen, zijn onderbroken door niet 
coderende stukken, intronen. Onder invloed van het regulerende deel van het gen, wordt 
een kopie gemaakt waarbij de intronen verwijderd worden, en het kopie, het 
boodschapper RNA (mRNA), fungeert als mal voor het aanmaken van het eiwit. 
Veranderingen in DNA waardoor er wijzigingen optreden in de regulatie of de codering 
van eiwitten worden mutaties genoemd. Mutaties kurmcn leiden tot het volledig stil 
leggen van het gen of kumlcn cen verandering in het eiwit veroorzaken waardoor het 
niet goed meer functioneert. 
Lysosomen zijn cen heterogene populatie van compartimenten, afgesloten van de 
rest van de eel door cen membraau, waarin zich vele eiwitten bevinden die betrokken 
zijn bij de a!braak van macro-moleculen van uiteenlopende oorsprong. Deze a!braak 
vindt plaats via enzymen die nauw op elkaar afgestemde processen begeleiden en de 
ontstane producten kunnen gebmikt worden als bouwstenen van nieuwe moleculen. 
Lysosomale stapelingsziekten zijn erfelijke aandoeningen, die worden gekenmerkt door 
cen mutatie in een van de vele enzymen hetrokken bij deze afbraakprocessen. Hierdoor 
vindt er een voortdurende opslag van substraten plaats die niet langer kurmen worden 
verwerkt. Uiteindelijk leidt dit tot de aantasting van de Iysosomale fllnctie en de zieke 
eel kan geYdentificeerd worden door de aanwezigheid van vele, gezwollen lysosomen. 
Aangezien Iysosomen in bijna elk cel type voorkomen, hebben patienten uiteenlopende 
klinische klachten, zoals beschadigingen aan het centrale zenuwstelsel en 
zwakzirmigheid, botafwijkingen, hart en vaat problemen en opgezette organen, zoals 
lever en milt. Lysosomale stapelingsziekten worden ingedeeld op grond van, en 
vemoemd naar, de moleculen die de voomaamste bron van de stapeling vormt. 
Het werk dat beschreven is in dit proefschrift is gebaseerd op de Iysosomale 
stapelingsziekte galactosialidosis. Mutaties in het protective protein/cathepsin A gen 
(PPCA) vormen de genetische basis voor deze ziekte. Het PPCA eiwit heeft de 
capaciteit om een complex te vomlen met twee andere lysosomale eiwitten, p-
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galactosidase en neuraminidase, waardoor deze twee eiwitten beschelmt worden tegen 
afbraak in de lysosomen. Een erfeIijke aandoening die het functioneren van het PPCA 
eiwit verstoort, leidt tot destabilisatie van het complex, wam'door de substraten die 
nomlaal door p~galactosidase en neuraminidase worden afgebroken, nu opgeslagen 
worden in de Iysosomen. Het PPCA eiwit heeft naast de besehetmende funetie in het 
complex, ook cen enzymatische activiteit, welke in staat is om bepaaJde honnonen te 
inactiveren. Deze enzymatische activiteit vindt plaats buiten de lysosomen en is 
volledig onafhankelijk van de besehennende rol van het PPCA eiwit. 
In hoofdstuk 2 en 3 wordt de isola tie en karakterisatie van het muize PPCA gen 
beschreven, alsmede de analyse van het gebied wat de basale funcHes voor de gen~ 
regulatie bevat, de promoter. Uit vergelijkelld onderzoek is gebleken dat het muize gen 
vele overeenkomstell vertoont met het humane gen. Gebieden die erg aan elkaar 
venvant zijn kunnen duiden op belangrijke domeinen in het gen, bijvoorbeeld voor de 
regulatie. Deze infOlmatie kan van belang zijn bij de analyse van patienten. De 
promoters van het humane en muize gen vertonen veel overeenkomsten met een familie 
van genen die omschreven worden als "huishoud" genen. Genen die tot deze familie 
behoren worden in vrijwel elk eel type tot expressie gebraeht en zijn vaak betrokken bij 
algemene processen die nodig zijn voor het onderhoud van de eel. Naast de promoter 
met de beschreven karakteristieken, heeft het muize gen nog een extra promoter, welke 
kenmerkcn heeft die de suggestie wekken dat het muize PPCA gen op een meer 
specifieke manier kan worden geaetiveerd. Het bestaan en de aetiviteit van de beide 
promoters van het muize gen zijn aangetoond met verschillende experimenten. Een 
belangrijke observatie is dat de meer specifieke muize promoter niet in elk eel type, 
waar de "huishoud" promoter actief is, geaetiveerd wordt. 
Met de verkregen illfonuatie uit de gen analyse, is vervolgens een muis model 
van galactosialidosis gemaakt door het PPCA gen specifiek te inactiveren, zoals 
beschreven is in hoofdstuk 4. De ontstane muis vcrtoont grate gelijkenis met het 
humane zicktebeeld: verhoogde excretie van suikers met sialyl groepen, nier afwijking, 
ataxia, vergrootte lever en milt en een verkorte levensduur. Transplantatie van 
beemuerg afkomstig van nonuale muizen, of van gemanipuleerde muizen die het 
humane PPCA eiwit hoog tot expressie brengen in de rode bloedcellcn, is in staat de 
aangetaste cellen van. de galactosialidosis muizen volledig te herstellen, met 
uitzondering van het centrale zenuwstelsel wat slechts gedecItelijk geneest. Dit 
experiment heeft tevens duidelijk gemaakt dat de hoge expressie van het humane PPCA 
eiwit, afkomstig van de gemanipulcerdc muis, een beter herstcl van de galactosialidosis 
116 
muis gaf dan nonnalc hoeveelheden PPCA, wat uit het beenmerg van wild type muizen 
korn!. Deze bemoedigende resuItaten hebben aangetoond dat eel therapie effectief is in 
de behandeling van galactosialidosis, en zij vormen een basis voor het ontwikkelen van 
llieuwe behandelingen in de toekomst. De transplantatie van beelllnerg van muizen die 
het PPCA eiwit aileen in de rode bloedcellen tot expressie brengen, heeft het mogelijk 
gemaakt 0111 een specifieke populatie cellen te onderzoeken en het effect van hun 
bijdrage aan het genezingsproces van de galactosialidosis muis te meten. 
Het in kaart brengen van de verschillende cellen die het typische beeld van een 
stapelingsziekte vertonen in de galactosialidosis mnis, zoals beschreven in hoofdstuk 5, 
kan bijdragen tot het begrijpen van het ziektebeeld. Het verspreidingspatroon van deze 
cellen vertooot een opvallende regionaliteit: sommige cellen vertonen duidelijke tekenen 
van stapeling en andere cellen weer absoluut niet. Het vergelijkcn van het expressie 
niveau van het PPCA mRNA en eiwit in nonnale muizen met de stapeling in 
galactosialidosis muizen vertoont een duidelijke corrclatie in de meeste gevallen: cell en 
die veel PPCA eiwit hebben, vertonen ook een hoge mate van stapeling. Het patroon 
komt echter niet aJtijd overeen met de expressie van het PPCA eiwit, aangezien 
sommige cellen die een hoge expressie hehben, totaal geen tekenen van stapeling 
vertonen, en vice versa. Deze discrepantie suggereert dat op die plaatsen, waar cen hoge 
gen/eiwit exprcssie is, maar geen aantoonbare stapeling aanwezig is in de 
galactosialidosis muis, de enzymatische activiteit van het PPCA eiwit een belangrijkere 
functie vervult dan zijn beschennende functie ten aanzien van p-galactosidase en 
neuraminidase. Tevens is het precies in kaart brengen van het stapelingspatroon in de 
muis belangrijk voor een COlTecte interpretatie van de resultaten die verkrcgen worden 
met therapeutische behandelingen van dc galactosialidosis muizen. 
In hoofdstuk 6 wordt de isolatie en karakterisatic van het muize neuraminidase 
gen beschreven, een van de enzymen die in complex is met het PPCA eiwit in 
lysosomen. Het neuraminidase eiwit vertoont grote gelijkenis met het humane eiwit en 
heeft de typische kenmerken van de neuraminidase familie, bestaande uit 
neuraminidases afkomstig van verscheidene organismen. Naast de isolatie van het gen, 
wordt cen mutatie beschreven die voorkomt in een muize starn dat cen verlaagde 
neuraminidase activiteit vertoont. De mutatie verlaagt de efficientie waarmce het 
neuraminidase zijn substraten kan venverken, tenviji de specificiteit van het eiwit voor 
zijn substraten ol1veranderd is. De karakterisatie van het gen zal het creeren van cen 
muis model voor sialidosis, de ziekte waarbij het neuraminidase gen defect is, 
vergemakkelijken. 
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De studies beschreven in dit proefschrift dragen bij tot een beter inzicht in het 
ziektebeeld van galactosialidosis en sialidosis. Met name de interactie tussen het PPCA 
en het neuraminidase eiwit kunnen nu beter en in meer detail bestudeerd worden. Ook 
kunnen belangrijke factoren die een rol spelen bij de expressie van beide genen 
opgehelderd worden. Een betere en uitgebreidere kelmis van het gedrag van beide 
eiwitten komen het testen en de evaluatie van toekomstige therapieen ten goede. Tevens 
kan de infonnatie dienen om de twee functies van het PPCA eiwit, de beschermende rol 
ten opzichte van p-galactosidase en neuraminidase en de enzymatische activiteit, beter 
te analyseren. 
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